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Abstract 
Good practices for take-back and disposal of unused pharmaceuticals in the Baltic Sea region 
 
Appropriate collection and disposal of medicine-related waste has been identified as one of the main 
ways to decrease the emission of active pharmaceutical ingredients (APIs) into the environment. Im-
provement to the take-back and treatment of collected pharmaceutical waste may be considered low-
hanging fruit when one is considering measures to reduce API emissions. However, comparable infor-
mation that would enable estimating the potential impact of these efforts has not been available. 
Directive 2004/27/EC, related to medicinal products for human use, mandates that EU member 
states implement appropriate collection schemes for unused or expired human-use medicinal products. 
However, it does not provide any guidelines on practical implementation of these schemes. Several 
studies have pointed out significant differences among Member States in this regard. 
In March 2019, the European Commission published the European Union Strategic Approach to 
Pharmaceuticals in the Environment. The actions specified therein cover all stages of the pharmaceutical 
life cycle, from design and production to disposal and waste management. It emphasizes such elements 
as sharing good practices, co-operating at international level, and improving understanding of the risks.  
This report is aimed at filling knowledge gaps and proposing good practices for take-back and dis-
posal of unused human and veterinary medicines and other pharmaceutical waste. The report is targeted 
to e.g. ministries, environment and medicines agencies, supervisory authorities, municipalities, hospi-
tals, NGOs, pharmacists, doctors, and veterinarians. 
For the report, current national practices for take-back and disposal of unused medicines and other 
pharmaceutical waste in Denmark, Estonia, Finland, Germany, Latvia, Lithuania, Poland, Russia, and 
Sweden were evaluated. The pharmaceutical waste originating from households, hospitals and other 
health care institutions, the pharmaceutical industry, and veterinary use was considered. 
The proportion of citizens who return unused pharmaceuticals via designated collection points var-
ies greatly between Baltic Sea countries, from about 10% to 70%, with 16–80% disposing of them of as 
mixed household waste and 3–30% flushing them down the drain. The most commonly cited reason for 
improper disposal of medicines on households’ part is lack of information about their environmental im-
pacts and how to get rid of them in an environmentally sound manner. Separate collection of unused 
household pharmaceuticals does not exist in Russia, and the collection mechanism functions poorly in 
Latvia, Lithuania and Poland. Information on the take-back schemes for unused human medicines is 
more readily available than is corresponding information on veterinary medicines. 
We identified, all told, 21 good practices and recommendations for take-back and disposal of un-
used pharmaceuticals and other pharmaceutical waste and for promoting the rational use of pharmaceu-
ticals in the Baltic Sea region. Nevertheless, implementing them at national level requires particular 
consideration due to differences in national legislation and other characteristics of the EU Baltic Sea 
countries and Russia. The good practices identified in this report answer the call issued in the EU strate-
gic approach for an efficient risk-reduction strategy. 
 
Keywords: good practices, unused pharmaceuticals, active pharmaceutical ingredients (APIs),  
pharmaceutical waste, take-back and disposal of pharmaceutical waste, Baltic Sea region,  
households, pharmaceutical industry, hospitals, health care institutions, veterinarians 
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Tiivistelmä  
Hyviä käytäntöjä käyttämättömien ihmis- ja eläinlääkkeiden sekä muun lääkejätteen  
keräämiselle ja hävittämiselle Itämeren alueella  
 
Lääkejätteen asianmukaisen keräämisen ja hävittämisen on osoitettu olevan merkittävä keino ympäris-
töön päätyvän lääkeainekuormituksen vähentämiseksi. Lääkejätteen keräyksen ja hävittämisen kehittä-
mistä voidaan pitää helposti toteutettavana keinona vähentää lääkeainekuormitusta, vaikka näiden toi-
mien tehokkuuden arvioimiseksi ei vielä ole olemassa riittävästi tietoa. 
Ihmiskäyttöön tarkoitettujen lääkkeiden käyttöä koskeva direktiivi 2004/27/EC velvoittaa EU:n jä-
senvaltioita toteuttamaan asianmukaisesti käyttämättömien ja vanhentuneiden lääkkeiden keräyksen.  
Direktiivi ei kuitenkaan anna käytännön ohjeita toteutukseen, ja jäsenvaltioiden välillä onkin useissa tut-
kimuksissa havaittu olevan merkittäviä eroja. 
Euroopan komissio julkaisi maaliskuussa 2019 Euroopan unionin strategisen lähestymistavan ym-
päristössä oleviin lääkeaineisiin. Sen toimenpiteet kattavat lääkeaineiden elinkaaren kaikki vaiheet 
suunnittelusta ja tuotannosta aina hävittämiseen ja jätehuoltoon. Strategia painottaa muun muassa hy-
vien käytäntöjen jakamista, kansainvälistä yhteistyötä ja riskien parempaa ymmärtämistä. 
Tämän raportin tarkoituksena on koota tietoa ja esittää hyviä käytäntöjä käyttämättömien ihmis- ja 
eläinlääkkeiden sekä muun lääkejätteen keräämiselle ja hävittämiselle. Raportti on suunnattu mm. mi-
nisteriöille, ympäristö- ja lääkevirastoille, alueellisille valvontaviranomaisille, kunnille, sairaaloille, 
kansalaisjärjestöille sekä apteekkareille, lääkäreille ja eläinlääkäreille. 
Raportissa arvioidaan nykyiset Tanskassa, Virossa, Suomessa, Saksassa, Latviassa, Liettuassa, Puo-
lassa, Venäjällä ja Ruotsissa esiintyvät käytännöt käyttämättömien lääkkeiden ja muun lääkejätteen ke-
räämiselle ja hävittämiselle. Tarkastelu kattaa kotitalouksissa, sairaaloissa ja muissa terveydenhuoltolai-
toksissa, lääketeollisuudessa ja eläinlääkinnässä syntyvän lääkejätteen. 
Niiden kansalaisten osuus, jotka palauttavat käyttämättömät lääkkeet niille osoitettuihin keräyspis-
teisiin vaihtelee suuresti Itämeren valtioiden välillä ollen noin 10–70 %. Vastaavasti noin 16–80 % kan-
salaisista hävittää käyttämättömät lääkkeet kotitalouksien sekajätteen ja 3–30 % viemärin kautta. Ylei-
simmät syyt epäasianmukaiselle hävittämiselle ovat tietämättömyys lääkeaineiden ympäristövaikutuk-
sista ja oikeasta ympäristöystävällisestä tavasta päästä eroon siitä. Venäjällä, erillistä järjestelmää kotita-
louksien käyttämättömien lääkkeiden keräämiselle ei ole tai se ei toimi kunnolla, kuten Latviassa, Liet-
tuassa ja Puolassa. Ihmislääkkeiden keräyksestä on eläinlääkkeitä enemmän tietoa saatavilla. 
Tunnistimme 21 hyvää käytäntöä ja suositusta käyttämättömien lääkkeiden ja muun lääkejätteen 
keräämiseksi ja hävittämiseksi sekä lääkkeiden järkevän käytön edistämiseksi Itämeren alueella. Käy-
täntöjen hyödyntäminen kussakin Itämeren EU-maassa ja Venäjällä edellyttää kuitenkin huolellista har-
kintaa johtuen eroavaisuuksista lainsäädännöissä ja muissa kansallisissa piirteissä. Tässä raportissa tun-
nistetut hyvät käytännöt toteuttavat lääkeaineiden elinkaaren eri vaiheet huomioon ottavaa EU:n 
riskinvähennysstrategiaa.  
 
Asiasanat: hyvät käytännöt, käyttämättömät lääkkeet, lääkeaineet, lääkejäte, lääkejätteen  
keräys ja hävitys, Itämeren alue, kotitaloudet, lääketeollisuus, sairaalat, terveydenhoitolaitokset,  
eläinlääkärit 
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Sammandrag  
Goda exempel för insamling och kassation av oanvända läkemedel i Östersjöregionen 
 
En välfungerande insamling och hantering av läkemedelsavfall är viktig för att minska utsläppen av lä-
kemedelsrester till miljön. Att förbättra insamlingssystemen och hanteringen av insamlat läkemedelsav-
fall är förhållandevis enkla åtgärder för att minska utsläpp av aktiva läkemedelssubstanser. Det har dock 
inte funnits jämförbar information för att kunna uppskatta den potentiella effekten av dessa åtgärder, vil-
ket påpekades av UNESCO & HELCOM (2017). 
Direktiv 2004/27/EG, om gemenskapsregler för humanläkemedel, uppmanar EU:s medlemsstater 
att ta fram insamlingssystem för oanvända läkemedel eller läkemedel vars sista förbrukningsdag har gått 
ut. Direktivet ger dock inga riktlinjer för hur genomförandet av systemen ska gå till praktiskt. Flera stu-
dier har pekat på betydande skillnader i genomförandet av direktivet mellan medlemsstaterna i EU. 
I mars 2019 offentliggjorde den Europeiska kommissionen Europeiska unionens Strategi för läke-
medel i miljön. Åtgärderna i strategin täcker alla stadier i ett läkemedels livscykel från design och pro-
duktion till kassation och avfallshantering. Strategin lyfter fram åtgärder som exempelvis att utbyta 
goda exempel och erfarenheter, att samarbeta på internationell nivå och att förbättra förståelsen för ris-
ker. 
Denna rapport syftar till att fylla kunskapsluckor och föreslå goda exempel för insamling och kas-
sation av oanvända humanläkemedel, läkemedel för djur och övrigt läkemedelsavfall. Rapporten riktar 
sig till beslutsfattare, miljö- och läkemedelsmyndigheter, regionala tillsynsmyndigheter, kommuner, 
sjukhus, icke-statliga organisationer och intresseorganisationer för apotek, läkare och veterinärer. 
I denna rapport utvärderades de nuvarande nationella metoderna för insamling och bortskaffande av 
oanvända läkemedel och övrigt läkemedelsavfall i Danmark, Estland, Finland, Tyskland, Lettland, Li-
tauen, Polen, Ryssland och Sverige. Läkemedelsavfall från hushåll, sjukhus och sjukvårdsinrättningar, 
läkemedelsindustrin och veterinärer ingick i utvärderingen.  
Andelen av befolkningen som lämnar in oanvända läkemedel till utsedda insamlingsställen varierar 
mycket mellan länderna runt Östersjön; från cirka 10 % till 70 %. Cirka 16–80 % av befolkningen läg-
ger läkemedelsresterna i hushållsavfallet och 3–30 % spolar ner dem i avloppet. Det vanligaste skälet till 
hushållens felaktiga hantering av läkemedelsavfall är bristen på information om läkemedlens miljöpå-
verkan och hur man kan göra sig av med dem på ett miljövänligt sätt. Separata insamlingssystem för 
oanvända läkemedel finns inte eller är inte organiserat i Ryssland, och i exempelvis Lettland, Litauen 
och Polen är insamlingen bristfällig. Det finns mer tillgänglig information om insamlingssystem för 
oanvända humanläkemedel än om läkemedel för djur. 
I projektet identifierades totalt 21 goda exempel och rekommendationer på insamling och bortskaf-
fande av oanvända läkemedel och annat läkemedelsavfall samt för att främja en rationell användning av 
läkemedel i Östersjöregionen. Men implementeringen av dessa exempel nationellt måste noggrant över-
vägas på grund av skillnaderna i nationell lagstiftning och andra förutsättningar i EU:s Östersjöländer 
och Ryssland. De framtagna goda exemplen i denna rapport uppfyller behov som lyfts i Europeiska un-
ionens strategi om läkemedel i miljön. 
 
Nyckelord: Goda exempel, oanvända läkemedel, aktiva läkemedelssubstanser (APIs), återlämning/ 
insamling, kassation/bortskaffande, läkemedelsavfall, Östersjöregionen, hushåll, läkemedelsindustrin, 
sjukhus, sjukvårdsinrättningar, veterinärer 
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Preface 
This report presents the current practices for take-back and disposal of unused human and veterinary 
medicines and other pharmaceutical waste in Baltic Sea coastal countries, and it proposes good practices 
for decreasing pharmaceutical emissions from improper disposal of that waste. The practices and their 
legal background are described country-specifically and then summarized for an overall picture at Baltic 
Sea level. All the relevant waste-producing activities are included – i.e., those of households, hospitals 
and other health care institutions, veterinarians and veterinary practices, farms, and the pharmaceutical 
industry. 
This study was part of the CWPharma project funded by the EU’s Interreg Baltic Sea Region Pro-
gramme 2014–2020. In supplemental work, information about national practices was collected with a 
questionnaire on management of medical waste, in cooperation with HELCOM. The report was pre-
pared by the following project partners: Jukka Mehtonen, Lauri Äystö, Ville Junttila and Noora Perkola 
from Finnish Environment Institute (SYKE), Terhi Lehtinen from Finnish Medicines Agency (Fimea), 
Jeppe Bregendahl from Kalundborg Utility, Ülle Leisk and Vallo Kõrgmaa from Estonian Environmen-
tal Research Centre (EERC), Pille Aarma from Estonian Waterworks Association (EVEL), Jan Schütz 
and Michael Stapf from Berlin Centre of Competence for Water (KWB), Anete Kublina and Ieva Kar-
kovska from Latvian Environment Geology and Meteorology Centre (LEGMC), Marlena Szumska, 
Aleksandra Bogusz and Radosław Kalinowski from the Polish Institute of Environmental Protection – 
National Research Institute (IOS),  and Sara Spjuth, Kristina Nyhlén and Torsten Jakobsson from 
County Administrative Board of Östergötland (CAB). Outside the project partnership, Sergej Suzdalev 
from Klaipeda University and Elena Kaskelainen from John Nurminen Foundation had a significant role 
in writing the country specific chapters on Lithuania and Russia respectively. 
In addition, we also received valuable information and feedback on the report and its recommenda-
tions from colleagues at the project’s Associated Organisation: Eevaleena Häkkinen from the Finnish 
Ministry of the Environment, Johanna Salimäki and Sanna Siissalo from the Association of Finnish 
Pharmacies, Evelina Jatko and Karin Ramstedt from CAB, Gunnar Thorsén and Christian Baresel from 
Swedish Environmnetal Research Institute (IVL), Katariina Parker and Maria Linderoth from the Swe-
dish Environmental Protection Agency, Kia Salin from the Swedish Medical Products Agency, and 
Bengt Mattson from the Swedish Association of the Pharmaceutical Industry (LIF). Also, other stake-
holders and colleagues provided valuable input to the report: Dmitry Frank-Kamenetsky from the HEL-
COM Secretariat, Johanna Borgendahl, Helena Ramström and Marie-Louise Ovesjö from Stockholm 
Regional Council, Lisa Stern from the Swedish Pharmacy Association, Venla Johansson from the City 
of Vantaa, Auli Westerholm from Fortum Waste Solutions Oy, and Päivi Fjäder from the Finnish Envi-
ronment Institute. 
I thank all the writers and contributors. With your efforts and expertise, we now have a valuable re-
port about the good and not-so-good practices that are currently being applied. It is my hope that this 
report will be used to increase regional collaboration and discussion surrounding this topic and to im-
prove the management of pharmaceutical waste in the region.   
 
Helsinki 7.5.2020  
Noora Perkola, CWPharma project Coordinator, Leading Researcher,  
Finnish Environment Institute (SYKE)  
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1 Introduction  
Jukka Mehtonen1, Lauri Äystö1, Ville Junttila1 and Noora Perkola1,  
Terhi Lehtinen2 
1Finnish Environment Institute 
2Finnish Medicines Agency 
Whilst pharmaceuticals enter the environment throughout the production, 
consumption and disposal of medicines, incorrect disposal of waste containing 
pharmaceuticals is considered one of the major pathways (EC 2019). Many 
publications have identified proper disposal of medicine waste as one of the 
main ways to decrease the emission of active pharmaceutical ingredients. 
1.1 Background 
Directive 2004/27/EC, related to medicinal products for human use, contains a mandate for EU member 
states to implement appropriate collection schemes for unused or expired human-use medicinal prod-
ucts. However, it does not provide any guidelines on practical implementation of these schemes, and 
several studies have pointed out significant differences among the member states in this regard (e.g., 
BIO Intelligence Service 2013, HCWH 2013). Some APIs are narcotic or psychotropic in nature and, as 
such, fall within the scope of international conventions designed to prevent the non-medical use of these 
substances, such as the United Nations Single Convention on Narcotic Drugs and the UN Convention 
on Psychotropic Substances (adopted in 1961 and 1971, respectively). These conventions specify re-
quirements for the handling and possession of the relevant substances, often reflected also in national 
waste legislation or guidelines. 
According to a survey in Germany, 51% of the general public there consider private households’ 
improper disposal of medicines down the toilet or sink to cause high or very high pharmaceutical emis-
sions (Götz et al. 2019). Respondents assumed this to be the second most important cause of pharma-
ceuticals’ presence in surface water, with emissions from the pharmaceutical industry presumed the 
most important. This is in contrast against current expert consensus, according to which the consump-
tion and excretion of medicines is the most significant pathway into the environment (e.g., EC 2019). 
As for solutions, according to Götz et al. (2019), 61% of the general public reported being interested in 
information on the correct disposal of medicines, and around 50% of experts from Germany, Hungary, 
and the UK considered standardised regulations on the disposal of unused pharmaceuticals to be one of 
the most effective ways to reduce pharmaceutical residues in the environment.  
The HELCOM status report on pharmaceuticals in the Baltic Sea region, hereinafter ‘the Status Re-
port’ (HELCOM & UNESCO 2017), provides region-level information on such matters as the inputs of 
several individual APIs on the Baltic Sea and their concentrations in freshwater and marine environ-
ments. However, the report also highlights several data gaps that need attention. One of these gaps in-
volves lack of information on the handling of pharmaceutical waste in several countries in the Baltic Sea 
region. Information was reported from Estonia, Finland, Germany, Sweden, and to some extent Russia 
but not from Denmark, Latvia, Lithuania, and Poland. Furthermore, only Estonia, Finland, and Sweden 
provided information on the amount of pharmaceutical waste collected and on their procedures for han-
dling pharmaceutical waste. Therefore, it was impossible to evaluate the hazards to the environment 
arising from disposal of unused medicines, whether human or veterinary. Additionally, the Status Re-
port contains very few data on veterinary pharmaceuticals in general. Therefore, the contribution of vet-
erinary pharmaceuticals to freshwater and marine pollution could not be assessed in the report. 
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The Status Report states among its conclusions that ‘measures to reduce the inputs of pharmaceuti-
cals should address all stages of the product life cycle from manufacturing to consumption to waste 
management’, where these measures may include both technical and policy solutions, alongside educa-
tional and awareness-raising initiatives. The Status Report takes a stand also on good practices for take-
back and disposal of unused medicines: ‘Take-back of unused medicines by pharmacies should be ap-
plied or developed in countries where such systems are not yet in place or are inefficient, in order to re-
duce the disposal of unused medicines via solid waste or sewers.’ 
The European Commission (EC) published a report on a study related to the preparation of an EC 
strategic approach to minimise the pollution due to pharmaceuticals (BIO Intelligence Service 2013). 
The authors concluded that in most EU member states, a large share of the unused human medicinal 
products is not collected separately, with some Member States not having implemented take-back 
schemes of any sort. Additionally, the report states that the take-back schemes for unused medicinal 
products represent the simplest ways to reduce the flows of pharmaceutical residues into the environ-
ment.  
The issue of implementing take-back schemes for unused medicines was further emphasised in the 
EC’s background document for public consultation on pharmaceuticals in the environment (Lockwood 
et al. 2017). Implementation of take-back schemes is extremely heterogeneous across the Member 
States, but the take-back of human medicines can be characterised as better organised than that of veter-
inary medicines in general.  
In March 2019, the European Commission published the European Union Strategic Approach to 
Pharmaceuticals in the Environment (EC 2019). This strategy document outlines six areas for action to 
reduce the risks posed by medicines and related products released into the environment. The actions 
cover all stages in the pharmaceutical life cycle, from design and production to disposal and waste man-
agement. For the action area ‘Reduce wastage and improve the management of waste’, it is stated that 
‘the Commission will assess the implementation of collection schemes for unused pharmaceuticals and 
consider how their availability and functioning could be improved, how to increase public awareness of 
the importance of using them, and how extended producer responsibility could play a role in reducing 
inappropriate disposal’. 
The OECD’s policy paper on pharmaceuticals (OECD 2019) recommends to ensure appropriate 
collection and disposal of pharmaceutical waste.  
Additionally, pharmacists are making strong calls for action to reduce the environmental impacts of 
pharmaceuticals, via such means as improved collection of medicine waste (PGEU 2019). As medicine 
experts, pharmacists are well positioned to increase public awareness, promote the prudent use and ap-
propriate disposal of pharmaceuticals, and provide advice on the availability of ‘greener’ pharmaceuti-
cals where such information is available. 
Proper collection and disposal of household pharmaceutical waste can contribute to reducing the 
impact of pharmaceuticals on the environment. Importantly, effective collection schemes would divert 
unused medicines from mixed-waste streams that are not designed to treat pharmaceutical waste 
(HCWH 2013). The improvement of take-back schemes for unused medicines may be one of the sim-
plest ways to reduce emissions of medicines in the environment (EEA 2010). 
1.2 The scope of the report 
 
This report is aimed at filling the knowledge gaps mentioned above and 
proposing concrete good practices for take-back and disposal of unused human 
and veterinary medicines and other waste containing pharmaceutical residues. 
The current national practices for take-back and disposal of unused medicines and other pharmaceutical 
waste in Denmark, Estonia, Finland, Germany, Latvia, Lithuania, Poland, Russia, and Sweden were 
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evaluated, with pharmaceutical waste from households, hospitals and other health care institutions, 
pharmaceutical-industry operations, and veterinary use being taken into consideration. Furthermore, 
Baltic Sea region wide best-practice recommendations for efficient take-back and disposal of unused 
medicines are offered. The aim in this is to spread good take-back and disposal methods that may al-
ready be in place in some Baltic Sea countries to countries where such practices are not yet in place or 
are inefficient. 
The report is targeted specifically at policy-makers (e.g., environment, agriculture, and social and 
health ministries), national environment and medicines agencies, regional supervisory authorities, mu-
nicipalities, hospitals, interest groups for practitioners (pharmacists, doctors, and veterinarians), and 
NGOs. 
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2 Current national practices for take-back and 
disposal of unused pharmaceuticals and other 
pharmaceutical waste 
In addition to EU legislation, the collection and handling of pharmaceutical 
waste is regulated by national legislation in each of the Baltic Sea countries. 
Therefore, the collection schemes and disposal methods may vary between  
the countries. Information about the legal basis for pharmaceutical waste 
management, and methods of collection and disposal of pharmaceutical waste 
originating from different sources was collected for Denmark, Estonia, Finland, 
Germany, Latvia, Lithuania, Poland, Russia and Sweden.  
2.1 Denmark  
Jeppe Bregendahl 
Kalundborg Utility 
2.1.1 Legal basis 
In Denmark, returning unused medicines is addressed by several distinct fields of law and, accordingly, 
affected by various laws and regulations. Among the government orders regulating pharmaceutical 
waste are the Executive Waste Order (1759/2018), the Executive Order on the Pharmacy Act 
(801/2018), and the Executive Order on the Waste Database (1742/2018). For veterinary medicines, 
there are also the Executive Order on the Veterinary Code (48/2017) and the Executive Order on the Act 
on Holds of Animals (1/2019). 
Unused medicines fall under the category of hazardous waste and the subcategory clinical hazard-
ous waste (per the Executive Waste Order). The requirements pertaining to both collection of such 
waste types and related instructions are administered by the individual municipality. The municipalities 
are free to construct their respective systems as they prefer. The nationwide practice is that the pharma-
cies are responsible for accepting any waste of this nature from within their region (1759/2018).  
The Executive Order of the Pharmacy Act (paragraph 11, part 7) states that all pharmacies that hold 
a national licence to distribute medicines are required to accept any unused medicines for destruction. 
This requirement covers all unused medicines presented by private persons, practising doctors and vet-
erinarians, and nursing homes and other institutions. Hospitals constitute an exception; they have a sep-
arate system by which pharmaceutical waste is collected, handled, and transported. All types of pharma-
ceutical waste from hospitals are classified as hazardous and treated in a similar way. Pharmacies and 
hospitals are not required to document the waste received or handled (801/2018).  
Waste-treatment plants authorised to treat pharmaceutical waste are required to register the amount 
handled but not the specific type of waste. This is the only documentation for pharmaceutical waste in 
Denmark.  
2.1.2 Current take-back practices  
Private individuals are responsible for the handling of their own medicines, as their private property. 
They can only be encouraged to dispose of expired or otherwise useless medicines through the 
Reports of the Finnish Environment Institute 34/2020   15 
pharmacies. On 1 September 2017, there were 237 pharmacies in Denmark and the same number of col-
lection points for unused medicine (Ministeriet for Sundheg og Forebyggelse 2009). 
Pharmaceuticals from doctors´ offices and clinics may be delivered to the pharmacy or be disposed 
of via containers and other collection points if this option is offered by the municipality. 
From the pharmacies, the hazardous waste is collected and transported to the treatment plant by 
companies certified to do so, as is all waste from containers and collection points. 
Hospitals are required to handle their own waste and send it directly to incineration.  
Pharmaceutical waste from the industry is sent for immediate destruction, through a separate co-
ordinated municipal system. The industry is the largest source of pharmaceutical waste, with waste from 
this source originating from production errors, discharge of reference material, errors in labelling, expiry 
of medicines, and products that do not work as intended. 
The industry accounted for more than 90% (or 7.7 t) of the pharmaceutical waste handled in 2006, 
when the latest calculation was done. Hospitals produced 3% (270 t) of the waste, and 4% (300 t) came 
from pharmacies. How large a fraction of the total amount is disposed of through household waste and 
toilets is unknown (Ministeriet for Sundheg og Forebyggelse 2009). 
Evaluation of the pharmacies’ take-back system  
The latest evaluation of the pharmacies’ take-back system was carried out in 2009. This was a qualita-
tive assessment of the composition of the medicines returned to 10 pharmacies. 
Table 1 presents the types of medicines sold and the types of medicines returned to the pharmacies. 
The study involved a survey of the 10 Danish pharmacies, covering one week. The amounts of the phar-
maceuticals were stated in numbers of packages, not by weight (Ministeriet for Sundheg og Foreby-
ggelse 2009). 
Table 1. The number of packages of pharmaceuticals sold and the proportion of these returned to the 
pharmacies (Ministeriet for Sundheg og Forebyggelse 2009). 
ATC group   Number of sold packages  
during the one week survey  
Share of  
returned (%) 
A Alimentary tract and metabolism 276 17 
B Blood and blood forming organs 69 4,1 
C Cardiovascular systems 272 16 
D Dermatologicals 86 5,1 
G Genito-urinary system and sex hormones 31 1,9 
H Systemic hormonal preparations 48 2,9 
J Antiinfectives for systemic use 98 5,9 
L Antineoplastic and immunomodulating agents 9 0,5 
M Musculo-skeletal system 91 5,4 
N Nervous system 402 24 
P Antiparasitic products 18 1,1 
R Respiratory system 175 11 
S Sensory system 96 5,7 
V Sensory organs 2 0,1 
Total  1 673 100 
 
The percentages for the types of medicine waste handed in at each pharmacy are in line with these 
types’ relative sales rates. Most pharmaceuticals handed in were of group N (nervous-system drugs), the 
category with the highest sales.  
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Table 2 presents the pharmaceutical items returned to the pharmacies by the cause for return. The 
data are from the above-mentioned study in 2009 (Ministeriet for Sundheg og Forebyggelse 2009). 
Table 2. The number of pharmaceutical items returned to the pharmacies and the reason for return 
(Ministeriet for Sundheg og Forebyggelse 2009).  
Cause  Number of returned  
packages / pharmaceuticals 
Share % Share without death  
and unknown % 
Death of patient  599 33,5 − 
Unknown cause 402 22,5 − 
Best before date crossed 285 15,9 40 
Treatment ended, with unused medicine left 136 7,6 19,1 
Treatment ended, stopped by doctor 127 7,1 17,8 
Treatment ended by patient 119 6,6 16,7 
Dose dispensing medicine, no cause given 77 4,3 − 
Treatment never started 18 1 2,5 
Patient was hospitalized 17 0,9 2,4 
Leftovers from transition to dose dispensing 
medicine 4 0,2 0,6 
Doubts regarding best before date 3 0,2 0,4 
Improper storage 3 0,2 0,4 
Total 1790 100 100 
 
The most common reason for handing in unused medicine was the death of its user. The study was 
carried out from an economic standpoint; therefore, there was no evaluation of the fraction disposed of 
in an improper fashion. The aim was, rather, to minimise economic losses by reducing the amount of 
pharmaceutical waste generated. 
The study found that the pharmaceuticals handed in correspond to 0.5% of the pharmaceutical items 
sold over the time covered by the survey (Ministeriet for Sundheg og Forebyggelse 2009). 
Veterinary medicines 
All veterinary medicines must be distributed by a veterinarian, pharmacy, or other approved institution. 
The pathway in distribution and take-back for veterinary pharmaceuticals follows that for human medi-
cines, with both passing through certain points – i.e., pharmacies or collection points. As the types of 
the unused medicines are not identified at the pharmacies or collection points, it is not possible to differ-
entiate the amount of veterinary medicines handed in and delivered for disposal. There have been no 
Danish studies to quantify this fraction or estimate the amounts of veterinary APIs ending up in the en-
vironment through animal-keeping, whether related to pets or husbandry (Miljø- og Fødevareministeriet 
2020a, Miljø- og Fødevareministeriet 2020b).  
Improvement needs 
Currently, the Danish system is well-controlled and trust in the system is good. The institutions, doctors 
and veterinarians are likely to follow the national and regional guidelines for handing in of pharmaceuti-
cals. The largest proportion of improper disposal of medicines probably arises from private households 
and individuals, and the cause of such improper disposal can be presumed to be either lack of infor-
mation or intentional inappropriate discharge.  
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To improve control of the disposal of human and veterinary medicines, it would be useful to have 
information on the take-back percentages. The point that is most easily controlled is the central take-in 
point, the pharmacy. Registration and quantification of the sources would improve the state of 
knowledge about the source. With regard to hospitals, it would be possible to introduce registration of 
the medicines disposed of here too. The information and data could serve as a central tool in efforts to 
improve the system and decrease the quantity of APIs entering the natural environment. 
2.1.3 Current disposal practices  
Denmark has banned all landfilling, and, therefore, the waste system is built around an incineration-
based disposal technique (1759/2018). All pharmaceuticals are incinerated at special, licensed plants at 
high temperatures, above 1100 °C (Brunn Poulsen et al. 2002). These plants are operated by private 
companies. 
Fortum Waste Solutions A/S is one of the biggest plants in Denmark to handle and dispose of haz-
ardous waste. They report decreasing amounts of pharmaceutical waste treated at their plant over the 
last four years. The reason cited for this is reduction in the amount of this waste coming in from the in-
dustry. 
The techniques used for incineration of the pharmaceutical waste are dictated by national legisla-
tion. They are required to follow the best available techniques (BAT). It can be assumed that this dis-
posal method functions as well as possible. 
2.1.4 Summary 
The main findings related to collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Denmark are presented in Table 3. 
Table 3. Summary of the collection, classification and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Denmark. 
Origin/type of 
pharmaceutical 
waste 
Types of 
pharmaceu-
ticals  
collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection 
point 
Types of  
pharmaceutical 
waste  
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human and 
companion animal 
medicines from 
households 
All Municipality Usually  
local  
pharmacy 
(depends on 
municipality) 
All 1759/2018  
§ 41 
801/2018 
§ 12 
High- 
temperature  
incineration 
(above  
1100 °C) 
Pharmaceutical  
industry (unsalable 
products, API- 
contaminated 
wastes, etc.) 
All products, 
waste frac-
tions and  
ingredients 
classified as 
hazardous 
waste 
Industry  
operator 
Organized 
and payed 
by the indus-
try operator. 
Depends on 
classification of 
the waste frac-
tion. Final prod-
ucts and certain 
ingredients are  
classified as 
hazardous. 
1759/2018  
§ 41 
High- 
temperature  
incineration 
(above  
1100 °C) 
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Origin/type of 
pharmaceutical 
waste 
Types of 
pharmaceu-
ticals  
collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection 
point 
Types of  
pharmaceutical 
waste  
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Pharmaceutical 
waste from hospitals 
and health care  
institutions 
All Hospitals,  
institutions and 
municipality 
Depends on 
municipality. 
Usually local 
pharmacy. 
Also individ-
ual hand in 
from hospital 
or health 
care institu-
tion. 
All 1759/2018 
§ 41 
801/2018 
§ 12 
High- 
temperature  
incineration 
(above  
1100 °C) 
Veterinary medi-
cines from veterinar-
ians and veterinary 
practices 
All Municipality Usually local 
pharmacy 
All 1759/2018 
§ 41 
1/2019 
High- 
temperature  
incineration 
(above  
1100 °C) 
Veterinary medi-
cines for farmed  
animals  
All Municipality Usually local 
pharmacy 
All 1759/2018 
§ 41 
1/2019 
High- 
temperature  
incineration 
(above  
1100 °C) 
 
The following key points were noted with regard to the Danish take-back system and disposal of 
unused pharmaceuticals: 
Advantages: 
+ The pharmacy take-back scheme appears efficient. The network of collection points is extensive 
and easy for the citizens to use when the pharmacies act as collection points. All the pharmaceu-
ticals are returned to professionals, and there is no chance of vandalism or possibility of phar-
maceuticals being retrieved by third parties from the collection point. One need not identify 
oneself when returning medicines to pharmacies. 
+ The waste returned to pharmacies consists of only active pharmaceuticals. The staff at the phar-
macy do not need to handle needles or mercury thermometers. 
+ The high-temperature treatment appears controlled, efficient, and well-implemented. 
+ The return scheme is operated well by the public institutions. 
Areas that need improvement: 
- The public information and data on the actual returning of unused pharmaceuticals by house-
holds are very sparse. 
- Lack of public awareness of the take-back scheme might limit its usage and lead to such results 
as inappropriate disposal via the toilet. Raising public awareness would certainly increase the 
proportion of pharmaceuticals disposed of correctly. 
- Statistics on the returned pharmaceuticals are needed, so that progress and the amounts of phar-
maceutical waste can be tracked and analysed 
Uncertainties: 
• Limited availability of data casts validation of the take-back scheme into doubt. Most of the 
studies and data available on the subject focus on the economic issues and do not address the 
environmental aspects. Also, the quantities of publicly available data and information on the 
high temperature incineration are limited, because it is performed by private companies. 
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2.2 Estonia 
Ülle Leisk1, Vallo Kõrgmaa1 & Pille Aarma2 
1Estonian Environmental Research Centre 
2Estonian Waterworks Association 
2.2.1 Legal basis 
The take-back and disposal of unused medicines in Estonia is regulated with two main laws – the Me-
dicinal Products Act and the Waste Act.  
The Medicinal Products Act (§35) states that all medicinal products not complying with quality re-
quirements, whose shelf life has expired, the use of which is prohibited in Estonia, or that for other rea-
sons cannot be used for their intended purpose must be withdrawn from the market.  
Persons handling pharmaceutical products professionally are required to separate unusable medici-
nal products from other goods and mark such products accordingly in a clearly understandable manner. 
Medicinal products withdrawn from the market must be stored under conditions that prevent their mar-
keting or use and must ensure that their storage is safe for humans, animals, and the environment. 
Unusable medicinal products that are defined as hazardous waste, in accordance with either Com-
mission Regulation (EU) 1357/2014 (OJ L 365, 19.12.2014, pp. 89–96) or the list established under 
Subsection 2(5) of the Waste Act, must be collected separately from other waste, in the manner speci-
fied for the relevant categories listed, and must be marked in line with the procedure established under 
Subsection 62(3) of the Waste Act. 
Special conditions apply for unusable narcotic drugs and psychotropic substances, which must be 
stored in conditions appropriate for such substances and destroyed as non-hazardous waste in the pres-
ence of a representative of the State Agency of Medicines.  
The non-hazardous substances must be separated from other waste, and the destruction procedure 
must be performed immediately (per the Medical Products Act’s §36, paragraphs 3 and 4, packaging 
used for collecting or transporting cytostatic or cytotoxic medicinal products must be marked with a 
clearly distinguishable additional warning to this effect). 
Unusable medicinal products regarded as hazardous waste must be destroyed by a licensed com-
pany. For the purposes of the Waste Act, destruction is disposal or recycling of pharmaceutical waste 
via a process that eliminates the hazardous properties of the active substances as specified in Commis-
sion Regulation (EU) 1357/2014. 
The person handling medicinal products to be destroyed as non-hazardous waste must, directly be-
fore their destruction, remove the packaging of the medicinal products, render any printed packaging 
material unreadable, and crush any solid medicine waste. The receiver of medicinal products from the 
handler must document the delivery information of the products and the identities of the persons in-
volved in delivery and reception of the medicinal products. The deliverer and recipient must verify the 
transaction by signing the document created. The handler of the medicinal products must document the 
destruction of these products, including the method of destruction. 
2.2.2 Current take-back practices 
The first press releases in Estonia about potential environmental problems associated with pharmaceuti-
cals were prepared about 10 years ago. At about the same time, universities started to investigate the oc-
currence and behavior of pharmaceutical residues in sewage sludge. Hospitals began putting more atten-
tion on reducing the environmental impact of health care activities, and municipal waste-collection 
stations were established, which improved the system for take-back of unused pharmaceuticals (Ruut 
2017). 
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Currently, people may dispose of unused medicines in either of two ways – bringing them to mu-
nicipal waste-collection stations or to pharmacies. Disposal is free of charge and usually requires no pa-
perwork. While Regulation of the Minister of Social Affairs 2005/25 states that people disposing of un-
used medicines at a pharmacy must supply their contact information (name and phone number) and that 
the names and quantities of unused medicines have to be documented against the signature of both par-
ties (with digital signing), this procedure is seldom strictly followed. Also, pharmacies must keep the 
returned unused medicines separate from other medicines before handing them over to waste-manage-
ment companies.  
Information about the nearest waste-collection station or pharmacy that takes back unused medi-
cines can be found easily via Web sites or apps (e.g., https://kuhuviia.ee/). Pharmacies are not obligated 
to accept other waste – such as food supplements, natural products, or medical devices. The unused 
medicines should be kept in their original packaging and not removed from it (for example, as separate 
pills).  
Unused pharmaceuticals generated through one’s business activities (incl. health and veterinary ser-
vices) must be transferred to a waste-management company that holds a licence for handling hazardous 
waste, including pharmaceuticals. As a rule, legal entities such as companies are not allowed to bring 
their pharmaceutical waste to the waste stations the local municipality has arranged for its residents; ra-
ther, these entities must have their own contract with a licensed waste-management company, while mu-
nicipalities cover only the costs of hazardous-waste management for their residents, not companies. For 
instance, if a farm is registered as a legal entity, then it must have a contract signed with a waste-man-
agement company. Exceptions are made only in cases wherein the contract is with the same waste-man-
agement company that manages the local collection station. In this event, the waste-management com-
pany must still have an agreement in place with the local municipality for making exceptions. 
Only those hospitals that have a waste permit must submit waste reports. These describe the facil-
ity’s generation of pharmaceutical waste and the waste quantities conveyed to waste management com-
panies. Pharmacies, small hospitals, clinics, dental practices, and other small-scale handlers do not have 
a reporting obligation, but the quantities of the unused medicines collected in these cases are still re-
ported by the waste-management companies.  
A similar system is applied for take-back of veterinary medicines from professional users (e.g., 
farms and veterinary hospitals). Farms that have an integrated environmental permit report on their use 
and handling of pharmaceutical waste, but smaller farms (not obliged to hold an environmental permit, 
because of their size) and veterinary hospitals do not have any obligation of reporting. As in the case of 
unused human-use medicines, smaller facilities gather their unused veterinary medicines and the infor-
mation about collection is presented by licensed waste companies. 
The reported quantities of unused medicines collected are presented in Figure 1 and Table 4. 
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Figure 1. The distribution of the unused medicines collected, by source. 
 
Figure 1 shows that most of the unused medicine is collected from hospitals. All bigger hospitals 
have in-house quality-management systems that regulate the collection of unused medicines. The veteri-
nary medicines reported upon are only those from professional use, and the figures from waste stations 
include both human and veterinary medicines used by households. 
Table 4: Reported quantities of unused medicines collected in Estonia. 
Tons per year Waste code 2014 2015 2016 2017 
Collected from hospitals 18 01 56,1 51,1 118 98,6 
Collected veterinary medicines 18 02 11,0 14,5 8,0 8,6 
Collected from waste stations 20 01 24,3 20,0 24,1 36,2 
Total  91,4 85,6 150 143 
 
There are no data about the functionality of the collection system by which unused medicines are 
collected from the population, and the quantity of unused medicines sent to municipal landfills as regu-
lar waste is unclear. 
2.2.3 Current disposal practices 
Unusable medicinal products deemed to be hazardous waste must be destroyed by an enterprise holding 
an appropriate licence for handling hazardous waste. In total, there are 76 companies in Estonia that are 
licensed to handle hazardous waste, including pharmaceuticals, but most of these companies do not han-
dle unused medicines. According to the waste reports received by the Environmental Board, between 
2014 and 2017, only 15 companies declared that they transport and/or collect unused medicines. There 
is one company in Estonia that uses combustion for pharmaceutical residues (waste-handling in line 
with code R1).  
According to the waste reports, the main methods of disposal of unused medicines are R1 (use prin-
cipally as a fuel or other means of generating energy) and R12 (exchange of waste for submission to any 
of the operations denoted as R1 to R11). In Estonia, the unused medicines collected are sent to Kunda 
Cement Plant’s incinerator and burned at 1300 °C. 
67.1%10.1%
22.8%
Hospitals
Veterinary
Waste stations
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2.2.4 Summary 
The main findings on collection, classification, and disposal of unused pharmaceuticals and other waste 
containing pharmaceutical residues in Estonia are presented in Table 5.  
Table 5. Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Estonia. 
Pharmaceutical 
waste 
Types of 
pharmaceu-
ticals  
separately  
collected 
Responsible 
party for  
arranging  
reception 
Collection  
point 
Types of  
pharmaceutical 
waste  
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human 
and companion 
animal  
medicines from 
households 
All pharma-
ceuticals 
Municipality  
(setting rules) 
Local  
pharmacy  
Or 
Municipal 
waste  
collection  
stations 
Prescribed  
pharmaceuticals 
Medicinal  
Products Act, 
Waste Act, local 
municipality 
waste manage-
ment rules 
Incineration at 
temperature 
of 1300°C 
Pharmaceutical 
industry  
(unsalable  
products, API-
contaminated 
wastes, etc.) 
All pharma-
ceuticals 
Industry  
operator; 
state rules 
Waste  
management 
company 
or municipal 
waste  
collection point 
Depends on the 
hazardous  
properties of  
the waste 
Medicinal  
Products Act, 
Waste Act, local  
municipality 
waste manage-
ment rules 
Incineration at 
temperature  
of 1300°C 
Pharmaceutical 
waste from  
hospitals and 
health care  
institutions 
All pharma-
ceuticals 
Hospitals and 
health care  
institutions; 
state rules 
Waste  
management 
company 
Depends on the 
hazardous  
properties of  
the waste 
Medicinal  
Products Act, 
Waste Act, local 
municipality 
waste manage-
ment rules 
Incineration at 
temperature 
of 1300°C 
Veterinary  
medicines from 
veterinarians 
and veterinary 
practices 
All pharma-
ceuticals 
Veterinarians 
and veterinary 
practices 
State rules 
Waste  
management 
company 
Depends on the 
hazardous  
properties of  
the waste 
Medicinal  
Products Act, 
Waste Act, local 
municipality 
waste manage-
ment rules 
Incineration at 
temperature  
of 1300°C 
Veterinary  
medicines for 
farmed animals  
All pharma-
ceuticals 
Farmer;  
state rules 
Waste  
management 
company 
Depends on the 
hazardous  
properties of  
the waste 
Medicinal  
Products Act, 
Waste Act, 
local municipal-
ity waste man-
agement rules 
Incineration at 
temperature  
of 1300°C 
 
In conclusion, the following points were identified with regard to the Estonian take-back system 
and disposal of unused pharmaceuticals. 
Advantages: 
+ The pharmacy take-back scheme appear efficient, and information on collection points is widely 
available via Web sites or apps. 
+ Pharmacy staff are trained in the take-back system and willing to participate in it.  
+ Consumers have an understanding of pharmaceutical residues as hazardous waste. 
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+ Controlled treatment of pharmaceutical waste is performed via high-temperature (1300 °C)  
incineration. 
Areas that need improvement: 
- The pharmaceutical production plants do not have any environmental permits, and their quanti-
ties of the waste types in question are unknown (handling is subject to private contracts). 
- A more detailed database should be available, to aid in analysing waste-management efficiency. 
- There should be more informational materials, for raising of public awareness. 
Uncertainties: 
• Scarcity of data on veterinary medicines makes analyses difficult. 
2.2.5 References 
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2.3 Finland 
Lauri Äystö1, Jukka Mehtonen1, Ville Junttila1 & Terhi Lehtinen2 
1Finnish Environment Institute 
2Finnish Medicines Agency 
2.3.1 Legal basis 
The collection, transport, and disposal of pharmaceutical waste in Finland are regulated by several legis-
lative acts. Among these are the Waste Act, or WA (646/2011); the Narcotics Act, or NA (373/2008); 
and the Act on the Medication of Animals, or AMA (387/2014), along with several decrees issued on 
the basis of these acts. Also, professionals in the pharmaceutical sector are required to comply with reg-
ulations issued by the Finnish Medicines Agency (Fimea), some of which also address handling of phar-
maceutical waste. 
The WA (§6) defines hazardous waste as any waste (whether substance or object) that is flamma-
ble, explosive, infectious, or hazardous to health or the environment, or that has some similarly hazard-
ous property. The European Commission’s list of waste (2014/955/EU) classifies unused cytostatic and 
cytotoxic pharmaceuticals as hazardous waste, while other types of pharmaceutical waste are considered 
non-hazardous. In a national exception, Finland has classified all pharmaceutical waste produced by 
health care institutions and households as hazardous waste, under Annex 4 to the Waste Decree, WD 
(179/2012). Pharmaceutical waste produced by the pharmaceutical industry may be classified as either 
hazardous or non-hazardous, depending on the hazard properties of the waste (concentrations of hazard-
ous substances and other properties). 
The operator is obliged to keep a record of the hazardous waste produced (WA, §118). The WA 
(§28) mandates that, in general, the holder of the waste must arrange its transport and management. In 
an exception to this rule, the reception and management of hazardous waste produced by households 
and reasonable amounts of hazardous waste produced by farming and forestry are to be arranged by the 
local municipality (WA, §32). This is often arranged through a bilateral contract between the municipal-
ity and local pharmacies. Thus, pharmacies are not obliged to arrange the reception of unused pharma-
ceuticals; they do so voluntarily. According to Fimea regulation 2/2016, pharmaceutical waste delivered 
to pharmacies must be handled and stored separately from the pharmaceuticals for sale there, and there 
must exist instructions for handling, storage, and release for transport.  
The municipal waste management regulated by Section 32 of the WA does not cover pharmaceuti-
cal waste streams originating from health care institutions, human or veterinary health care practitioners, 
or the pharmaceutical industry, as these operators are required to arrange their own waste management, 
according to Section 28 of the WA. For instance, veterinarians are obliged to ensure that unused phar-
maceuticals are disposed of appropriately (AMA, §14) and to keep records of the pharmaceuticals dis-
posed of (AMA, §21). It is the veterinarian’s responsibility to deliver expired or otherwise unusable 
pharmaceuticals for hazardous-waste treatment (under the Ministry of Agriculture and Forestry’s decree 
on the use and transfer of medicines in veterinary medicine, MMMa 17/2014, Annex 1; see also the 
WA). Veterinarians also must provide customers with sufficient instructions on storage and disposal of 
pharmaceuticals that are handed over to customers (MMMa 17/2017, Annex 1). The veterinary practi-
tioner/hospital’s records on pharmaceutical waste must specify at least the quantities and generation 
dates for pharmaceutical waste, along with the method of final treatment for the waste (per the Ministry 
of Agriculture and Forestry’s decree on veterinarians’ medical records, MMMa 22/2014, §8). The rec-
ord must be retained for, at minimum, five years, and it must be presented to the competent authorities 
upon request (MMMa 22/2014, §10). 
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According to the NA (§26), narcotic substances must be stored in a separate locked compartment, 
with restricted access. Operators are obliged to deliver all unused narcotics for hazardous-waste treat-
ment (§28). 
According to the WA’s Section 29, waste may only be handed over to a party that holds the envi-
ronmental permits or similar authorisation that the Environmental Protection Act (527/2014) mandates 
for receiving the waste in question. Section 16 of the WA states that hazardous waste must be accompa-
nied by all of the necessary information and must be packaged and marked in a way that allows the 
waste transport to be tracked all the way from the waste originator (excl. households) to final treatment. 
Hazardous-waste streams may be diluted or mixed with other waste only if this is necessary for the 
treatment of that waste and if the operator holds the necessary environmental permits (WA, §17). 
2.3.2 Current take-back practices 
Human-use medicines 
In Finland, all pharmaceutical waste produced by the health care sector and households is classified as 
hazardous waste. Hazardous waste must be collected as a separate waste fraction. Under the Waste Act, 
municipalities are responsible for collection, transportation, and disposal of unused medicines from 
households. It must be guaranteed that the number of collection points for hazardous waste is sufficient 
and that the collection points are easily reachable and information about collection of hazardous waste is 
shared frequently and in sufficient extent. In the vast majority of municipalities, pharmacies act as col-
lection points for unused medicines. At the end of 2017, there were 812 pharmacies in Finland. It should 
be noted that, in practice, all pharmacies in Finland arrange reception of unused pharmaceuticals, de-
spite not having any legal obligation to do this.  
Without charging, the pharmacies voluntarily accept all medicines and mercury thermometers re-
turned by customers. In return for acting as collection points, pharmacies may include their own phar-
maceutical waste with the material collected, without incurring costs. The municipality provides the 
pharmacy with transportation containers for the pharmaceutical waste and transports the waste to a haz-
ardous-waste facility for proper disposal/treatment. The municipalities pay for the transport and treat-
ment of the waste, and the costs are eventually covered by waste-disposal fees collected from the waste 
producers. 
It has been estimated that 3–4% of the medicines sold in Finland (by medicine price, not production 
quantity) goes unused (Association of Finnish Pharmacies 2017). According to a survey conducted by 
Yliopiston Apteekki in 2006, 64% of customers return unused pharmaceuticals to the pharmacies while 
17% dispose of them as mixed household waste and 15% flush them down the drain. About 9% of the 
survey respondents indicated that they did not dispose of medicines in any way. 
In a survey Yliopiston Apteekki carried out in 2009, 9% of Finns admitted to having thrown medi-
cines into mixed waste or flushed them into the sewer system. The reason most commonly given for im-
proper disposal of medical waste was not knowing how to handle it (i.e., not knowing that pharmacies 
take it back for free). Other reasons mentioned in the survey were indifference, being in a hurry, long 
distances to collection points, and the medicine consisting of only a small amount or being thought to be 
harmless. 
In a more recent survey, by the Association of Finnish Pharmacies (Kujala ym. 2016, Salimäki & 
Kujala 2016), the main reasons cited for returning medicines were changes in medication, adverse ef-
fects, and the amount used being smaller than that prescribed. Of all the prescription medicines returned, 
around 50% was returned in the original package, and the amount of returned pharmaceutical waste had 
an estimated worth of 95–125 million euros annually. In addition, it is estimated on the basis of earlier 
studies that about 60–80% (65% in 2010; see Association of Finnish Pharmacies 2010) of unused medi-
cines gets returned to pharmacies. 
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Municipalities are responsible only for management of residential waste and, therefore, not for the 
waste generated at social- and health service facilities or locations such as veterinary clinics. Under the 
legislation in force, each operator has to keep a record of the hazardous waste produced. Pharmaceutical 
waste produced at a health care institution has to be collected and transferred to a hazardous-waste man-
agement plant. For hospitals, the collection and transfer for disposal is usually handled through the hos-
pital pharmacy.  
Per a Fimea ordinance (6/2012), unused medicines from domiciliary care and from supported and 
service housing should be disposed of in a co-ordinated manner by transfer to the pharmacies that pro-
vide medicines for the facility. However, there have been no surveys on the actual waste-management 
practices of the health care institutions. 
Transportation companies collect unused medicines from pharmacies on an as-needed basis or at 
fixed intervals. Waste-transport companies do not accept pharmaceutical waste for which collection is 
not ordered or otherwise subject to contract (Marttila 2018). The transportation company delivers new 
collection containers to the pharmacies at the time of pick-up. 
A study of pharmaceutical waste’s collection from households and public health care (Syrjälä 2012) 
indicated that the pharmaceutical-waste collection system in Finland is of a high standard on interna-
tional scale. Additionally, the collection network is extensive and the waste is appropriately treated. 
Nevertheless, problematic issues were noted. Lack of clarity as to liabilities and instructions were 
sources of dissatisfaction for pharmacies and waste-management companies, with more than half of the 
pharmacies indicating that sorting of pharmaceutical waste took too much time and nearly 70% experi-
encing some difficulties with it. The study showed also that many pharmacies do not have appropriate 
space for storing pharmaceutical waste and that occupational safety hazards are common. One recom-
mendation made in the report is that national instructions on pharmaceutical waste’s collection be cre-
ated. The instructions should specify the liabilities and sorting practices related to the waste’s collection. 
Finally, all relevant actors should be sufficiently informed about these instructions. 
Veterinary medicines 
Municipalities are responsible for organizing the collection of unused veterinary medicines generated 
within households and, in reasonable amounts, in agriculture. Both households and farms are instructed 
to return their unused veterinary medicines to local pharmacies, with the costs of collection and disposal 
covered by municipalities.  
Farmers are obliged to keep records of all medicines given to the animals. The information about 
the medicines used must be recorded in the health care monitoring system. Veterinary practitioners, in 
turn, are obliged to keep a record of the medicines they purchase, allocate, dispose of, and give or order 
to be given to animals. Factories, wholesalers, and pharmacies are obliged to keep records of the thyreo-
static, beta-agonist, oestrogenic, and androgenic veterinary medicines produced, sold, distributed, im-
ported, or used. Wholesalers are required to report their sales of antimicrobials to the Finnish Medicines 
Agency twice a year. 
2.3.3 Current disposal practices 
According to Fimea-issued administrative regulations (Fimea 2016), pharmacies must dispose of cus-
tomers’ unused medicines as medical waste. A suitable space separate from sale-connected storage must 
be allocated for storage of medical waste, and a guide on handling of medical waste must be available. 
Special attention must be paid to preventing the misuse of unused medicines.  
All medical waste must be marked as hazardous waste. In hospitals, all medical waste must be re-
turned to the facility’s pharmacy, where the packages containing medical waste must be sealed and the 
contents recorded. Hazardous waste is to be transferred – in accordance with regulations on the transport 
of hazardous waste – to a hazardous-waste processing plant. In the case of non-household waste, the 
 
28   Reports of the Finnish Environment Institute 34/2020 
holder of the waste is responsible for maintaining the transfer book for transportation of hazardous 
waste. 
Veterinary clinics, health care institutions, etc. are responsible for organising the treatment of haz-
ardous waste in accordance with the applicable waste legislation, at their own expense. These operators 
are instructed to arrange this treatment with waste-management companies that have a permit to receive 
the relevant type of hazardous waste. All pharmaceutical waste is to be disposed of at a hazardous-waste 
incineration plant. 
There are no nationally implemented detail-level instructions on how the personnel at, for example, 
veterinary clinics should dispose of unused medicines. The Finnish Food Authority has instructed veter-
inarians to dispose of pharmaceutical waste as hazardous waste and stated that it is the operators’ re-
sponsibility to ascertain the local practices (there may be variations in the practices’ specifics). 
In Finland, most separately collected pharmaceutical waste is incinerated at Fortum Waste Solu-
tions Oy’s hazardous-waste treatment plant. The transport containers, manufactured either from rigid 
cardboard or from plastics, are incinerated without opening, except in the case of random inspection. 
According to the environmental permit of the plant (permit YSO/119/2007), the temperature of the in-
cineration process in the reel oven has to be above 1050 °C when the halogen concentration (measured 
in terms of chlorine) in the feed material is greater than 1% or unknown. At this temperature, the medi-
cines are disposed of irreversibly (they lose their pharmaceutical properties). Additionally, combustion 
gas is treated via BAT with, for instance, an HCl scrubber and removal of dioxins and mercury via acti-
vated carbon. In practice the temperature is 1 100 – 1 300 °C during incineration (Marttila 2018 & 
Westerholm 2019). To some extent, material in pharmaceutical waste collected separately is exported to 
Sweden and Germany, where the waste is processed in accordance with national requirements. 
2.3.4 Summary 
The main findings on collection, classification, and disposal of unused pharmaceuticals and other waste 
containing pharmaceutical residues in Finland are presented in Table 6. 
Table 6. Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Finland. 
Pharmaceutical 
waste 
Types of phar-
maceuticals 
collected sepa-
rately 
Responsi-
ble party for  
arranging 
reception 
Collection  
point 
Types of pharma-
ceutical waste 
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human 
and companion 
animal medi-
cines from 
households 
All  
pharmaceuticals 
Municipality Usually local 
pharmacies; sel-
dom municipal 
waste collection 
stations (de-
pends on munic-
ipality) 
All Waste 
Act 
32 § 
Mainly high-
temperature in-
cineration 
(1100-1300°C) 
Pharmaceutical 
industry  
(unsalable  
products, API-
contaminated 
wastes, etc.) 
All waste  
classified as 
hazardous 
waste 
Industry  
operator 
To be organized 
by the industry 
operator, some-
times specified 
in environmental 
permit 
Depends on  
hazard properties 
of waste (concen-
trations vs. con-
centration limits of 
hazard classified 
substances) 
Waste 
Act 
28 § 
Depends on the 
classification of 
the waste, 
sometimes 
specified in the 
environmental 
permit of the in-
dustrial plant 
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Pharmaceutical 
waste 
Types of phar-
maceuticals 
collected sepa-
rately 
Responsi-
ble party for  
arranging 
reception 
Collection  
point 
Types of pharma-
ceutical waste 
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Pharmaceutical 
waste from  
hospitals and 
health care  
institutions 
All  
pharmaceuticals 
Hospital or 
health care 
institution or 
municipality 
To be organized 
by the hospital 
or health care  
institution / for 
hospitals usually 
hospital phar-
macy 
All Waste 
Act 
28 § 
Mainly high- 
temperature  
incineration 
(1100-1300°C) 
Veterinary  
medicines from  
veterinarians 
and veterinary  
practices 
All  
pharmaceuticals 
Veterinarian 
or veterinary 
practice 
To be organized 
by the veterinar-
ian or veterinary 
practice 
All Waste 
Act 
28 § 
Mainly high- 
temperature  
incineration 
(1100-1300°C) 
Veterinary  
medicines for 
farmed animals -  
reasonable 
amounts 
All  
pharmaceuticals 
Municipality Usually local 
pharmacies;  
seldom munici-
pal waste collec-
tion stations  
(depends on 
municipality) 
All Waste 
Act 
32 § 
Mainly high- 
temperature  
incineration 
(1100-1300°C) 
Veterinary  
medicines for 
farmed animals -  
unreasonable 
amounts 
All  
pharmaceuticals 
Farmer To be  
organized by  
the farmer 
All Waste 
Act 
28 § 
Mainly high- 
temperature  
incineration 
(1100-1300°C) 
 
The following points were noted with regard to conclusions on the Finnish take-back system and 
Finland’s disposal of unused pharmaceuticals. 
Advantages: 
+ The country’s separate collection based on municipality–pharmacy co-operation appears quite 
efficient (with 60–80% of pharmaceutical waste being collected properly). 
+ There is an extensive network of pharmacies and collection points, making the scheme easy for 
citizens to use. 
+ The system encourages pharmacies’ appropriate disposal of unused medicines, in that pharma-
cies can include their own pharmaceutical waste with the collected waste to be delivered for 
proper disposal and incur no additional costs for this. 
+ Knowledge about the collection system is quite widespread among citizens. 
+ There are no direct costs for the household users, and they do not need to identify themselves 
when returning the medicines to pharmacies. 
+ The treatment of pharmaceutical waste via high-temperature (1100–1300 °C) incineration 
seems efficient. 
Areas that need improvement: 
- There remains some ignorance and lack of information about proper sorting on citizens’ part, so 
continued education and awareness-raising among citizens are needed. 
- Instructions on sorting of waste (iodine-containing waste etc.) are slightly heterogeneous. 
- Unclear liabilities and instructions create dissatisfaction among pharmacies and waste manage-
ment companies. Over half of the pharmacies surveyed indicated that separation of pharmaceu-
tical waste takes too much time, and nearly 70% reported having had some difficulties with it. 
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- The collection of veterinary medicines is not uniformly arranged at veterinary clinics, and infor-
mation on specific collection practices is not reaching veterinary clinics’ personnel. 
- No information is available on the actual amounts of unused pharmaceuticals by mass. 
Uncertainties: 
• Is high incineration temperature of 1100–1300 °C necessary for the irreversible treatment of 
pharmaceutical waste, or would a lower temperature, such as the 850 °C used for household 
waste be suffice? 
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2.4 Germany 
Jan Schütz & Michael Stapf  
Berlin Centre of Competence for Water 
2.4.1 Legal basis 
General waste 
The management of general waste (its collection, transport, and disposal) in Germany is regulated by 
the Waste Management Act, or Kreislaufwirtschaftgesetz, KrWG (2012). The general principle under-
pinning the KrWG is promotion of circular economy (§1). This includes avoidance of waste, appropriate 
waste disposal, recovery, and elimination of waste (§3, Abs. 19–28 ff). The duty to recover and dispose 
of waste follows the ‘polluter pays’ principle (per § 7 and §15). This means that the producer and owner 
of waste must fulfil their obligation of waste’s recycling and disposal, in principle. It is possible to au-
thorise third parties such as service providers, associations, or institutions of the self-governance bodies 
of industry (under § 17 and §22). If producers or owners of waste cannot fulfil their waste-recycling and 
disposal obligation, they have to hand over the waste to the municipal waste-disposal authorities (per 
the same sections of law). 
The KrWG is supplemented by a series of other regulations, which specify and complement the 
terms of the KrWG by means of waste-class lists and waste-monitoring provisions, requirements related 
to waste disposal, operation regulations, product- and production-related regulations, and specifications 
addressing the treatment of sewage sludge and organic waste.  
European regulations such as the European List of Waste (2000/532/EC), or LoW (2000), and An-
nex III to Directive 2008/98/EC are implemented through the Waste Register Ordinance, or Abfallver-
zeichnis-Verordnung (AVV 2017).  
Since June 2005, a requirement has been in place that municipal waste be treated via a mechanical 
biological pre-treatment stage or advanced solid-waste incineration, ASWI (at 850–1300 °C). Hazard-
ous classes of waste are to be treated only by means of hazardous-waste incineration, HWI (at 1000–
1300 °C).  
Pharmaceutical waste from manufacturer facilities is classified as commercial/industrial waste and 
has to be treated at special plants that ensure safe destruction of hazardous compounds (e.g., high-tem-
perature incineration, physico-chemical treatment, or incineration by a power plant). 
Waste from medical and veterinary institutions 
Collection, transport, and disposal of waste from medical and veterinary health care institutions are 
specified by the LAGA guideline document titled ‘Richtlinie über die ordnungsgemäße Entsorgung von 
Abfällen aus Einrichtungen des Gesundheitsdienstes’ (LAGA 2015), which is based on the KrWG and 
the AVV. Following these guidelines is obligatory for the health sector, defined as including human 
medical facilities, the rescue and ambulance services, veterinary facilities, laboratories, and pharmaceu-
tical distributors. 
Hospitals, pharmaceutical manufacturers, and veterinary institutions are obliged to implement a 
waste management system compliant with national regulations (KrWG 2012, AVV 2017) and also re-
gional specifications of these acts and decrees. The operators themselves are responsible for the separate 
collection of the various waste fractions. Consumer-use pharmacies, medical practices, and veterinary 
practices are not obliged to implement a waste-management system, but their hazardous medical waste 
still must be collected and disposed of separately.  
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In general, hazardous waste types such as unused cytostatic and cytotoxic pharmaceuticals have to 
be treated on special incineration sites, whereas non-hazardous classes of waste may be disposed of with 
municipal waste. 
2.4.2 Current take-back practices 
Human-use medicines 
No unified national take-back system for unused pharmaceuticals exists in Germany, and pharmacies 
and pharmaceutical manufacturers are not obliged to take back unused pharmaceuticals. Some pharma-
cies do take back unused pharmaceuticals on a voluntary basis, however, even though they themselves 
have to pay for the disposal. Pharmacies recommend that their customers dispose of unused pharmaceu-
ticals with municipal waste. 
Veterinary medicines 
No take-back system exists for unused veterinary pharmaceuticals. 
2.4.3 Current disposal practices 
Human-use medicines 
In the context of the German national research project RiSKWa, recommendations to customers for 
dealing with unused pharmaceuticals were published on the Internet1. The recommendations are speci-
fied at local level. Disposal is possible via the following options: 
• Inclusion in municipal waste, in locations where municipal waste is incinerated or mechanical
biological treatment is available
• Use of a mobile collection vehicle, through which many municipalities offer disposal of chemi-
cals (incl. pharmaceuticals) at local collection points at regular intervals (the waste is transferred
from the vehicle for incineration or mechanical biological treatment)
• Recycling centres
• Collection at pharmacies
The disposal mechanisms recommended for each of the eight districts of the federal state of Meck-
lenburg-Vorpommern (in the Baltic Sea region) are summarised in Table 7. 
1 http://www.arzneimittelentsorgung.de/ 
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Table 7: The options for disposal of unused pharmaceuticals recommended on the RiSKWa project 
Web site2 (RiSKWa 2018) for the eight districts of Mecklenburg-Vorpommern, in the Baltic Sea region. 
Districts Municipal  
waste 
Mobile collection  
vehicle 
Recycling  
centres 
Pharmacies 
Landkreis Rostock  x x x 
Ludwigslust-Parchim  x   
Mecklenburgische Seenplatte  x  x 
Nordwestmecklenburg x x  x 
Rostock x x x x 
Schwerin x    
Vorpommern-Greifswald  x  x 
Vorpommern-Rügen  x x x 
Veterinary medicines 
According to the German national drug law, or Arzneimittelgesetz (AMG 2017), and the regulation on 
animal-husbandry medicinal products and certification (Tierhalter-Arzneimittelanwendungs- und Na-
chweisverordnung) (THAMNV 2015), farmers and veterinarians are obliged to document all pharma-
ceuticals purchased, assigned, and given to the animals. Farms must have a waste-management system 
in place. Hazardous waste must be collected separately and treated by means of hazardous-waste incin-
eration, while non-hazardous pharmaceutical waste may be disposed of via municipal waste or through 
a contracted service provider. Pet-owners may dispose of their unused pharmaceuticals with municipal 
waste or use the disposal routes recommended for the relevant district. 
Evaluation of behaviour related to disposal of unused human-use medicines 
Information about disposal behaviour related to unused human pharmaceuticals in Germany is scarce. In 
a non-representative study, Zimmer et al. (2000) reported that 71% of respondents return their unused 
pharmaceuticals to the pharmacy while 22% dispose of them with household waste. No information was 
provided on the disposal behaviour of the remaining 7% of respondents. A few years later, Goetz and 
Keil (2007) carried out a representative study that used 2,000 interviews to investigated the extent to 
which consumers in Germany dispose of their unused pharmaceuticals via the toilet and by other means. 
The main research question was this: to what degree have respondents ever disposed of liquid pharma-
ceuticals via the toilet or sink?  
The results of the survey are shown in Table 8. About 43% of the respondents stated that they had 
disposed of liquid pharmaceutics via the toilet or sink, whereas only 16% of them had done the same 
with solid pharmaceutics (e.g., tablets or pills). One possible explanation for this disposal behaviour 
might be found in the high level of willingness to recycle among the German population (Götz 2007). 
Liquid pharmaceuticals are usually sold in plastic tubes or glass bottles, which are often disposed of 
separately from household waste, in line with Germany’s waste-separation system. Hence, consumers 
might send their liquid pharmaceuticals down the drain and then dispose of the plastic tubes or glass 
bottles separately via the common recycling path. Disposal of unused pharmaceuticals at pharmacies 
was an option for about two thirds of the respondents, while disposal along with household waste was 
                                                
2 www.riskwa.de 
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available in recommended form for just under half the respondents (43%). Discarding the items as haz-
ardous or as packaging waste was an option for about 15% and 23%, respectively.  
Within the last few years, pharmaceutical residues in wastewater and drinking water, the (inappro-
priate) disposal of unused pharmaceuticals, and other such topics have been discussed more extensively 
in the media. Therefore, disposal behavior might have changed in the years since Goetz and Keil’s 
study.  
In 2020, a nationwide media campaign whose title translates to ‘Do not flush down the toilet!’ is 
being conducted by the Federal Environment Ministry (BMU) in order to inform citizens not to discard 
unused pharmaceuticals via the toilet or sink. The recommended ways of disposing of unused pharma-
ceuticals are to deliver them to the pharmacies or mobile collection vehicles and to include them in 
household waste3. 
In addition, the Interreg project MORPHEUS4 has increased public awareness of proper disposal of 
unused medicines in Germany, Lithuania, and Poland. 
Table 8: Behaviour identified by Goetz and Keil (2007) with regard to the various pathways for disposal 
of unused pharmaceuticals (multiple answers were possible). 
 
Pharmacies 
[%] 
Household 
Waste  
[%] 
Hazardous 
Waste 
[%] 
Toilet/Sink 
(solid) 
[%] 
Toilet/Sink 
(liquid) 
[%] 
Packaging 
Waste 
[%] 
Yes 28,9 6,5 1,1 1,0 10,2 2,3 
Yes, most 11,0 9,4 1,8 2,1 8,3 3,4 
Yes, sometimes 15,0 14,3 4,1 6,8 13,1 8,2 
Yes, rare 11,4 13,1 7,7 5,8 11,8 9,0 
No 33,7 56,7 85,3 84,3 56,6 77,1 
 
The quantities of unused human and veterinary pharmaceuticals disposed of are recorded only for 
hazardous pharmaceuticals (codes 18 01 08 and 18 02 07). Figure 2 presents the quantities of this type 
of waste disposed of in Mecklenburg-Vorpommern (the country’s Baltic Sea area). 
When the data were gathered, the hazardous pharmaceutical waste from Mecklenburg-Vorpommern 
was treated at facilities outside the region. Detailed breakdowns of the quantities of unused hazardous 
medicines disposed of by pharmacies, hospitals, and households are not available (Mecklenburg-Vor-
pommern 2014). 
                                                
3 http://www.bmu.de/richtigentsorgenwirkt\ 
4 http://www.morpheus-project.eu/dont-flush/ 
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Figure 2. The mass of the hazardous pharmaceuticals disposed of in Mecklenburg-Vorpommern in 
2009–2013 (Mecklenburg-Vorpommern 2014).  
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2.4.4 Summary 
The main findings related to the collection, classification, and disposal of unused pharmaceuticals and 
other waste that contains pharmaceutical residues in Germany are presented in Table 9. 
 
Table 9: Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Germany. 
Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected 
separately 
Responsible 
party for  
arranging  
reception 
Collection 
point 
Types of  
pharmaceutical 
waste  
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human 
and companion 
animal  
medicines from 
households 
Nothing  
separately  
collected 
Municipality Depends  
on the  
municipality 
Cytostatic  
and cytotoxic  
pharmaceuticals 
AAV, 
KrWG 
Mechanical biologi-
cal pre-treatment 
stage, advanced 
solid waste incin-
eration (850-1300 
°C) or high-temper-
ature incineration  
(1000-1300°C) 
Pharmaceutical 
industry  
(unsalable  
products, API-
contaminated 
wastes, etc.) 
All Service  
provider,  
industrial  
operator 
To be  
organized by 
the industry 
operator 
All unsalable  
products, API- 
contaminated 
wastes, etc. 
LAGA, AAV 
KrWG, 
AMG 
High-temperature 
incineration (1000-
1300 °C), physico-
chemical treatment, 
or incineration in 
power plants. 
Pharmaceutical 
waste from  
hospitals and 
health care  
institutions 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Hospital,  
service  
provider 
To be  
organized by 
the hospital 
or health 
care  
institution 
Cytostatic  
and cytotoxic  
pharmaceuticals 
LAGA, AAV 
KrWG, 
AMG 
Hazardous waste: 
High-temperature 
incineration (1000-
1300 °C).  
Non-hazardous 
waste: Mechanical 
biological pre-treat-
ment stage or an 
advanced solid 
waste incineration 
(850-1300 °C). 
Veterinary  
medicines from 
veterinarians 
and veterinary 
practices 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Veterinarian  
or veterinary 
practice,  
service  
provider 
To be orga-
nized by the 
veterinarian 
or veterinary 
practice 
Cytostatic  
and cytotoxic 
pharmaceuticals 
AAV, 
KrWG, 
AMG, 
THAMNV 
See above Pharma-
ceutical waste from 
hospitals and health 
care institutions 
Veterinary  
medicines for 
farmed animals  
- reasonable 
amounts 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Municipality, 
service  
provider 
Usually local 
pharmacy 
(depends  
on the  
municipality) 
Cytostatic  
and cytotoxic 
pharmaceuticals 
LAGA, 
AAV 
KrWG, 
AMG, 
THAMNV 
See above Pharma-
ceutical waste from 
hospitals and health 
care institutions 
Veterinary  
medicines for 
farmed animals - 
unreasonable 
amounts 
Cytostatic  
and cytotoxic 
pharmaceuticals 
Farmer,  
industrial  
operator 
To be  
organized by 
the farmer 
Cytostatic  
and cytotoxic  
pharmaceuticals 
LAGA, AAV 
KrWG, 
AMG, 
THAMNV 
See above Pharma-
ceutical waste from 
hospitals and health 
care institutions 
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The following points were noted with regard to Germany’s system for take-back and disposal of 
unused pharmaceuticals, in conclusion. 
Advantages: 
+ Recommendations for customers on how to dispose of unused pharmaceuticals correctly are 
available from the Web site http://www.arzneimittelentsorgung.de/. 
+ Ever since the KrWG amendment entered force in 2005, municipal waste must be treated by 
means of a mechanical biological pre-treatment stage or advanced solid-waste incineration 
(850–1300 °C), whereas hazardous waste-fractions (e.g., cytostatic and cytotoxic pharmaceuti-
cals) always have to be disposed of via hazardous-waste incineration (1100–1300 °C). 
+ Waste streams from pharmaceutical production are regarded as commercial/industrial waste, 
which is, for the most part, classified as hazardous waste. Pharmaceutical waste generated by 
manufacturers has to be treated at special plants that ensure safe destruction of hazardous com-
pounds (e.g., high-temperature incineration, physico-chemical treatment, or incineration at a 
power plant). 
Areas that need improvement: 
- No unified national take-back scheme for unused pharmaceuticals exists (e.g., at the level of 
pharmacies or recycling boxes at grocery stores).  
- Pharmacies are not obliged to take back unused pharmaceuticals. While some of them do so on 
a voluntary basis, they have to pay for the disposal themselves. 
- Consumers’ awareness related to proper means of disposing of their unused pharmaceuticals 
should be increased. 
Uncertainties: 
• No recent data have been available on German people’s disposal behaviour since the study by 
Goetz and Keil (2007). Since topics such as pharmaceutical residues in wastewater and drinking 
water but also, more directly, (inappropriate) disposal of unused pharmaceuticals have received 
more media attention in the last few years, disposal behaviour might have changed. 
• No data on the amount of unused pharmaceuticals disposed of, either from human or from vet-
erinary usage, are available for Germany. 
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2.5 Latvia 
Anete Kublina & Ieva Karkovska 
Latvian Environment Research Centre  
2.5.1 Legal basis 
According to Cabinet Regulation 302, of 19.4.2011, waste that includes cytotoxic and cytostatic phar-
maceuticals is classified as hazardous waste. This includes 
• cytotoxic and cytostatic pharmaceutical waste originating from human health care activities 
(class 18 01 08), 
• cytotoxic and cytostatic pharmaceutical waste originating from veterinary activities (class 18 02 
07), and  
• separately collected cytotoxic and cytostatic pharmaceutical waste (class 20 01 31). 
Other types of pharmaceutical waste, such as those belonging to waste classes 18 01 09, 18 01 08, 
18 02 08, and 18 02 07 (please see Appendix 1 for the waste classes), are not classified as hazardous 
waste. Chapter 20 of the Cabinet Regulation “Domestic waste (household waste and similar waste from 
commercial and industrial enterprises and institutions), including separately collected waste types” spec-
ifies which types of waste are to be collected separately: cytotoxic and cytostatic pharmaceuticals (class 
20 01 31) and other pharmaceutical waste (class 20 01 32). 
The Waste Management Law’s Section 16 provides that the initial producer or holder of municipal 
waste shall cover all costs related to the management of that waste, inclusive of municipally produced 
hazardous waste. Section 8 states that a local government in its administrative territory, in conformity 
with the binding regulations of the local government regarding management of municipal waste, taking 
into account the State waste management plan and regional plans, shall organize the management of all 
municipal waste, including municipally produced hazardous waste.  
The actions presented in the State Waste Management Plan for 2013–2020 are related to those types 
and streams of medical waste regarded as hazardous waste, including medical treatment waste and 
waste from practising veterinary medicine. Under the plan, medical treatment facilities and veterinary 
medical practices must provide separate collection, packaging, labelling, and storage of hazardous 
waste. Medical institutions and veterinary medical practices may themselves stabilise separately col-
lected hazardous waste and prepare it for final treatment. The majority of hazardous waste generated at 
medical institutions and veterinary medical practices is managed by waste-management companies spe-
cialising in the management of hazardous waste. No take-back scheme for pharmaceuticals from resi-
dents or animal-owners is specified in the State Waste Management Plan.  
A good example of the regulation of waste management at municipal level can be found in the City 
of Riga’s binding regulations of 17.12.2013 on municipal waste management. In Chapter IV (‘Obliga-
tions of the household waste holder’), point 17 stipulates that it is prohibited to place hazardous waste 
and infectious waste in waste tanks. The city’s binding regulations contain no rules for the take-back of 
pharmaceutical waste at pharmacies or special collection points, but there are take-back-related require-
ments published on the Web pages of the Department of Housing and Environment, under Riga City 
Council jurisdiction. In the section ‘Waste management’, the online materials state that household phar-
maceutical waste should be taken to pharmacies. This rule applies to pharmaceuticals that have expired 
or are not being used; aerosol packaging; sharp objects such as syringes, needles, and scalpels; and mer-
cury thermometers.  
In Latvia, pharmaceutical waste from medical treatment institutions, social-care institutions, and 
distributors of human medicinal products is classified as hazardous waste, as specified in these regula-
tions: 
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• Cabinet Regulation 220, of 27.3.2007, prescribes the procedures by which medical treatment 
institutions and social-care institutions shall acquire, store, and use medicinal products and dan-
gerous psychotropic substances that may be abused and are specified by Register III of narcotic 
substances, psychotropic substances, and precursors as to be controlled in Latvia. It also sets 
forth the procedures by which narcotic and psychotropic substances shall be registered and dis-
posed of.  
• Cabinet Regulation 416, of 26.6.2007, prescribes the procedures for such operations as the dis-
tribution and quality control of medicinal products (except veterinary medicinal products). The 
collection and disposal of unused medicines must be arranged in accordance with the regula-
tions pertaining to hazardous waste. The same applies to the disposal of medicaments that are 
not suitable for distribution. 
• Cabinet Regulation 353, of 22.5.2012, dictates that low-quality or unsuitable medicines that are 
not returned to suppliers belong to either hazardous waste or waste handled as hazardous waste. 
This applies also for waste from cytotoxic and cytostatic medicinal products. 
With respect to waste from veterinary medicinal products, there are no specific requirements in 
place for smallholdings or for owners of companion animals. Their unused veterinary medicines fall un-
der general waste-management legislation. Latvian regulations assign medicine waste from veterinary 
medical practice institutions the category of hazardous waste and that from ‘large productive animal 
holdings’ the category of general waste: 
• Cabinet Regulation 768, of 10.9.2013, sets requirements related to the handling of veterinary 
waste, including unused veterinary medicines. Its point 9.2 states that ‘veterinary medical waste 
is collected and disposed of in accordance with the regulations regarding the management of 
hazardous waste’. 
• Cabinet Regulation 326, of 31.5.2016, sets forth requirements for the distribution and control of 
veterinary medicinal products in large productive animal holdings. According to this regulation, 
veterinary medicinal products not issued or not used are to be disposed of in accordance with 
regulations regarding waste management (per point 19.4). 
• Cabinet Regulation 1456, of 15.12.2009, specifies in its Chapter IV (‘Procedures for the de-
struction of narcotic and psychotropic medicines’) that the primary packaging of insufficient-
quality narcotic medicines and psychotropic medicinal products and of used medicines shall be 
destroyed or handed over for disposal in accordance with the waste-management legislation. 
• Cabinet Regulation 258, of 5.4.2011, states in its Chapter II (‘Procedures for the purchase and 
storage of medicinal products’), under point 10, that the veterinary medical care institution and 
the practising veterinarian submits non-quality or unused medicinal products and primary pack-
aging for used medicines for disposal in accordance with the requirements of regulations on 
waste management’ 
2.5.2 Current take-back practices 
Human-use medicines 
Some of Latvia’s pharmacies accept unused medicine but doing this is not an obligation. Under Latvian 
legislation, medical treatment institutions and social-care institutions are obliged to deliver unused med-
icine to an operator holding a permit to manage hazardous waste. Residents are to return unused medici-
nal products to pharmacies, special disposal sites, or hazardous-waste sorting sites voluntarily. Only 
some medicine-related waste is considered hazardous waste. 
A representative of the Ministry of Environmental Protection and Regional Development of Latvia 
has explained that the Ministry of Health takes the position that any additional requirements for pharma-
cies, for example, to ensure the collection and further management of medicinal products not suitable 
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for use would lead to an increase in prices of medicines. This was cited as the reason for the lack of such 
mandatory terms in the country’s legislation (Bierande 2011). 
Veterinary medicines 
Under the legislation mentioned in the previous section, large animal holdings are required to deliver 
their unused medicine to an operator with a permit to manage hazardous waste.  
The Food and Veterinary Service of Latvia controls veterinary medical-practice institutions and 
large productive animal holdings. This body controls the storage of veterinary medicine that is not suita-
ble for use and the primary packaging of used medicine and these materials’ delivery to hazardous-
waste managers. Such waste is not controlled at the level of individual households (Survey of Food and 
Veterinary Service of Latvia, 2018). 
Take-back practices 
Human-use medicines 
In all member states of the EU, Latvia being no exception, unused medicines may be delivered to phar-
macies or special collection points for hazardous waste. However, the process is not an organized one in 
Latvia, and not all pharmacies accept them. This is not a duty that pharmacies are required to fulfil – it 
is a matter of the free will of each pharmacy. The disposal of unused medicine creates additional costs 
such as those for a contract with a hazardous-waste manager, which entity must be licensed – and this is 
not an inexpensive service. 
Veterinary medicines 
Residents can bring unused veterinary medicinal products to the same pharmacies where unused medici-
nal products intended for human use are returned or to special collection points for hazardous waste. 
Veterinary medicines should be prepared for hand-over in the same way as unused human-use medicinal 
products: the outer carton from the package should be removed, and the tablets, bottles, ampoules, gel 
tubes, etc. must be placed in a plastic bag.  
As for veterinary pharmacies and practices, there are no provisions for hand-over of unused medici-
nal products in place. 
Evaluation of the take-back practices 
Human-use medicines 
Research was conducted in 2012 to assess household medicine waste (Menise 2012).  The results of that 
survey indicate that 62% of respondents had expired, leftover, or otherwise unwanted medicines at 
home. According to the statistics reported from the survey, 
• only 5% of respondents actually bring such medicines to pharmacies; 
• 1% of respondents bring such medicine to special hazardous-waste disposal sites; 
• most respondents (41%) discard unwanted medicines via household rubbish; 
• 12% flush unwanted medicine down the toilet; 
• 33% of respondents continue storing medications at home after the expiry date, just in case; and 
• 8% do not have pharmaceuticals at home. 
Statistics are available from one network of pharmacies that cover the total amount of returned 
medicines delivered for disposal. The EURO Aptieka pharmacy network (with 40 pharmacies in total) 
concluded an agreement with special hazardous-waste management company BAO SIA, and the associ-
ated data provided on the chain’s Web site indicate that, on average, they collect 10 kilograms of 
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expired medicine per month at each of their pharmacies in Riga and around five litres at each pharmacy 
in other areas.  
In 2014, Latvia’s society of pharmacists arranged a campaign with the theme of taking ‘invalid’ 
medicines back to pharmacies. The campaign, which was very enthusiastically supported by pharma-
cies, was designed with the goal of educating people and informing them about how to get rid of unnec-
essary medicines properly. It was financially supported by the Latvian Environmental Protection Fund. 
The campaign involved around 600 pharmacies, and it included displaying posters and distributing in-
formative materials and bags for the transfer of unused medicines to pharmacies. In the opinion of the 
Latvian Environmental Protection Fund, the number of people who are aware of the problem and of the 
correct way of behaving in response is still small, however. No single project can resolve the situation; 
long-term education and awareness-raising is needed. The situation requires interest on the part of all 
key players in the industry and demands sufficient motivation to mitigate the problem.  
In 2014, the NGO Health Projects for Latvia carried out a study examining residents’ awareness of 
the possibilities related to disposal of medicinal products and surveying their habits. This study (Prola 
2017) found that 
• the majority of respondents (62%) discard unwanted medicines with general rubbish, 
• only 10% of respondents in Latvia take unnecessary medicines back to pharmacies or discard 
them in suitable containers, 
• 17% of respondents continue to store medicine at home, 
• 5% of respondents flush medicine down the toilet, 
• 4% of respondents burn medicine, and 
• 2% of respondents gave some other response related to their behavior.  
The main reason for the low proportion of correctly discarded medicines is a lack of information: 
60% of respondents admitted to not being aware of how to get rid of medicines properly. The second 
major reason is lack of motivation – not thinking about the consequences or believing that their behav-
ior does not harm the environment. 
Health Projects for Latvia recommends highlighting information about the negative impact on the 
environment, getting people motivated not to discard unused medicines as municipal waste, and encour-
aging them to use medicines rationally and not to buy unnecessary ones.  
As part of an analysis-oriented survey (Purmale 2018), an experiment was done on the ways in 
which invalid medicines are accepted by pharmacies. Twelve pharmacies, in the pharmacy groups 
Mēness Aptieka, Saules Aptieka, and BENU, were examined. The results indicate that the ways in 
which medicines are accepted differ even within the same pharmacy network, with pharmacies vari-
ously 
• leaving the medicine in its blister pack after removing it from the cardboard box; 
• leaving the medicine in the blister pack after taking it out of the cardboard box, then putting the 
blister pack in the plastic bag for collection; 
• leaving the medicine in its full package; and 
• separating the tablets from the solutions, squeezing doses out of blister packs, and placing the 
solutions and solids in separate plastic bags. 
During this research, Purmale’s team asked some residents whether they were aware of the possibil-
ity of taking unused medicines back to pharmacies. Three of the four people interviewed indicated that 
they knew about this possibility, but two of those three did not do so, because it consumes time, energy, 
and resources or because of living in the countryside where such options are not available. The people 
who did not bring medicines to pharmacies stated that they get rid of them by discarding or burning.  
Purmale (2018) also referred to a statement by the State Environmental Service of Latvia. In this 
opinion, the agency stated that bringing unused medicines back to pharmacies is sufficient and ensures 
their further processing. In addition, Purmale presented some fresh statistics for the medicines that have 
been taken back to pharmacies, comprising 
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• in total, 100 kg a month for the BENU pharmacies and 
• 1,5 kg in the first six months of 2018 (250 kg/month) for the Apotheka pharmacy network. 
General information about domestic hazardous waste is provided via the online portal Atkritumi5. 
The requirements addressing how medicines should be delivered to pharmacies are summarised thus: 
• Tablets should be taken out of their cardboard packaging, and foil blister packs should all be 
placed in a single plastic bag. 
• Ampoules should be removed from their cardboard packaging. 
• Syrups and drops are to be removed from the cardboard packaging. 
• Mercury thermometers should be placed in a water-filled glass container that is closed with a 
metal lid. 
In the CWPharma project, LEGMC reviewed the way information is made available online about 
the possibility of bringing unused medicines back to pharmacies and calculated the proportion of phar-
macies where this is possible. 
Medical waste is generated at medical treatment institutions, by pharmaceutical producers, and at 
veterinary institutions, as well as by residents. Medical waste includes expired and unused drugs, spray 
bottles, sharp tools (syringes, needles, and scalpels), and mercury thermometers. This waste is hazard-
ous on account of its specific biological activity. For instance, unused medical preparations in combina-
tion with other waste may cause toxic compounds to develop, and they may be harmful to the environ-
ment.  
The Atkritumi portal provides information about where in Latvia one can hand over invalid medica-
tion and mercury thermometers for further processing (see Figure 3), with information available for the 
EURO Aptieka and Mana Aptieka networks and on the BAO waste-collection points. When the user 
clicks on any of the locations marked on the map shown, information is displayed about the relevant 
company’s Web site, its physical address, and what kind of waste can be handed over. For most loca-
tions, there is a phone number provided and there are guidelines on how to prepare the medicines for 
hand-over. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The portal’s presentation of hazardous-waste disposal points (marked in red)  
and waste-sorting locations (marked in blue) in Latvia. Map data ©2020 Google. 
                                                
5 https://www.atkritumi.lv/lv/karte/sadzive-radusies-medicinas-atkritumi/ 
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There are four waste-sorting locations in Latvia, all of which are in the Riga region. These are in 
Riga, Olaine, Rumbula, and Kekava parish (Figure 3). Residents can hand over invalid medicines at any 
of these sorting facilities.  
There are five networks of large pharmacy companies in Latvia and a few smaller pharmacies. 
There are 350 pharmacies of different owners (independent pharmacies). The total number of pharma-
cies in Latvia in 2010 was 945, but the figure had fallen to 899 at the beginning of 2017. It should be 
noted that there are still regions of Latvia without any pharmacies.  
In 2010, 60% of the country’s pharmacies were independent and the other 40% belonged to a com-
pany network. The figures were reversed by 2017: 60% of pharmacies were part of networks while 40% 
remained independent (Spakovska 2017). 
The information available on the Internet indicates that Latvia has 334 pharmacies where people 
may hand over invalid medicines. These medicines may be turned in to a pharmacist or discarded in 
special containers at the pharmacies.  
Medicines become invalid for many reasons. They expire; there is no longer an obvious use for 
them; the name of the product is not readable or the packaging is damaged; the products were improp-
erly stored; or the look, smell, or taste of the medicine has changed.  
Availability of information via pharmacy Web sites: 
• The EURO Aptieka Web site suggests handing over invalid medicines to the chain’s pharma-
cies and gives information on how the medicines should be prepared for hand-over. There is no 
information on which pharmacy residents can visit to hand in the invalid medicines.  
• On the Web site for a. Apotheka, users can easily find information indicating which pharmacies 
they can visit to turn in their invalid medicines.  
• On the BENU Aptieka company Web site, one can readily find information about the pharma-
cies where invalid medicines can be handed over.  
• For Mēness Aptieka, the Web site lets the user easily find information about which pharmacies 
permit hand-over of invalid medicines.  
• For Aptieku Alianse, the company Web site presents easily findable information about the phar-
macies at which invalid medicines can be handed over.  
No information on where to hand over invalid medicines could be found on the company Web sites 
of the Saules Aptieka, Latvijas Aptieka, or Mana Aptieka pharmacies. 
For each network, Table 10 presents the total number of pharmacies in Latvia and the number of 
pharmacies where invalid medicines can be handed over. 
Table 10: A summary of Latvia’s pharmacies and the related disposal opportunities. 
Pharmacy network Number of pharmacies  
in Latvia 
Number of pharmacies where invalid 
medicines can be handed over 
a. Apotheka 114 114 
BENU aptieka 74 67 
EURO aptieka 50 50 
Mēness aptieka 221 71 
Latvijas aptieka 66 66 
Mana aptieka 95 33 
Aptieku alianse 42 31 
Saules aptieka 3 1 
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The Web site of waste-management company Lautus states that they co-operate with the a. 
Apotheka and BENU pharmacy companies in the management of invalid medicines.  
Several interest groups and actors in the management of unused medicines and other medical waste 
have offered opinions on the matter. The Pharmaceutical Advisory Board of Latvia maintains that fi-
nancing for the management of medical waste should come not from the pharmacies but from sources 
such as other parties involved, such as municipalities, the state, the pharmaceutical industry, and phar-
maceutical wholesalers. The board concluded that the contribution from pharmacies should be non-fi-
nancial (Pharmaceutical Advisory Board meeting of 23.3.2016). The opinion of the Latvian Pharmaceu-
tical Wholesalers´ Association is that the collection of invalid medicines could be optimised via their 
transfer to pharmaceutical wholesalers and onward to a waste-management company (Pharmaceutical 
Advisory Board meeting of 23.3.2016).  
The opinion of the Ministry of Environmental Protection and Regional Development of Latvia, 
meanwhile, is that Latvian legislation is developed in accordance with EU legislation, under which med-
icines are not primarily classified as hazardous waste. The ministry stresses that medicines should be 
prescribed and used rationally, for avoidance of households’ accumulation of invalid medicines. Under 
Latvia’s waste-management laws, the municipalities are responsible for organising the collection of mu-
nicipal waste in their territory. The fee for managing certain categories of waste could be included in the 
service’s total cost to municipalities and cover the expenses incurred by pharmacies, which could then 
conclude contracts with waste managers. The cost should include both waste collection and processing. 
In contrast, increasing natural-resources tax is not a good solution, according to the ministry, because it 
would increase medicine prices. In the Ministry of Health’s opinion, it is necessary to draw a distinction 
between household waste and other medical waste – e.g., waste from the pharmaceutical industry, hos-
pitals, and other health care institutions (Pharmaceutical Advisory Board meeting of 23.3.2016). 
Veterinary medicines 
There is no information available on the quantities of invalid veterinary medicines handed in at pharma-
cies or taken to waste-sorting facilities. In Latvia, there is no requirement to specify what kinds of medi-
cines one is returning to a pharmacy or taking to a waste-sorting location. 
2.5.3 Current disposal practices 
Companies specializing in the management of hazardous waste are responsible for disposal of unused 
medicines after the waste-producing operators have transferred the waste to them. Hazardous-waste 
management companies must have a permit for polluting activity of this type (Law on Pollution; Cabi-
net Regulation 1082, of 30.11.2010).  
Medicines are burned in high-temperature hazardous-waste incinerators so that pollution of the en-
vironment (including water) is avoided. Hazardous waste produced in Latvia is incinerated in Estonia 
(Gulbinska et al. 2017). 
There are two main companies that manage medical waste in Latvia. They are described below. 
BAO covers the full spectrum of medical-waste management services in Latvia, and it owns the 
hazardous waste storage site in Gardene. According to its permit for category-A polluting activity, the 
company imports, recycles, and passes on both cytotoxic and cytostatic human and veterinary unused 
medicines and other types of unused human and veterinary medicines (waste classes 18 01 08, 18 01 09, 
18 02 07, 18 02 08, and 20 01 32; see Appendix 1). They are passed on and transported in suitable con-
tainers. According to statistical report “3-Waste”, BAO transfers non-cytotoxic and non-cytostatic hu-
man medical waste (class 18 01 09) to Tartu, Estonia, conveying it to the company Epler & Lorenz. Ac-
cording to the Epler & Lorenz Web site, the company incinerates pharmaceutical waste in a process that 
is strictly controlled, to reduce harmful emissions. 
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Lautus is a limited-liability company that manages various types of medical waste, including inva-
lid medication. The company provides collection and short-term storage for all types of pharmaceutical 
and medicine waste (waste classes 18 01 08, 18 01 09, 18 02 07, 18 02 08, 20 01 31, and 20 01 32; see 
Appendix 1). Unsorted medical waste collected from medical institutions is sterilized, after which recy-
clable waste – plastic, glass, and metal – is manually separated. Cytotoxic and cytostatic drugs are not 
subject to sterilization. Separately collected non-cytotoxic and non-cytostatic pharmaceuticals (waste 
class 20 01 32) are cracked at a Vecoplan plant and transported to the Getliņi landfill. The terms of the 
company’s permit include a requirement from the State Environmental Service to manage medication 
after the storage or cracking process in accordance with the Basel Convention methodological guide-
lines for the environmentally safe management of biomedical and health care waste. The activities of 
Lautus are considered to be an interim recovery operation, which must in all cases be followed by an 
appropriate final operation such as incineration per the methodological guidelines. 
In the course of the CWPharma project, LEGMC reviewed how much waste of classes directly re-
lated to medicines (18 01 08, 18 01 09, 18 02 07, 18 02 08, 20 01 31, and 20 01 32) is created, collected, 
imported, exported, disposed of, and recycled by means of ‘3-Atkritumi’ statistical reports. The results 
are presented in Figure 4. There are no summary statistics for other medicinal waste under code 18 – 
such as used syringes and nappies – in connection with which API pollution is commonplace. Statistics 
for cytotoxic and cytostatic pharmaceuticals for human use (class 18 01 08) are available only from 
2016 (1 kg collected) and 2017 (3 kg collected). Statistics for other types of medicines for human use 
(class 18 01 09), in contrast, can be found for a span of several years for the waste created, collected, 
exported, disposed of, and recycled. On average, the amount of non-cytotoxic and non-cytostatic human 
medicaments medicines from human health care institutions in 2011–2017 came to 
• 5.8 t of waste generated, 
• 54 t of waste collected, 
• 0.6 t of waste exported, 
• 47 t of waste disposed of, and 
• 23 t of waste pre-treated for recycling and recovery. 
Figure 4. Waste in medicine-related classes that was created, collected, imported, exported, disposed 
of, and recycled in 2011–2017. 
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The exported waste was incinerated in Estonia (4% of the waste of class 18 01 09 collected in Lat-
via, per data for 2017). All other waste of class 18 01 09 collected is delivered to municipal landfills af-
ter shredding. Waste of class 18 01 06 (filter residues) also contains APIs; in 2017, the amount of this 
waste collected was 26.3 t, of which exported waste (sent for incineration) accounted for 7.1 t.   
Statistics for waste in class 18 01 09 (non-cytotoxic and non-cytostatic human medicines) are re-
ported from human health care institutions, pharmaceutical and chemical companies, prisons, and nurs-
ing homes. 
Appendix 2 provides more information on the medicine-waste study carried out by LEGMC within 
the framework of the CWPharma project. 
2.5.4 Summary 
The main findings related to collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Latvia are presented in Table 11. 
Table 11: Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Latvia. 
Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection 
point 
Types of 
pharmaceuti-
cal waste 
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human 
and companion 
animal  
medicines from 
households 
All  
pharmaceuticals 
Municipality / 
state for  
hazardous 
types of waste 
Usually  
local  
pharmacy  
or waste 
sorting area 
Cytotoxic and  
cytostatic  
medication 
Waste  
management 
law, section 
16, p.2,  
section 8, p.1 
Incineration at  
850 °C or waste 
disposal at mu-
nicipal landfill af-
ter shredding – 
for taken-back  
medicines 
Pharmaceutical 
industry  
(unsalable  
products, API-
contaminated 
wastes, etc.) 
All  
pharmaceuticals 
Industry  
operator 
To be  
organized by 
the industry 
operator 
Cytotoxic and  
cytostatic  
medication;   
API pollution is 
common also 
for waste class 
of residues of 
filter, that is 
hazardous 
waste 
Cabinet  
Regulation of 
26.06.2007. 
Nr. 416,  
p. 144 
Incineration at  
850 °C (waste of 
class 180106) / 
waste disposal at 
municipal landfill  
after shredding 
(waste of class 
180109) 
Pharmaceutical 
waste from  
hospitals and 
health care  
institutions 
All  
pharmaceuticals 
Hospital or  
institution 
To be orga-
nized by the  
hospital or 
health care 
institution 
Cytotoxic and 
cytostatic 
medication 
Cabinet  
Regulation of 
22.05.2012. 
Nr. 353, p. 3 
Waste  
management 
law, section 17 
Waste disposal 
at municipal 
landfill  
after sterilization, 
shredding 
Veterinary  
medicines from 
veterinarians 
and veterinary 
practices 
All  
pharmaceuticals 
Veterinarian or 
veterinary 
practice 
To be orga-
nized by the 
veterinarian 
or veterinary 
practice 
Cytotoxic and 
cytostatic 
medication 
Cabinet  
Regulation of 
10.09.2016 
Nr. 768, p. 9.2. 
Waste disposal at  
municipal landfill  
after sterilization, 
shredding 
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Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection 
point 
Types of 
pharmaceuti-
cal waste 
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Veterinary  
medicines for 
livestock - 
reasonable 
amounts 
All  
pharmaceuticals 
Farmer To be  
organized by 
the farmer 
Cytotoxic and 
cytostatic 
medication 
Cabinet  
Regulation of 
31.05.2016. 
Nr. 326, p. 
19.4 
Waste disposal at 
municipal landfill 
after sterilization, 
shredding 
Veterinary  
medicines for 
livestock - 
unreasonable 
amounts 
All  
pharmaceuticals 
Municipality / 
state for  
hazardous 
types of waste 
Usually local 
pharmacy or 
waste sorting 
area 
Cytotoxic and 
cytostatic 
medication 
Waste  
management 
law, section 
16, p.2,  
section 8, p.1 
Incineration at  
850 °C or waste 
disposal at munici-
pal landfill after 
shredding –  
for taken-back 
medicines 
 
In conclusion, the following points were noted with regard to the take-back system and the disposal 
of unused pharmaceuticals in Latvia. 
Advantages: 
+ Pharmacies are quite active in ensuring take-back of invalid medicines (67% of pharmacies en-
sure it), although they have no obligation to do so. 
+ Waste from medical treatment institutions (waste in all ‘18’ classes) is delivered to hazardous-
waste collection points. After sterilisation and shredding, the materials are unable to spread in-
fections and are safe with regard to uncontrolled consumption by humans, birds, or other ani-
mals. 
Areas that need improvement: 
- Residents’ level of information is low with regard to the possibility of bringing unused medi-
cines back to pharmacies (10% of residents availed themselves of this opportunity in 2014). 
- A large proportion of invalid medicines from pharmaceutical wholesalers and manufacturing 
companies is delivered to landfills for municipal waste after shredding at hazardous-waste col-
lection points, thanks to clear labelling – it is unambiguous that the material is not to be classi-
fied as hazardous waste. Roughly 96% of waste from class 18 01 09 was delivered to landfills 
for municipal waste in 2017 after shredding. 
- Improvements are needed in gathering of waste statistics, to reveal the amount of waste that res-
idents return to pharmacies. Waste managers should label medicine waste from pharmacies with 
code 20 01 32 (not 18 01 09 as before). Corresponding improvements are needed for veterinary 
waste of class 18 02 08. 
Uncertainties: 
• It is impossible to obtain information about waste or medicines from veterinary pharmacies and 
veterinary-medicine institutions, and same is true for farmers. 
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2.6 Lithuania 
Ville Junttila1 & Sergej Suzdalev2  
1Finnish Environment Institute 
2Klaipėda University 
2.6.1 Legal basis 
According to the Lithuanian Law on Pharmacy (No. X-709, of 22 June 2006), pharmaceutical waste is 
defined as medicinal products that are subject to disposal and chemical materials either used in imple-
mentation of trials for medicinal products or that are defective / past their expiry date and were acquired 
for the purpose of conducting such trials. 
The same law specifies that ‘pharmaceutical waste shall be collected from the residents and phar-
maceutical waste holders, managed and paid for according to the procedure established by the Govern-
ment. The management of pharmaceutical waste collected from the residents shall be paid for from the 
State budget’. 
Requirements for the management of veterinary medical waste (approved by an order of the direc-
tor of the State Food and Veterinary Service) establishes procedures for sorting, packaging, labelling, 
initial processing, temporary storage, and accounting for veterinary medical waste in Lithuania. 
In Lithuania, medical waste must be collected as a separate category of waste and treated in accord-
ance with waste-management regulations. 
2.6.2 Current take-back practices 
All pharmacies are obligated to accept unused and expired medicines and pass them to a waste manage-
ment organization established by the government. Specialist organizations carry out the transport and 
disposal of pharmaceuticals, which is financed by the local government (CCB 2017). 
The hazardous-waste managers (enterprises holding a license to collect and dispose of hazardous 
waste, including unused medicines) are entities selected by the Lithuanian Ministry of Health in accord-
ance with established public-procurement procedures. 
Pharmacies must document the medicines collected not later than the next working day after their 
collection. The following information is registered in the journal: the date, the type of waste received, 
the code (per the Waste Management Regulations and European Waste Codes (EWC) classification), 
and the weight (CCB 2017). 
The government is responsible for the financing of the system, but, because the roles of the various 
institutions remain unclear, the pharmacies are currently paying the costs for disposing of the unused 
medicines collected. Therefore, pharmacies do not actively distribute information on their obligation to 
receive unused medicines. In interviews conducted in 2013, more than 60% of the subjects stated that 
they did not remember having received information about the correct ways of disposing of pharmaceuti-
cals. (HCWH 2013) 
According to an interview-based study (HCWH 2013) carried out in 2013, 54% of participants were 
aware of the possibility of returning unused and expired medicines to pharmacies or hazardous-waste 
collection sites. Only 10–13% of subjects indicated that they did return unused medicines to these col-
lection points, while 50–64% discarded medicines by throwing them in the rubbish bin (HCWH 2013). 
In 2007, 73% of survey respondents reported not knowing that pharmacies would take back medicines 
and 50–80% stated that they indeed throw unused medicines away with standard rubbish (Kusturica et 
al. 2016). 
The quantities of unused medicines collected by the hazardous-waste management authorities are 
officially reported annually by the Lithuanian Environmental Protection Department (see Table 12). 
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There are no official statistical data on the amount of unused medicines flushed into the sewers 
and/or discarded with municipal waste. 
Table 12: Amounts of unused medicines (in tons) collected by the hazardous-waste management 
operators in Lithuania. 
Waste name 
(code) 
Year Collected and 
generated 
Exported Incineration 
(R1) 
Incineration 
(D10) 
D8, D9, 
D14, R12 
Chemicals consisting of or  
containing hazardous  
substances 
(18 01 06) * 
2014 29   29 2,9 
2015 34  13 26 0,4 
2016 60   62 1,6 
2017 35   43 2,0 
Chemicals other than those  
mentioned in 18 01 06 
(18 01 07) 
2014 0,44     
2015 0,70  0,096 0,28  
2016 0,64   0,77 0,14 
2017 1,4   1,9  
Cytotoxic and cytostatic  
medicines 
(18 01 08) * 
2014 7,0   6,8  
2015 22  0,29 23  
2016 4,9   5,5  
2017 2,1   1,9  
Medicines other than those  
mentioned in 18 01 08 
(18 01 09) 
2014 230 91   140 
2015 170 57 100   
2016 120 58 22 45  
2017 140 45 70 90 1,8 
Chemicals consisting of or  
containing hazardous  
substances 
(18 02 05) * 
2014 4,8   0,78  
2015 3,4   2,1  
2016 1,7   3,6  
2017 2,1   2,3 0,076 
Chemicals other than those  
mentioned in 18 02 05 
(18 02 06) 
2014 0,001     
2015     0,001 
2016      
2017    0,003  
* Classified as hazardous waste.  
R1=Use principally as fuel or other means to generate energy (not considered recovery to a final product). 
R12=Exchange of wastes pending any of the operations numbered R1 to R12 (excluding temporary storage, pending 
collection, on the site where it is produced). 
D8=Biological treatment resulting in final compounds or mixtures which are discarded by any of the operations numbered 
D1-12 
D9=Physico-chemical treatment resulting in final compounds or mixtures which are discarded by any of the operations 
numbered D1-12 such as evaporation, drying, calcination 
D10=Incineration on land. 
D14=Repackaging prior to submission to any of the operations numbered D1 to D12. 
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2.6.3 Current disposal practices 
By law, medicinal products to be disposed of by the general public are to be treated in accordance with 
the requirements pertaining to hazardous-waste management and must be handed over to the waste man-
agers (currently UAB „AV investicija“) selected by the Ministry of Health. These waste managers have 
the right to handle hazardous waste in the manner prescribed by the Lithuanian Law on Waste Manage-
ment and other acts of law. 
‘Inactivated’ hazardous medical and pharmaceutical waste is material that has been rendered non 
hazardous. This makes it suitable for storage (repository time is up to a year) and ready for landfilling, 
incineration, or recycling (CCB 2017). 
The medical waste collected is incinerated. Reports state that 31 t of medical waste was collected in 
2009, but there is no clear information on whether this figure refers only to household medical waste or 
covers other categories of medical waste too (HCWH 2013, CCB 2017). 
2.6.4 Summary 
The main findings pertaining to collection, classification, and disposal of unused pharmaceuticals and 
other waste containing pharmaceutical residues in Lithuania are presented in Table 13. 
Table 13: Summary of the collection, classification, and disposal of unused pharmaceuticals in 
Lithuania. 
Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection 
point 
Pharmaceutical 
wastes  
classified as  
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human and 
companion animal 
pharmaceuticals 
from households 
No information Unclear; govern-
ment responsible 
for financing but in 
practice pharma-
cies pay the costs 
Local  
pharmacies 
Not known − Incineration 
(tempera-
ture not 
known) 
 
The following points were noted as conclusions related to the Lithuanian system for the take-back 
and disposal of unused pharmaceuticals. 
Advantages: 
+ The situation related to collection of obsolete pharmaceutical products is improving, and the 
amount of pharmaceutical waste collected by pharmacies is increasing (CCB 2017). 
Areas that need improvement: 
- The roles of the various actors and the financing for collection and disposal of unused medi-
cines should be clarified.  
-  People are bringing other kinds of waste to pharmacies also – such as outdated food additives 
(CCB 2017). 
- The incineration temperature employed for unused human-use and companion animal pharma-
ceuticals is not known. 
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2.7 Poland 
Marlena Szumska, Aleksandra Bogusz & Radosław Kalinowski  
Polish Institute of Environmental Protection – National Research Institute 
2.7.1 Legal basis 
The main law regulating waste management in Poland is the Waste Act, or WA (Dz. U. 2013, poz. 21). 
This act specifies the management principles (recovery, means of preventing emergence, recycling, 
treatment, disposal, storage, and transport) for various types of waste, including medical and veterinary 
waste. In addition, the act specifies the competencies and responsibilities of individual territorial author-
ities with regard to waste management and monitoring. Medical waste and veterinary waste, for the pur-
poses of the WA, is waste arising in connection with the examination and treatment of people and ani-
mals or in the provision of medical and veterinary services, along with that generated in connection with 
scientific research, including medical trials and experiments using animals. 
The European Commission’s list of waste categories (2014/955/EU) classifies unused cytostatic 
and cytotoxic pharmaceuticals as hazardous waste and declares other types of pharmaceutical waste non 
hazardous. This is the classification system in use in Poland. 
The WA imposes an obligation to supervise and dispose of medical waste, including pharmaceuti-
cals, at the level of Polish territorial units. 
Current collection practices 
Waste must be collected by distinct waste type in the place where it is produced. Collecting medical and 
veterinary waste beyond the location of its production is forbidden (WA, Art. 23, item 2). The marshal 
of the voivodeship, by way of a decision, may authorise the collection of this waste for safety reasons or 
to ensure continuity of waste collection. In the case of providing medical services on request, the pro-
ducer of such waste is obliged to deliver it immediately to rooms adapted for this purpose and meeting 
the requirements for the storage of such waste (WA, Art. 23, items 8 and 9). The economic operator pro-
ducing the waste is required to obtain the appropriate permits for that waste’s generation (per the WA’s 
articles 18–22) and must submit reports on the waste amounts to the National Waste Base (BDO). At 
present, the BDO database is in the implementation stage. The access to this public database has been 
possible since January 2020 via the Ministry of the Environment Web site, http://www.bdo.mos.gov.pl.  
Responsibility for waste generated 
Each operator is obliged to manage its own waste. In the case of waste generated at organisational facili-
ties, such as a hospital, clinic, or pharmacy, the producer of the waste is responsible for its disposal, 
while the municipalities are responsible for seeing to the management of pharmaceutical waste from 
households (Dz. U. 1996, No. 132, poz. 622 and amendments: Dz. U. 2012, poz. 391 and 951 and Dz. 
U. 2013, poz. 21 and 228). In practice, this has been implemented via municipal agreements with phar-
macies or pharmacy-operated points for the selective collection and treatment of pharmaceuticals. Once 
the material has been disposed of at a hazardous-waste incineration plant, the producer of medical and 
veterinary waste is relieved of the responsibility for the waste generated. The transfer of responsibility 
for waste management to the next waste holder is documented via the document confirming neutralisa-
tion (DPU) (WA, Art. 27, items 5 and 6 and Dz. U. 2014, poz. 107). The DPU document is issued at the 
request of the waste producer (WA, Art. 95, item 4). 
The office monitoring compliance with the Waste Act is the Inspection of Environmental Protection 
(IEP) entity, in accordance with the act of law on inspection of environmental protection (Dz. U. 2018, 
poz. 1471 and 1479). Also, any irregularities related to waste management may be reported to the IEP 
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by other control units, such as Veterinary Inspection, Pharmaceutical Inspection, and Sanitary and Epi-
demiological Inspection. 
Several regulations have been issued in conjunction with the WA, which address various details of 
the issues of classification and handling of waste. These are the most important:  
•  The regulation of the Minister of Environment pertaining to the waste catalogue (see Appendix 
1) (Dz. U. 2014, poz. 1923). Under the WA, every operator handling hazardous waste is obliged 
to keep up-to-date records of its quantities and types in accordance with the categories presented 
in the ordinance. 
• The regulation issued by the Minister of Health (Dz. U. 2016, poz. 1819) on requirements and 
disposal methods to be applied for medical and veterinary waste, which specifies the following: 
permissible means of disposal (see Table 14, based on Annex 1 to said regulation), conditions 
for carrying out the D10 incineration process (see Annex 2 to the regulation) and D9 process 
(per Annex 3), the method and scope for monitoring of disposal processes, and the methods and 
frequency for testing of waste generated as a result of these processes. The pharmaceutical 
waste in Poland is combusted in hazardous-waste incinerators. 
• The regulation from the Minister of Health on dealing with medical waste (Dz. U. 2010, No. 
139, poz. 940). This applies to medical waste with several codes (§1.1) and lays down detailed 
rules for the collection of medical waste, its temporary storage before its subjection to a disposal 
process, and the relevant transport conditions.  
• The regulation issued by the Minister of Health (Dz. U. 2015, poz. 1116) on medical and veteri-
nary waste that may be subject to recovery (e.g., surgical instruments, bedding, chemical rea-
gents, and waste containing dental amalgams if these do not contain infectious material). In con-
trast, drugs are not consisdered recoverable in Poland. 
Table 14: Permissible methods of disposing of medical waste and veterinary waste that do not have 
infectious properties in Poland (Dz. U. 2016, poz. 1819). 
Waste code Medical and veterinary waste Disposal method 
18 01 08 Cytotoxic and cytostatic drugs 
Thermal transformation on land 
(D10) 
 
18 01 09 Medicines other than those mentioned in 18 01 08 
18 02 07 Cytotoxic and cytostatic drugs 
18 02 08 Medicines other than those mentioned in 18 02 07 
 
Medical and veterinary cytotoxic and cytostatic drugs are classified in Poland as hazardous waste 
and other medicines as non-hazardous waste (according to waste catalogue), but additionally in Appen-
dix 4 of WA, there is a list of ingredients that may cause waste a hazardous waste. The list includes 
pharmaceuticals and other compounds used in medicine and veterinary medicine. Therefore, the inter-
pretation of the regulations is unclear, and it should be assumed that all pharmaceuticals in waste are 
hazardous waste. 
Another important legal mechanism regulating issues related to pharmaceuticals in Poland is the 
Pharmaceutical Act, or PA (Dz. U. 2001, No. 126, poz. 1381; Dz. U. 2017, poz. 2211; Dz. U. 2018, poz. 
650, 697, 1039, 1375, 1515, 1544, 1629, 1637, and 1669). 
These are the most important issues regulated by the PA with regard to pharmaceutical waste: 
• The rules and procedures for admitting medicinal products to trading – addressing their quality, 
effectiveness, safety of use, manufacturing, and marketing conditions. The regulation also in-
cludes requirements for specifying the particulars of the environmental hazards posed by a par-
ticular medicine, in the marketing-authorisation dossier. 
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• The tasks of Pharmaceutical Inspection and Veterinary Inspection and the competencies of the 
offices in question: supervision of production processes, trade, marketing, and return of medici-
nal products (per articles 67.1 and 122). 
• The obligation to keep records of the medicinal products sold and maintain an inventory of 
medicines given to animals, required under the PA and specified in combination with the act on 
animal health care and fighting contagious diseases among animals (Dz. U. 2004, No. 69, poz. 
625). This makes it possible to determine the size of the market for veterinary medicines and, 
potentially, the amount of waste generated. 
In addition to the PA, several other legal instruments specify details of the rules for trading in phar-
maceuticals: 
• The regulation of the Minister of Health about basic conditions for running a pharmacy (Dz. U. 
2002, No. 187, poz. 1564 and 1565). This imposes, among other obligations for the pharmacy, a 
requirement to keep detailed records of expired and damaged medicines submitted for disposal, 
as well as documentation on medicinal products for which a decision on suspension of sale or 
withdrawal from the market has been issued. 
• The act of law for countering drug addiction, or DA (Dz. U. 2005, No. 179, poz. 1485), and the 
regulation of the Minister of Health (Dz. U. 2012, poz. 236) that regulates the obligation to no-
tify Pharmaceutical Inspection about the expiry of narcotic and psychoactive substances, the 
rules and methods for the appropriate protection of these against unwanted use until the time of 
destruction, and formal requirements to be followed during the destruction procedure. 
2.7.2 Current take-back practices 
Poland has one of Europe’s highest consumption of medicines, especially ones available without a pre-
scription. In autumn 2009, nearly 71% of the population used pharmaceuticals, and the value of the 
country’s pharmaceutical market reached PLN 38.5 billion (about 9 billion euros) in 2017, according to 
QuintilesIMS analysts. 
According to the data provided by the Rynek Aptek Web site6, in the April of 2020 there were: 
• 12 424 generally accessible pharmacies, 
• 1 210 pharmacy points, 
• 1 278 hospital and other pharmacies – e.g., company and government pharmacies, and 
• 307 pharmacies without permission. 
The high consumption of medicines in Poland creates the risk of producing large amounts of phar-
maceutical waste. For 2011–2013, the Council of the Supreme Audit Office (NIK) has reported the 
numbers of medical-waste producers  shown in Figure 5 and the amounts of medical waste generated 
that are presented in Figure 6 (NIK 2014). 
                                                
6 http://www.rynekaptek.pl/,  
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Figure 5. The number of medicine-waste producers (hospitals, other health care institutions, pharma-
ceutical plants, etc.) in the individual voivodeships in 2011–2013 (NIK 2014). 
 
Figure 6. The amount of medical waste produced in the individual voivodeships in 2011–2013 and the 
share of hazardous waste in it (NIK 2014). 
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Operator responsibility for take-back of unused medicines 
According to the WA, the operator responsible for collecting and handling expired pharmaceutical and 
veterinary waste is the producer of waste. Health care facilities (i.e., hospitals and clinics), pharmacies 
and medical academies are obliged to collect all their medical waste (incl. pharmaceuticals) in an appro-
priate manner, as set out by regulations, and then transfer it to the appropriate disposal operators. The 
proof of transferring the waste (and, thereby, of responsibility for the waste) to the next operator – the 
recycling company – is the DPU document.  
Expired pharmaceuticals from households should be collected in accordance with their type and de-
posited in marked locations – e.g., at pharmacies, health care facilities, municipal offices, or waste-col-
lection points. The authority responsible for the reception of expired medicines from households is the 
municipality. In practice, this is implemented through mutual agreements between municipalities and 
pharmacies. 
Actual take-back practices of unused medicines; how it is organized 
Unused medicine may be delivered to pharmacies or to special points for hazardous-waste collection. 
However, the process is not organised, and not all pharmacies participate in this programme. Most of-
ten, it is implemented on the basis of a bilateral agreement with the municipal office. All pharmacies are 
obligated to keep records of all waste sent for disposal via high-temperature incineration. 
Unused veterinary medicinal products from households may be handed over to pharmacies where 
unused human-use medicinal products are taken back or at special points for hazardous-waste collec-
tion. Animal breeders who use veterinary pharmaceuticals in Poland have an obligation to retain records 
of these and to document their consumption and disposal. 
The report released by the Council of the Supreme Audit Office (NIK 2014) on the treatment of 
medical waste in Poland revealed several irregularities in many national medical centres’ compliance 
with the WA regarding the controls related to the provision of health services and conducting medical 
research and experiments. The audit covered such aspects as: 
• organization of the medical waste’s management, 
• activities related to the disposal of medical waste and the associated recording and reporting, 
• proceedings related to the conclusion of contracts with entities collecting waste, and 
• organization of sanitation supervision activities connected with the handling of medical waste. 
The assessment of these was negative, on account of the scale of the irregularities found. The fol-
lowing shortcomings were identified: 
• Information on the disposal of hazardous waste and on its management in a manner other than 
that required by law is lacking – there are deficiencies in the relevant disposal documentation. 
• Reliability is lacking with regard to reporting on the quantity and nature of the waste generated, 
a situation often stemming from errors in the records and in classification of waste (incorrectly 
assigned waste codes) but one that has also been created deliberately for economic reasons. 
• There is failure to comply with the proximity principle referred to in the WA, which has often 
resulted in transfer of infectious or dangerous waste over long distances. This is a result of fa-
vouring the economic criterion in selection of the contractor for the waste disposal service. 
• At 83% of the facilities inspected, the waste was segregated, stored, and transported incorrectly 
(NIK 2014). 
Evaluation of the take-back practices of unused medicines 
All medications in Poland should be utilised in thermal transformation employing the D10 method, but, 
as research by Staniszewska et al. (2015) has shown (Figure 7), the way pharmaceutical waste is dealt 
with in practice deviates significantly from that mandated by the WA. According to their questionnaire 
based survey, which involved two groups of respondents –  patients with chronic illnesses, who are 
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permanently on medication (the ‘Ch’ group), and patients taking drugs occasionally (the ‘O’ group) – 
the most common way of dealing with expired medications was to discard them with ordinary rubbish 
(about 60%) or flush them down the toilet (24–33%), which attests to low public awareness. Discarding 
them in marked containers, at a pharmacy, accounted for under 10% of the responses. The main sources 
of knowledge about expired-medication collection programmes were (from the most to the least often 
cited) the radio, posters/leaflets, family/friends, television, the Internet, the press, and pharmacies. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The most common ways of dealing with expired medications among respondents (n=198), 
where ‘Ch’ refers to patients with chronic illnesses, who are on medication permanently, and ‘O’  
denotes patients who use drugs only occasionally (Staniszewska et al. 2015). 
 
2.7.3 Current disposal practices 
Operator responsibility for disposal of unused medicines 
In Poland, the operators responsible for disposal of unused medicines are the companies that utilise the 
waste. They pick up the selectively collected waste from medical/veterinary centres and pharmacies. 
The transfer of waste to utilisation must be reported upon (by 15 March each year) to the Marshal’s Of-
fice of the relevant voivodeship. Utilisation is confirmed by the DPU document. 
An operator performing recovery, disposal, collection, and transport of waste is obligated to hold 
the following permits for carrying out the business in question (per the WA’s articles 232 and 233 and 
Section 4 of the Environmental Protection Law (Dz. U. 2001, No. 62, poz. 627): 
• An integrated permit 
• Permission to operate in the field of collection or transport of waste 
• Permission to collect and process waste 
• Permission for the transport of hazardous and non-hazardous waste 
• Registration in the register of the Chief Inspectorate of Environmental Protection (CIEP) 
Actual disposal practices of unused medicines 
After medicines are delivered to hazardous-waste management companies, they are subjected to high 
temperature hazardous-waste incineration (using the D10 method: thermal transformation at a tempera-
ture of 1100 °C) for purposes of avoiding pollution of the environment (water etc.). In Poland, the phar-
maceutical waste collected may be incinerated at a hazardous- or municipal-waste incineration plant. 
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In 2014, there were 45 active medical-waste incineration plants (NIK 2014) and seven municipal-
waste incineration plants in Poland. The former plants are found mainly at hospitals and handle the dis-
posal of infectious waste and other types of waste generated at medical facilities. 
Evaluation of the disposal practices of unused medicines 
On behalf of the NIK, Inspection for Environmental Protection carried out inspections of 29 of the 45 
entities operating thermal waste-treatment installations in 2014. These uncovered significant irregulari-
ties connected with more than 62% of the entities audited. The deficiencies identified are related to ei-
ther not performing legally required measurements of pollutant emission levels or performing them at 
times other than those dictated by administrative decisions, untimely transfer of waste data to supervi-
sion authorities, irregularities in storage and records, and lack of appropriate authorisation of various 
types. 
From the information presented above, it can be concluded that the management of medical phar-
maceutical waste in Poland is duly regulated by law but also that various types of information and train-
ing actions are required for compliance with the law in this regard. 
2.7.4 Summary 
The main findings on collection, classification, and disposal of unused pharmaceuticals and other waste 
containing pharmaceutical residues in Poland are presented in Table 15. 
Table 15: Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Poland. 
Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected 
separately 
Responsible 
party for  
arranging  
reception 
Collection  
point 
Types of  
pharmaceutical 
waste classified 
as hazardous 
Legal  
basis 
Method of  
disposal 
Unused human 
pharmaceuticals 
from households 
All  
pharmaceuticals 
Municipality Usually local 
pharmacy  
(depends on  
municipality) 
or other collec-
tion points 
Cytotoxic and  
cytostatic drugs 
waste // All phar-
maceuticals (ap-
pendix 4 of WA) * 
WA, Act 
about main-
taining 
cleanliness 
and order in 
communes, 
High  
temperature 
incineration 
(1100°C) 
Unused com-
panion animal 
pharmaceuticals 
from households 
No information Veterinarian or 
veterinary 
practice 
Municipality 
Veterinarian or 
veterinary  
practice 
Usually local 
pharmacy  
(depends on 
municipality) 
Cytotoxic and  
cytostatic drugs // 
All  
pharmaceuticals * 
WA, art 23. High  
temperature 
incineration 
(1100°C) 
Pharmaceutical 
industry  
(unsalable  
products, API-
contaminated 
wastes, etc.) 
All pharmaceuti-
cals, active  
substances, 
semi-finished 
products and 
API-contami-
nated wastes 
Industry  
operator 
To be orga-
nized by the 
industry  
operator, 
sometimes 
specified in the 
environmental 
permit of the 
industrial plant 
All  
pharmaceuticals 
WA, and  
Environmen-
tal Protection 
Law 
Pre-treat-
ment of 
wastes 
 
High  
temperature 
incineration 
(1100°C) 
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Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected 
separately 
Responsible 
party for  
arranging  
reception 
Collection  
point 
Types of  
pharmaceutical 
waste classified 
as hazardous 
Legal  
basis 
Method of  
disposal 
Pharmaceutical 
waste from  
hospitals and 
health care  
institutions 
All  
pharmaceuticals 
Hospital or 
health care  
institution– 
To be orga-
nized by the 
hospital or 
health care  
institution 
All  
pharmaceuticals 
WA, art 23 High  
temperature 
incineration 
(1100°C) 
Veterinary  
medicines from 
veterinarians 
and veterinary 
practices 
All  
pharmaceuticals 
Veterinarian or 
veterinary 
practice 
To be orga-
nized by the 
veterinarian or 
veterinary 
practice 
All  
pharmaceuticals 
WA, art 23 High  
temperature 
incineration 
(1100°C) 
Veterinary  
medicines for 
farmed animals 
No information Veterinarian or 
veterinary 
practice 
Municipality 
Veterinarian or 
veterinary 
practice 
Usually local 
pharmacy  
(depends on 
municipality) 
Cytotoxic and  
cytostatic drugs // 
All  
pharmaceuticals * 
WA, art 23 High  
temperature 
incineration 
(1100°C) 
* problems with interpretation of national legislation 
 
 
 
In conclusion, the following points were noted with regard to Poland’s take-back system and dis-
posal of unused pharmaceuticals. 
Advantages: 
+ The pharmacy take-back scheme appears to be efficient, and third parties cannot retrieve phar-
maceuticals from the collection point. 
+ The legal system’s specification of the method of dealing with pharmaceutical waste is adequate 
– pharmaceutical waste must be directed to a suitable disposal process (recovery of such waste 
is not permitted). 
+ The system is easy for citizens to use – they are not required to identify the waste categories in-
volved. 
+ There is an extensive network of pharmacies and collection points. 
+ There are no direct costs to the consumer. 
+ The treatment of pharmaceutical waste via high-temperature (1100 °C) incineration seems effi-
cient. 
Areas that need improvement: 
- Interpretations of the regulations remain unclear. 
- Low public awareness of the take-back scheme could result in inappropriate disposal. 
- Public awareness would certainly increase the proportion of pharmaceuticals disposed of cor-
rectly – citizens’ ignorance and lack of information on proper sorting point to a need for contin-
ued education and awareness-raising. 
- The law does not specify any technical requirements related to pharmaceutical waste’s treat-
ment. 
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Uncertainties: 
• Scarce data available call the take-back scheme’s validation into question. Most of the study re-
ports and data published on the subject focus on an economic perspective and do not take the 
environmental side of matters into consideration.  
• There is a paucity of public data/information on the amounts of discarded pharmaceuticals that 
are disposed of at high temperatures. Only general data on the amount of medical waste utilised 
are available. 
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2.8 Russia 
Elena Kaskelainen1, Ville Junttila2 & Jukka Mehtonen2 
1John Nurminen Foundation 
2Finnish Environment Institute 
2.8.1 Legal basis 
Russian legislation does not regulate collection and disposal of household pharmaceuticals. Neither does 
it require pharmacies to collect unused medicines from the public (CCB 2017).  
Article 59 of the Law on Medicinal Product Circulation sets out general procedural requirements 
and grounds for medicinal products’ destruction. According to that law, substandard and counterfeit me-
dicinal products shall be withdrawn from circulation and destroyed. Another law prescribes the proce-
dure for the disposal of controlled drugs and precursors. 
Federal Law 61-FZ on Circulation of Medicinal Products, dated 12.4.2010 
In 2019, this law was amended, with the amendments taking effect on 1 March 2020. The law includes 
the following specifications, among others, regarding the medicinal products: 
• Substandard and counterfeit medicinal products shall be withdrawn from circulation and de-
stroyed in accordance with the procedure established by the Government of the Russian Federa-
tion. 
• Counterfeit medicinal products shall be withdrawn from circulation and destroyed in accord-
ance with a court decision. 
• The owner of counterfeit, substandard, or falsified medicinal products shall provide reimburse-
ment for the destruction costs. 
• The owner of relevant medicinal products must submit a certificate of destruction or a duly cer-
tified copy thereof to the authorised federal executive authority. 
• The authorised federal executive authority making a decision to destroy medicinal products 
shall be responsible for supervising their destruction. 
• Medicinal products shall be destroyed by duly licensed operators at specially equipped sites, at 
landfills, or on specially equipped premises, in compliance with the environmental requirements 
specified by Russian laws and regulations. 
• Narcotic, psychotropic, and radiopharmaceutical drugs shall be destroyed in accordance with 
Russian laws and regulations. 
Ordinance 382 of the Ministry of Health of the Russian Federation on Guidelines on the 
Procedure of Medicinal Product Destruction, dated 15.12.2002 
This ordinance’s terms specific to medicinal products’ destruction dictate the following: 
• Liquid medicinal products shall be destroyed by dilution with water at a 1:100 ratio, with the 
solution to be flushed into the industrial sewer system.  
• Solid water-soluble drugs shall be destroyed by crushing into a powder, after which dilution 
with water is to be performed (1:100) and the solution flushed into the industrial sewer system. 
• Solid water-insoluble and soft medicinal products (ointments etc.) shall be destroyed by incin-
eration.  
• Narcotic drugs and psychotropic substances shall be destroyed in accordance with Russian laws 
and regulations.  
• Flammable drugs, explosive drugs, and pharmaceutical raw materials with a high radionuclide 
content shall be destroyed under special conditions by means of a special technique available to 
disposal operators, in accordance with their licence.  
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When medicinal products are destroyed, a certificate of destruction is prepared and signed by the 
persons participating in the procedure. Pharmaceutical-industry entities shall be responsible for medici-
nal products’ destruction in accordance with Russian laws and regulations. 
2.8.2 Current take-back practices 
Russia has no official centralised system to collect expired pharmaceuticals and medical waste (pack-
ages, syringes, IV lines, etc.) from the public without charge. Pharmacies do not make collection points 
for unused pharmaceuticals available to the public, and neither they nor other health care institutions 
(hospitals and clinics) accept any pharmaceutical waste from households (Malina 2018).  
Russia does not have any coherent system for handling of unused pharmaceuticals from house-
holds. Therefore, these medicines end up at landfills or in municipal sewer systems (HELCOM & 
UNESCO 2017). Nevertheless, about four tonnes of pharmaceutical waste are collected every year in 
Russia. This collection is arranged via mobile collection points and recycling centres (CCB 2017). 
However, Russian legislation does specify procedures for handling and disposal of medical waste 
from health care institutions and pharmacies (CCB 2017).  
According to various sources, up to 1,000,000 tonnes of medical waste is generated in Russia annu-
ally. 
A survey (Trofimova & Getman 2013) conducted in the country’s large cities indicated that 
• 80% of expired pharmaceuticals is disposed of in household waste or taken to landfills and 
• 15% is flushed into the sewer system. 
Roughly 50% of respondents were aware that such disposal methods can harm the environment and 
indicated that they were ready to support the initiative to collect expired and unwanted pharmaceuticals 
in special containers installed at pharmacies for their safe disposal. 
Currently, while some operators in Russia are licensed to provide commercial services for pharma-
ceutical waste’s transportation and disposal, no government support is available for such companies, re-
grettably. These operators accept expired pharmaceuticals for a fee from both health care institutions 
and the public. The price per kilogram of pharmaceuticals is, on average, between 150 and 250 Russian 
rubles (about 2–3 euros). Such operators have a special licence for performing the activities in question, 
and they carry out pharmaceutical-waste collection, transportation, and disposal at landfills. However, 
there are very few such operators in Russia at present. 
The Russian Ministry of Health has been receiving requests for establishment of special collection 
points where the public can return expired pharmaceuticals. A decision has not been made yet. There are 
hopes that the Pharma-2030 Strategy is going to address the issue of pharmaceutical-waste collection 
and disposal and that Russia will implement a system for collecting household pharmaceutical waste 
with segregation by hazard class. 
2.8.3 Current disposal practices 
According to the guidelines issued by the then Ministry of Health and Social Development in 2010, the 
following methods may be used: incineration, discharge into industrial sewers, and landfilling at desig-
nated sites. However, environmentalists argue that none of these methods is environmentally safe. Ac-
cording to Russian environmentalists, the most efficient pharmaceutical-waste disposal method is a ther-
mal technique with multi-stage flue-gas cleaning. Such incineration and dumping of medical waste at 
designated sites have been identified as the most preferable destruction method for medicines in Russia 
(CCB 2017). 
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Disposal of pharmaceuticals by health care institutions (hospitals, health care centres and 
pharmacies) 
According to Regulation SanPiN 2.1.7.2790-10, titled ‘Sanitary and Epidemiological Requirements for 
Medical Waste Disposal’, expired pharmaceuticals and waste from laboratories, pharmacies , and the 
pharmaceutical industry are categorised as Class G toxic substances and subject to destruction accord-
ingly.  
The following destruction methods shall be applied:  
• Thermal (incineration)  
• Chemical (use of alkalis or acids)  
• Thermochemical (crushing, heating, and immobilisation) 
Specialist licensed operators transport waste from medical or pharmaceutical institutions to desig-
nated immobilisation and disposal sites, in special vehicles. Large health care institutions have their 
own equipment (microwave treatment units) for medical waste’s immobilisation and disposal. Thus, 
pharmacies, hospitals, and (other) large health care institutions take care of the disposal of the pharma-
ceutical waste they produce. 
2.8.4 Summary 
The main findings related to the collection, classification, and disposal of unused pharmaceuticals and 
other waste containing pharmaceutical residues in Russia are presented in Table 16. 
Table 16: Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Russia. 
Pharmaceutical 
waste 
Types of  
pharmaceuti-
cals collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection  
point 
Types of  
pharmaceutical 
waste  
classified as 
hazardous 
Legal  
basis 
Method of  
disposal 
Unused human 
and companion 
animal pharma-
ceuticals from 
households 
None; legislation 
does not cover  
unused pharma-
ceuticals of  
households 
No responsible 
party 
Not exist; small 
proportion of 
pharmaceutical 
waste collected 
via mobile  
collecting points 
and recycling 
centres 
Not known No legal 
basis 
Landfilling 
Pharmaceutical 
industry  
(unsalable  
products, API-
contaminated 
wastes, etc.) 
Not known Not known Not known Not known Ordinance 
382 
15.12.2002 
Incineration, 
discharge 
into industrial  
sewers and 
landfilling at 
designated 
sites  
Pharmaceutical 
waste from  
hospitals, health 
care institutions 
and pharmacies 
Not known Not known Not known  Not known SanPiN 
2.1.7.2790-
10 
Incineration, 
chemical 
and thermo-
chemical  
destruction 
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In conclusion, the following issues related to Russia’s take-back and disposal system for unused phar-
maceuticals were noted as representing improvement needs: 
- Community outreach campaigns would be beneficial for raising public awareness of the envi-
ronmental impacts created by unused medicines’ inappropriate disposal and of the importance 
of their proper collection and disposal. For unused and expired pharmaceuticals, targeted infor-
mation and awareness-raising activities are needed, making use of the information resources of 
health care institutions and pharmacies.  
- Establishment of a collection-point network for unused medicines in Russia should be pro-
moted, and the public should be encouraged to take medicines to such points rather than dispose 
of them with household rubbish. 
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2.9 Sweden 
Kristina Nyhlén, Sara Spjuth & Torsten Jakobsson 
County Administrative Board of Östergötland 
2.9.1 Legal basis 
Waste-handling for pharmaceuticals in Sweden is regulated primarily by three pieces of legislation: the 
Environmental Code (SFS 1998:808), the Waste Ordinance (SFS 2011:927), and the ordinance on pro-
ducer responsibility for pharmaceuticals (SFS 2009:1031). The overall legal basis for handling of waste, 
of any type, is found in the Environmental Code and the Waste Ordinance. The Environmental Code 
provides the overall legal basis for all environmental legislation in Sweden and, together with various 
ordinances, sets forth the provisions related to emission to the air, water, and soil. That code and its pro-
visions promote sustainable development and apply to all activities that could cause negative impacts on 
human health or the environment. It addresses, for instance, management of land and water, nature con-
servation, protection of flora and fauna, environmentally hazardous activities, water-related operations, 
genetic engineering, chemical products, and waste management. The Environmental Code sets out the 
framework for implementing environmental protection, while the Waste Ordinance contains details on 
handling of waste. In addition, there are several ordinances on special waste types, including one on 
producer responsibility for pharmaceuticals.  
According to the Waste Ordinance, cytotoxic and cytostatic pharmaceuticals are classified as haz-
ardous waste and, in consequence, must not be mixed or diluted with other waste, substances, or mate-
rial, not even other forms of hazardous waste. Transportation of hazardous waste requires a permit un-
der the Waste Ordinance, and this permit must be renewed every five years. 
Take-back of household pharmaceuticals 
The ordinance on producer responsibility for pharmaceuticals describes provisions for the take-back of 
leftover household pharmaceuticals. This ordinance states that any retailer of pharmaceuticals (these are 
mainly pharmacies) is obliged to take back leftover household pharmaceuticals without financial com-
pensation and, further, should inform the public about how and why they should hand in their pharma-
ceuticals at pharmacies. However, the ordinance on producer responsibility for pharmaceuticals states 
that the pharmacies are only obliged to take back pharmaceuticals in proportion to the amount of phar-
maceuticals that they sell (Sveriges Apoteksförening 2019). For other retailers (such as food stores or 
petrol stations) selling non-prescription pharmaceuticals over the counter, the party responsible for take-
back of pharmaceuticals is the pharmacy that distributed those pharmaceuticals to the retailer (Swedish 
Medical Products Agency 2012).  
Cytostatic and cytotoxic pharmaceuticals are classified as hazardous waste and should be handled 
as such in accordance with the Waste Ordinance. According to the ordinance on producer responsibility 
for pharmaceuticals, the collection of hazardous waste falls outside the retailer’s responsibilities. Conse-
quently, any leftover cytostatic and cytotoxic pharmaceuticals should not be collected by the pharma-
cies, per that ordinance and the Waste Ordinance. Instead, the municipalities are responsible for collec-
tion, transport, and destruction of any hazardous waste from households. However, cytostatic and 
cytotoxic pharmaceuticals are handled mainly by hospitals, other health care providers, and veterinaries, 
so only a very small amount of household pharmaceuticals is classified as hazardous waste. 
Veterinary pharmaceuticals (apart from cytostatic and cytotoxic ones) used by households are also 
covered by the ordinance on producer responsibility for pharmaceuticals. They should be returned to 
pharmacies for collection, as long as they are not classified as hazardous waste.  
Reports of the Finnish Environment Institute 34/2020   69 
The Swedish municipalities have a responsibility to take adequate care of any leftover household 
pharmaceuticals that are not handed in at pharmacies (Swedish Environmental Protection Agency 
2009). 
2.9.2 Current take-back practices 
Sweden has a long tradition (established in 1971) of returning unused pharmaceuticals to pharmacies; 
this was introduced by the Swedish monopoly pharmacy chain for security reasons. Sweden’s ordinance 
on producer responsibility for pharmaceuticals has been in effect since 2009, including provisions for 
the take-back of leftover household pharmaceuticals, and other legislation addresses producers’ respon-
sibility and the management of hazardous waste. 
The managers of hospitals, health care entities, and veterinary clinics are obliged to collect unused 
pharmaceuticals and other medical products and make sure they are conveyed to an approved waste-
handling system and destroyed by incineration. The most commonplace solution is to have agreements 
in place with companies approved for incineration of pharmaceutical waste.  
All pharmaceutical waste must be separated from other waste, and the pharmaceuticals classified as 
hazardous waste should be handled separately from other pharmaceuticals. The hospitals and human-
health care and veterinary clinics have a responsibility for the traceability of hazardous waste until its 
destruction by an approved company. 
Take-back from households and pharmacies 
The take-back collection system consists of a chain of responsibilities that starts with the producers. The 
ordinance on producer responsibility for pharmaceuticals requires producers to ensure that their pharma-
ceutical waste from fabrication activities is transported and disposed of in compliance with the law. 
When the pharmacies have received the pharmaceuticals, they are required to ensure the availability of 
free take-back collection systems for pharmaceutical waste from households. 
The households are, for their part, responsible for sorting their leftover pharmaceuticals and return-
ing them to the pharmacies. The same is true of veterinary pharmaceuticals.  
Take-back at region level from hospitals and veterinary clinics 
Pharmaceutical waste from hospitals or veterinary practices is not covered by the ordinance on producer 
responsibility for pharmaceuticals. These parties are responsible for their own appropriate waste-han-
dling activities, under the Environmental Code.   
Sweden is divided into 21 regions, politically controlled organisations responsible for leading the 
work toward sustainable development on regional level, with the mission being primarily to manage 
public hospitals and health care. Region-level health care is composed of primary care, local health care, 
and specialist care, which together result in many prescriptions of pharmaceuticals. Hence the regions 
have a significant responsibility to reduce the impact that pharmaceuticals may entail for the environ-
ment (MistraPharma 2011).  
Most hospitals and health care centres have their own environmental stations for source-separated 
waste. The majority of the sorted waste, such as outdated and leftover pharmaceuticals, is sent directly 
for incineration, per agreements with waste contractors. Some regions send their outdated or leftover 
pharmaceuticals to pharmacies, which, in turn, send them to special incinerators (Johansson 2019). For 
those pharmaceuticals classified as hazardous, such as cytostatic and cytotoxic pharmaceuticals, the hos-
pitals and centres must have agreements with transport and handling facilities licensed to destroy phar-
maceutical waste (Johansson 2018, Region Östergötland 2019, Region Stockholm 2019). 
In Sweden there are also advanced home care (ASIH) or specialized, hospital connected home care 
(LAH or SAH) that offers an alternative for patients of all ages with multiple diagnoses or serious 
chronic diseases (Region Stockholm 2020 & Nationella rådet för Pallativ vård 2014). Thus, health care 
 
70   Reports of the Finnish Environment Institute 34/2020 
for severely ill patients is increasingly provided in the home, so pharmaceutical waste from this kind of 
treatment represents an important issue. The routines for advanced treatment in the home may differ 
slightly between regions, but in most cases the patients themselves are responsible for seeing that the 
unused portions of the drugs prescribed are returned to pharmacies. As for pharmaceuticals that the care 
personnel bring for the home treatment of patients, it is the responsibility of those personnel to return 
the waste to the hospitals and discard it in accordance with current practices applied in the health care 
sector (Jatko & Ramstedt 2019). 
Information about take-back systems and environmental factors 
In 2012, a national campaign was conducted primarily under the auspices of the Swedish Medical Prod-
ucts Agency, together with all pharmacy chains and a trade association, the Swedish Association of the 
Pharmaceutical Industry (LIF). The focus of the campaign was on raising environmental awareness and 
on spreading the information that leftover pharmaceuticals, wherever they were bought, should be 
handed in at pharmacies for disposal (Swedish Medical Products Agency 2012). Since then, the pharma-
cies themselves have been working for the dissemination of information on the environmental impacts 
of pharmaceuticals and on how households can reduce these impacts. For example, all pharmacies pre-
sent information about take-back of unused pharmaceuticals on the Web, although the extent of this var-
ies. The individual chains also work separately, with their own campaigns, to increase the take-back of 
unused drugs, while also taking part in efforts co-ordinated by the Swedish Pharmacy Association. 
In 2014, one of the chains conducted an online interview-based survey of members of the Swedish 
public, examining habits in handling of unused pharmaceuticals. Only 60% of the participants reported 
returning their leftover drugs to the pharmacies; on the basis of this result, the pharmacy company initi-
ated concerted efforts to improve the take-back of leftover pharmaceuticals (Burlin Hellman 2014).  
In 2017, one of the pharmacy chains introduced the ‘big collection day’ for unused pharmaceuticals 
in order to raise awareness among the Swedish public. The campaign continued for four weeks, offering 
customers double the usual amount of bonus points as an ‘environmental bonus’ for handing in unused 
pharmaceuticals. During the campaign, the number of customers handing in unused pharmaceuticals tri-
pled, and that year saw the collection systems of the country’s various pharmacies receive, in total, 
1,200 t (i.e., 1,200,000 kg) of material. The big collection day was repeated in 2018, with twice as many 
customers as in 2017 handing in pharmaceuticals (Sveriges Apoteksförening 2018, Frisk 2018). 
Almost all of the pharmacy chains offer their members bonus credits for handing in unused pharma-
ceuticals. This has proved to be an effective incentive for citizens’ return of their leftover pharmaceuti-
cals. Also, it benefits the pharmacies when customers visit the location and might buy some products 
while there (Bergeå 2018).  
Evaluation of the take-back practices  
Jointly with the largest pharmacy entity in Sweden, LIF conducted surveys aimed at assessing the public 
awareness related to handling of leftover prescription and/or non-prescription pharmaceuticals in Swe-
den. These were performed in the years 2001, 2004, 2007, 2011, and 2012. The results (Table 17) show 
that the larger-scale campaign in 2012 might have had a positive effect with regard to people handing in 
their pharmaceutical waste at pharmacies, and they also show that ongoing campaigns are necessary for 
long-term awareness. 
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Table 17: The Swedish public’s awareness about the handling of pharmaceutical waste (per Persson et 
al. 2009, Swedish Medical Products Agency 2012). 
Year Aware that pharmaceutical waste should be 
handed in to pharmacies (% of respondents) 
Handed in pharmaceutical waste to 
pharmacies (% of respondents) 
2001 86 no data 
2004 85 67 
2007 85 73 
2011 84 69 
2012 82 75 
 
The Swedish Medical Products Agency has estimated that 1,500 t of pharmaceuticals will get de-
stroyed or otherwise disposed of in Sweden every year. The bulk of this material is taken care of appro-
priately, but approximately 250 t gets flushed down drains or discarded with household waste (see Table 
18). The latter accounted for about 5% of all prescription pharmaceuticals sold in 2011, with an esti-
mated value of 1,500 million Swedish crowns, equivalent to circa 140 million euros (UNESCO & HEL-
COM 2017). 
Table 18: Amounts of pharmaceutical waste collected in Sweden in 2011 (UNESCO & HELCOM 2017). 
Pharmaceuticals estimated to be involved in take-back schemes 1 500 tons 
Returned to pharmacies 800 tons 
Ending up in the mixed waste from households 250 tons 
From public municipalities recycling centres 10 tons 
Discarded by internal operations of the pharmacies 50 tons 
Discarded by the internal operations of the wholesale’s traders 250 ton 
Discarded in hospital health care 100 tons 
 
In 2003, a study was performed among Swedish pharmacy customers for investigating the factors 
in their disposal of unused pharmaceuticals (Ekedahl 2006). The four most commonly cited reasons for 
pharmaceuticals going unused were that they had passed their expiry date (22% of the respondents), that 
the patient was deceased (19%), that the pharmaceuticals were not needed anymore on account of an 
improvement in the user’s health (18%), and that the pharmaceutical therapy employed had changed 
(23%). 
Since 2011, there has been neither any calculation of the quantities of pharmaceutical waste col-
lected nor any statistical information from the Medical Products Agency. Since 2017, the Swedish Phar-
macy Association has reported the amounts of pharmaceuticals returned to pharmacies. They felt a need 
to collect this kind of information for purposes of forming an overview of the management of pharma-
ceuticals. Hence, they have compiled materials on the pharmaceutical industry as a whole. In their last 
business report, they showed that the total amount of pharmaceuticals collected by the pharmacies in 
2018 came to 1,400 t (Sveriges Apoteksförening 2019).  
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2.9.3 Current disposal practices 
In Sweden, pharmaceutical waste is currently collected by pharmacies, by municipalities’ collection sys-
tems (at recycling centres), and via other health care or hospital management. The hospitals and health 
care units have well-established routines for handling pharmaceutical waste. For example, some regions 
have central guidelines regarding disposal of pharmaceuticals, and their health care centres have their 
own routines and instructions in place that address local circumstances. The pharmacies and regions, 
then, have agreements with facilities in Sweden that are licensed to destroy pharmaceutical waste 
(UNESCO & HELCOM 2017).  
When pharmaceuticals are returned to pharmacies, they should be placed in transparent plastic bags 
(to ensure easy identification of the contents) provided by the pharmacies. The pharmaceutical waste is 
then placed in sealed boxes and transported to the authorised waste destruction facilities. After this, the 
pharmaceuticals are subjected to controlled burning at 850–1100 °C, and the gas produced is cleaned 
before release (per the ordinance on incineration of waste, SFS 2013:253). Through this process, com-
plete destruction of the pharmaceutical waste is achieved (Swedish Medical Products Agency 2012, 
Persson et al. 2009). The same procedures are applied for veterinary pharmaceuticals from households 
and (in cases of reasonable amounts) from farmers and veterinary clinics.  
All farmers and all other traders are obliged to report to the municipality if their activities give rise 
to hazardous waste. When the veterinary pharmaceuticals used for farmed animals extend to ‘unreasona-
ble’ amounts, primary responsibility to ensure that the pharmaceutical waste is treated in accordance 
with the law lies with the farmer/trader. In these cases, the farmers often have an agreement in place 
with facilities licensed to destroy pharmaceutical waste. 
Evaluation of the disposal practices  
The practices for disposal of unused pharmaceuticals function well in Sweden. Awareness of the system 
for disposal of pharmaceutical products is high among citizens (with regard to returning unused pharma-
ceuticals to pharmacies and not discarding them as household rubbish or via the drain). The system it-
self is structured with several actors involved, having their own distinct areas of responsibility, which 
can present both an advantage and a challenge. One benefit for the actors responsible for waste manage-
ment is that they can divide up the tasks, but pharmaceutical waste can still be found in the hazardous-
waste area at recycling centres (mainly because of misunderstanding of the take-back system) rather 
than returned to pharmacies as it should be.  
While the Swedish system for disposal of unused pharmaceuticals can offer good examples for 
other countries, there are areas that need improvement. The proportion of pharmaceuticals that goes to 
waste can still be decreased, by such means as developing solid routines related to orders and prescrip-
tions (MistraPharma 2011). 
2.9.4 Summary 
The main findings pertaining to collection, classification, and disposal of unused pharmaceuticals and 
other waste containing pharmaceutical residues in Sweden are presented in Table 19. 
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Table 19: Summary of the collection, classification, and disposal of unused pharmaceuticals and other 
waste containing pharmaceutical residues in Sweden. 
Pharmaceuti-
cal waste 
Types of  
pharmaceuti-
cals collected  
separately 
Responsible 
party for  
arranging  
reception 
Collection  
point 
Types of  
pharmaceu-
tical waste  
classified as 
hazardous 
Legal  
basis 
Method of  
disposal 
Unused  
human and 
companion  
animal  
pharmaceuti-
cals from 
households 
All  
Pharmaceuticals 
Pharmacies, 
Municipalities 
Pharmacies Cytostatic  
and cytotoxic  
pharmaceuti-
cals 
SFS 
2009:1031, 
 
SFS 
2011:927 
Incineration for  
collected waste  
800-1000°C 
For hazardous 
waste may other 
methods be use, 
such as wet 
chemical treat-
ment, biological 
treatment or  
disposal 
Pharmaceuti-
cal industry  
(unsalable  
products, API- 
contaminated 
wastes, etc.) 
All products, 
waste fractions 
and ingredients 
classified as 
hazardous 
waste and  
pharmaceuticals 
Pharmaceuti-
cal industry 
Agreements with  
facilities licensed to  
destroy hazardous 
waste 
Depending 
on the  
classification 
of waste 
fraction 
SFS 
2011:927, 
 
Environmen-
tal Code 
1998:808 
See above 
Pharmaceuti-
cal waste from  
hospitals and 
health care  
institutions 
All  
Pharmaceuticals 
Hospital, 
health care  
institutions 
management 
Routines and agree-
ments with pharmacies 
and facilities licensed  
to destroy hazardous 
waste 
Cytostatic  
and cytotoxic  
pharmaceuti-
cals 
SFS 
2011:927, 
 
Environmen-
tal Code 
1998:808 
See above 
Veterinary  
pharmaceuti-
cals from  
veterinarians 
and veterinary 
practices 
All  
Pharmaceuticals 
Veterinarian, 
veterinary 
practices 
Pharmacies,for  
hazardous waste the 
farmer has agreements 
with pharmacies and  
facilities licensed to de-
stroy hazardous waste 
Cytostatic  
and cytotoxic 
pharmaceuti-
cals 
SFS 
2011:927, 
 
Environmen-
tal Code 
1998:808 
See above 
Veterinary  
pharmaceuti-
cals for live-
stock  
animals - 
reasonable 
amounts 
All  
Pharmaceuticals 
Farmers Pharmacies, for  
hazardous waste the 
farmer has agreements 
with pharmacies and  
facilities licensed to de-
stroy hazardous waste  
Cytostatic  
and cytotoxic 
pharmaceuti-
cals 
SFS 
2011:927, 
SJVFS 
2019:32, 
 
Environmen-
tal Code 
1998:808 
See above 
Veterinary 
pharmaceuti-
cals for live-
stock animals - 
unreasonable 
amounts 
All  
Pharmaceuticals 
Farmers For hazardous waste 
the farmers must have 
an agreement with 
transport and facilities  
licensed to destroy  
medical waste 
Cytostatic  
and cytotoxic 
pharmaceuti-
cals 
SFS 
2011:927, 
SJVFS 
2019:32, 
 
Environmen-
tal Code 
1998:808 
See above 
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In conclusion, the following aspects of Sweden’s take-back system and the disposal of unused phar-
maceuticals in Sweden were identified as noteworthy. 
Advantages: 
+ The pharmacy take-back scheme appears to be efficient. There is clear legislation that articu-
lates the division of responsibility for take-back of unused pharmaceuticals. 
+ Public awareness of take-back management for unused pharmaceuticals is relatively high, at 
about 80%. 
+ There are no direct costs to the consumer for returning leftover pharmaceuticals. In fact, cus-
tomers often get rewarded via bonus systems at the pharmacies, which create an incentive for 
citizens to return these pharmaceuticals. 
+ Swedish pharmacies see environmental profiling as a competitive advantage, which may act in 
favour of the take-back system’s further development and aid in the environmental aspects of 
pharmaceutical management.  
Areas that need improvement: 
- More information needs to be distributed to the public about handling of unused pharmaceuti-
cals, along with pharmaceutical management overall. Sweden has a well-functioning take-back 
scheme, but the amounts of unused pharmaceuticals and their mishandling should still be de-
creased. For example, consumers often keep additional amounts of pharmaceuticals at home 
‘for safety’s sake’, and this necessitates changes in behaviour.  
- The pharmacies’ costs for handling returned household pharmaceuticals are presumed to be 
covered by trade margins set by the Dental and Pharmaceutical Benefits Agency (TLV) in Swe-
den. This margin, consisting of a fixed amount and a percentage surcharge based on the pur-
chase price, is meant to cover the costs of dispensing prescriptions, providing related counsel-
ling to the customer, and handling generic exchange of medicines. If other factors are added in, 
however, such as keeping pharmaceuticals in stock and the labour involved in take-back of left-
over pharmaceuticals, the pharmacies are underfunded. Either the trade margins have to rise or 
some changes to regulations must be made, to prevent pharmacies from finding it difficult to 
maintain their current level of service in the long run (Sveriges Apoteksförening 2019). 
Uncertainties: 
• According to the HELCOM report from 2018, 70% of Sweden’s unused pharmaceuticals are 
collected. This is a healthy figure, but uncertainties remain with regard to what this 70% really 
represents: the mass of the actual pharmaceuticals or mostly their packages. We need more up-
to-date information also. 
• There is some uncertainty related to proposing more ‘starter’ packages. On one hand, there are 
advantages to smaller packages for medicines, which enable easier adjustment of the prescrip-
tion after the necessary dosage has been ascertained. On the other hand, these packages are 
more expensive and often are not stocked by pharmacies. 
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3 Findings on national practices for take-back 
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In general, the information basis of this study is scarcer for Lithuania and 
Russia than for Denmark, Estonia, Finland, Germany, Latvia, Poland and 
Sweden. This should be kept in mind when considering the results brought up in 
chapter 3. Statistics about pharmaceutical waste do not allow for 
comprehensive comparison between masses produced by households, 
industrial activities and other sources for the whole Baltic Sea Region. 
3.1 Classification of pharmaceutical waste 
In general, the Baltic Sea region displays great variation with regard to which types of pharmaceutical 
waste are classified as hazardous waste (see Table 20). In Denmark and Finland, all unused household 
pharmaceuticals, those meant for humans and those intended for companion animals alike, are consid-
ered to be hazardous waste. In Germany, Latvia, Poland, and Sweden, only unused cytostatic and cyto-
toxic pharmaceuticals are regarded as hazardous waste in line with the European Commission’s list of 
waste categories (2014/955/EU). In Estonia, only unused prescribed pharmaceuticals are deemed haz-
ardous waste. The Lithuanian and Russian situation related to this issue is unknown. 
In general, the classification of the waste produced by the pharmaceutical industry in the Baltic Sea 
region depends on the hazardous properties of the waste fraction. 
The classification varies also in the cases of hospitals and residential institutions, veterinarians, and 
farms. In Denmark and Finland, all unused pharmaceuticals from these sectors are classified as hazard-
ous waste; in Estonia, their classification depends on the hazardous properties of the waste; and in Ger-
many, Poland, and Sweden, cytostatic and cytotoxic pharmaceuticals are classified as hazardous. In Lat-
via, all pharmaceutical waste from hospitals, residential institutions, veterinarians, and veterinary 
practices is classified as hazardous, but in cases of farms this is true for only that waste generated in the 
process of animals’ birth; the diagnosis, treatment, or prevention of illness in animals; and experiments 
involving animals. The classification schemes employed in Lithuania and Russia are unknown. 
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Table 20: Summary information on which kinds of unused human-use and veterinary pharmaceuticals 
and other waste containing pharmaceutical residues are classified as hazardous waste in the countries 
studied. 
Country Households  
- humans 
Households  
- companion  
animals 
Industry Hospitals and 
healthcare in-
stitutions 
Veterinarians 
& veterinary 
practices 
Farms 
(livestock) 
D
en
m
ar
k 
All All 
Depending on 
classification of 
the waste  
fraction. Final  
product and  
certain ingredients 
are classified as 
hazardous 
All All All 
Es
to
ni
a Prescribed  
pharmaceuticals 
are considered as 
hazardous waste 
Prescribed  
pharmaceuticals  
are considered as 
hazardous waste 
Depends on  
hazardous  
properties of  
the waste 
Depends on 
hazardous  
properties of  
the waste 
Depends on  
hazardous  
properties of  
the waste 
Depends on  
hazardous  
properties of  
the waste 
Fi
nl
an
d 
All All 
Depends on  
hazardous  
properties of 
the waste 
All All All 
G
er
m
an
y 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
All unsalable prod-
ucts, API-contami-
nated wastes, etc.,  
depends on haz-
ardous properties 
of the waste 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
La
tv
ia
 Cytostatic  
and cytotoxic  
pharmaceuticals 
Waste, that occurs 
in the process  
of animal birth,  
diagnosing,  
treating or  
preventing animal 
illness as well as 
experiments  
using animals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
All All 
Waste, that occurs 
in the process  
of animal birth,  
diagnosing,  
treating or  
preventing animal 
illness as well as 
experiments  
using animals 
Li
th
ua
ni
a 
Unknown Unknown Unknown Unknown Unknown Unknown 
Po
la
nd
 Cytostatic &  
cytotoxic pharma-
ceuticals// All 
pharmaceuticals* 
Cytostatic &  
cytotoxic pharma-
ceuticals// All 
pharmaceuticals* 
All unsalable prod-
ucts, API-contami-
nated wastes, etc.,  
depends on haz-
ardous properties 
of the waste 
All All 
Cytostatic &  
cytotoxic pharma-
ceuticals / All 
Pharmaceuticals 
R
us
si
a 
Unknown Unknown Unknown Unknown Unknown Unknown 
S
w
ed
en
 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Depending on the 
classification of 
waste fraction 
Cytostatic  
and cytotoxic 
pharmaceuticals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
Cytostatic  
and cytotoxic  
pharmaceuticals 
* Problems with interpretation of the national legislation. 
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3.2 Take-back and collection of unused pharmaceuticals and other 
waste containing pharmaceutical residues 
First, it is important to note that the statistics about pharmaceutical waste are often based on EU waste 
codes, which do not provide detailed information about the composition of the waste. However, other 
remarks and conclusions can be made based on available information. 
3.2.1 Households 
Unused human pharmaceuticals 
In general, the proportion of surveyed citizens who return the unused pharmaceuticals to the designated 
collection points varies greatly between the Baltic Sea countries; from about 10% to 70% (no infor-
mation from Denmark, Estonia and Germany). Respectively, about 16–80% disposed them of as mixed 
household waste and 3–30% flushed them down the drain (Table 21). Thus, the situation in the Baltic 
Sea region is similar to that in EU in general, because in the majority of EU member states, a big share 
of unused medicines (50–90%) are not collected or returned to pharmacies or other appropriate take-
back sites (BIO Intelligence Service 2013). It should be noted that uncertainties remain concerning what 
the figures presented in Table 21 really represent. The figures pertaining to such activities as returning 
the unused pharmaceuticals indicate the share of people, not the share of the weight of the actual medi-
cines or number of medicine packages. Nevertheless, the figures probably indicate roughly well the dif-
ferences between BSR countries although they do not include actual amounts of returned unused phar-
maceuticals.  
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Table 21. Citizens ways to get rid of unused pharmaceuticals in the BSR. 
Country / year of interviews  
or year when study  
was published 
Share of the surveyed 
people that returned  
unused pharmaceuti-
cals to pharmacies  
and hazardous waste 
collection points 
Share of the surveyed 
people that flushed 
unused pharmaceuti-
cals to sewer 
Share of the surveyed 
people that disposed  
unused pharmaceuti-
cals to mixed  
household waste 
Finland / studies made 2009–2010 65% (60–80%) 3% 16% 
Latvia / studies made in 2012 & 2014 6–10% 5–12% 41–62% 
Lithuania / study made in 2013 10–13% no info 50–64% 
Poland / 2015 (study published) 5-8% 24–33% 57–60% 
Sweden / studies made in 2011 & 2012 69–75% ≈ 17% 
Russia / 2013 (study published) no info 15% 80% 
 
The main findings on national take-back schemes of unused human pharmaceuticals from house-
holds are as follows (Table 22): 
• The responsible party for arranging reception of unused pharmaceuticals from households is 
usually the municipality, as it is in Denmark, Estonia, Finland, Germany, Latvia, Poland and 
Sweden. In Sweden also pharmacies are responsible for arranging the reception. In Lithuania 
the responsible party is unclear. In Russia there is no legislation and thus no responsible party 
for arranging the reception.  
• Russian legislation does not regulate collection of unused pharmaceuticals from households. 
• In general, the pharmacies are the collection points in the Baltic Sea region, except in Germany 
and Russia:  
• in Germany, Latvia and Poland only some pharmacies receive unused human pharmaceuti-
cals. 
• It varies a lot what kind of unused household pharmaceuticals are separately collected in the 
Baltic Sea countries: 
• all unused pharmaceuticals separately collected in Denmark, Estonia, Finland, Latvia, Po-
land and Sweden, 
• no separate collection for unused pharmaceuticals in Germany and Russia. 
o In Germany, where mixed household waste is often incinerated, people are in-
structed to dispose unused pharmaceuticals with mixed household waste. How-
ever, in case household waste is not incinerated, disposal of pharmaceuticals at 
mobile collection vehicles or recycling centres is recommended. 
• Pharmacy-based take-back system is well established, extensive and functions quite well. There 
is clear legislation which states the division of responsibility for take-back of unused drugs in 
Denmark, Estonia, Finland and Sweden. 
• In some countries (Germany, Latvia, Poland) some pharmacies accept unused medicines on vol-
untary basis, but that is not their obligation and the collection system is not properly organized. 
Partly due to these reasons, the citizens of these countries return their unused medicines rela-
tively rarely to pharmacies but dispose them of into toilet or sink or to mixed household waste.   
• The most common reason for improper disposal of medicines from households appears to be the 
lack of information on how to get rid of them in an environmentally sound manner. Other rea-
sons are indifference, hurry, long distances to collection points and that the amount of the medi-
cine was small or that it was thought to be harmless (e.g., Denmark, Finland, and Latvia).  
• The returning of unused pharmaceuticals is commonly free of charge for cítizens (e.g., Estonia, 
Finland, and Sweden). In Sweden pharmacy customers get sometimes rewarded with bonus-
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systems at the pharmacies. This creates an incentive for the citizens to return their unused medi-
cines. 
• Pharmacy-based take-back systems that were assessed to be efficient, have several common 
positive features:  
• an extensive pharmacy (i.e., collection-point) network 
• absence of direct costs for the citizens  
• status as a well-known collection system among citizens  
• encouragement of also the pharmacies to dispose of unused medicines properly, because 
pharmacies can for free include their own pharmaceutical waste among the collected waste 
to be delivered to proper disposal. 
• The Swedish pharmacies see environmental profiling as a competitive advantage, which bene-
fits the development of more efficient take-back system. 
Table 22. The national practices on take-back of unused human and companion animal 
pharmaceuticals from households. 
Country Types of pharmaceuticals 
collected separately 
Responsible party for 
arranging reception 
Collection point 
Denmark – human and 
companion animal 
All pharmaceuticals Municipality Usually local pharmacies  
(depends on municipality) 
Estonia – human and  
companion animal 
All pharmaceuticals Municipality Local pharmacies and municipal 
waste collection stations 
Finland – human and  
companion animal 
All pharmaceuticals Municipality Usually local pharmacies;  
seldom municipal waste  
collection stations (depends  
on municipality) 
Germany – human and 
companion animal 
Nothing Municipality Depends on municipality 
Latvia – human and  
companion animal 
All pharmaceuticals Municipality /state for 
hazardous waste 
Usually local pharmacies  
and waste sorting areas 
Lithuania – human and 
companion animal 
No information Unclear Pharmacies 
Poland – human All pharmaceuticals Municipality Usually local pharmacies or  
other collection points  
(depends on municipality) 
Poland – companion  
animal 
Lack of information Veterinarian or  
veterinary practice /  
municipality 
Veterinarian or veterinary  
practice. Usually local pharmacy 
(depends on municipality). 
Russia – human and  
companion animal 
None No responsible party Not exist 
Sweden – human and  
companion animal 
All pharmaceuticals Pharmacies / 
municipalities 
Pharmacies 
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Unused companion animal pharmaceuticals 
The main findings on national take-back practices on unused companion animal pharmaceuticals from 
households are: 
• Municipalities are the responsible party for arranging the reception of unused medicines in Den-
mark, Estonia, Finland, Germany, Latvia, Poland and Sweden. 
• In Poland also veterinarians are responsible for arranging the reception. 
• In Latvia state is responsible for hazardous waste. 
• In Sweden also pharmacies are responsible for arranging the reception. 
• Pharmacies act as main collection points in Denmark, Estonia, Finland, Latvia, Poland and 
Sweden.  
• In Poland also veterinarians or veterinary practices act as collection points. 
• In Germany, Latvia and Poland only some pharmacies receive unused companion animal 
pharmaceuticals. 
• In Lithuania pharmacies are obligated to receive unused medicines from households and 
this presumably concerns companion animal medicines, but the pharmacies do not inform 
citizens about this. 
• Russian legislation does not regulate collection of companion animal pharmaceuticals from 
households. 
• There is no information about quantity or quality of unused companion animal medicine. 
 
Identified areas for improvement   
Areas of improvement concerning take-back of unused household pharmaceuticals are as follows: 
• Raising public awareness on proper disposal of unused household pharmaceuticals is important 
and would increase the fraction of unused medicines correctly returned (e.g., Denmark, Estonia, 
Finland, Germany, Latvia, and Sweden). 
• Scarce data makes the validation of the take-back scheme questionable. Most of the studies fo-
cus on economic aspects and do not consider the environmental aspects. More research-based 
information regarding the take-back fractions and actual amounts of unused pharmaceuticals is 
needed in order to follow and improve the efficiency of take-back scheme of human medicines 
(e.g., Denmark, Estonia, Finland, Germany, Latvia, and Sweden). 
• In some countries the interpretations of the regulations are unclear (Poland) and there are seri-
ous deficiencies in legislation (Lithuania and Russia).  
• Unclear liabilities and instructions cause dissatisfaction to pharmacies and waste management 
companies (e.g., Finland). 
• The project has raised the question of the difference between hazardous-waste management and 
the management of unused pharmaceuticals. The take-back systems in different countries could 
benefit from the development of recycling centres so that all household waste can be collected 
in the same place. It might decrease the mishandling of unused pharmaceuticals and be an in-
centive for people to leave their pharmaceutical waste to proper management. 
3.2.2 Pharmaceutical industry 
The main findings on national management practices on pharmaceutical industry waste containing phar-
maceutical residues are as follows (Table 23): 
- In each of the countries, industrial operators are responsible for arranging the treatment of the 
pharmaceutical waste produced in their activities.  
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- In each country, the separate collection of pharmaceutical waste produced by industry is either 
organised through collaboration with waste-management companies or otherwise arranged by 
the industry operator. 
- Pharmaceutical industry is the largest source of pharmaceutical waste at least in Denmark. This 
waste originates for instance from errors in production and labelling, and expiry of medicines. 
However, statistics about pharmaceutical waste do not currently allow for comprehensive com-
parison between masses produced by households, industrial activities and other sources for the 
whole Baltic Sea Region. Industry might produce more waste in areas, where there are more in-
dustrial activities. The highest number of pharmaceutical industry sites within the Baltic Sea 
catchment area is located in Poland, Denmark and Sweden (Leisk et al. 2020, Wallberg et al. 
2014). 
- There is no information from Lithuania and Russia. 
Table 23. The national practices on take-back of unused pharmaceuticals from pharmaceutical industry. 
Country Types of waste containing 
pharmaceutical residues  
collected separately 
Responsible party for  
arranging reception 
Collection point 
Denmark All products, waste fractions and 
ingredients classified as hazard-
ous waste and pharmaceuticals 
Industry operator Organized and paid by the  
individual industry operator 
Estonia No information Industry operator Licensed waste management  
company or municipal waste  
collection point, if a special  
agreement 
Finland All waste classified as  
hazardous waste 
Industry operator Organized by the industry operator 
Germany All Service provider,  
Industry operator 
Organized by the industry operator 
Latvia All Industry operator, State for 
hazardous types of waste 
Organized by the industry operator 
(delivered to hazardous waste 
manager with appropriate  
environmental permits) 
Lithuania No information No information No information 
Poland All products, waste fractions and 
ingredients classified as hazard-
ous waste and pharmaceuticals 
Industry operator Organized by the industry operator 
Russia No information No information No information 
Sweden All products, waste fractions and 
ingredients which are classified 
as hazardous waste and  
pharmaceuticals 
Industry operator Pharmaceutical industry routines 
through agreements with facilities 
licensed to destroy hazardous 
waste 
3.2.3 Hospitals and health care institutions 
The main findings on national take-back practices on unused pharmaceuticals from hospitals and other 
health care institutions are as follows (Table 24): 
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• In Estonia, Denmark, Finland, Germany, Latvia, Poland and Sweden hospitals arrange the han-
dling of pharmaceutical waste by themselves. In Estonia pharmaceutical waste generated as the 
result of other health services must be transferred to a licensed waste management company. 
• In Poland and Sweden also other health care institutions than hospitals are obligated to collect 
their pharmaceutical waste and transfer them to the appropriate disposal operators. 
• In Denmark practising doctors, nursing homes and health care institutions other than hospitals 
can return unused medicines also to pharmacies. In Finland the unused medicines from domicil-
iary care or from supported and service housing are usually disposed in a coordinated manner 
via pharmacies. 
• Although practice in which hospitals arrange the handling of pharmaceutical waste by them-
selves appears to be simple and efficient, there is hardly any actual surveys done about how 
well this practise is accomplished.  
• In Poland, it has been recognized that practices in health care institutions are not always compli-
ant with national waste legislation.  
• In Lithuania and Russia the situation is unknown. 
Table 24. The national practices on take-back schemes of unused pharmaceuticals in hospitals and 
health care institutions. 
Country Types of pharmaceuticals 
collected separately 
Responsible party for  
arranging reception 
Collection point 
Denmark All pharmaceuticals Hospitals or health care  
institutions / municipality 
Individual hand in by hospitals,  
or municipally organized hand in,  
usually pharmacy. 
Estonia All pharmaceuticals Hospitals or health care  
institutions 
Licensed waste management  
company 
Finland All pharmaceuticals Hospitals or health care  
institutions / municipality 
Organized by the hospital or  
health care institution / for hospitals 
usually hospital pharmacies 
Germany All pharmaceuticals Hospitals or health care  
institutions 
Organized by the hospital or  
health care institution 
Latvia All pharmaceuticals Hospitals or health care  
institutions 
Organized by the hospital or  
health care institution 
Lithuania No information No information No information 
Poland All pharmaceuticals Hospitals or health care  
institutions 
Organized by the hospital or  
health care institution 
Russia No information No information No information 
Sweden All pharmaceuticals Hospitals or health care  
institutions 
Hospital and health care institutions  
routines and agreements with  
pharmacies and facilities licensed  
to destroy hazardous waste 
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3.2.4 Veterinarians and veterinary practices 
The main findings on national take-back practices on unused veterinary pharmaceuticals from veterinary 
practices are as follows (Table 25): 
• In Estonia, Finland, Germany, Latvia, Poland and Sweden veterinaries are responsible for ar-
ranging the collection of their own unused medicines. 
• Usually, there are no specific collection points, but veterinarians and veterinary practices make 
their own arrangements. 
• In Denmark and Sweden: can also return to pharmacies. 
• In Lithuania and Russia the situation is unknown.  
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Table 25. The national practices on take-back of unused pharmaceuticals from veterinarians and 
veterinary practices. 
Country Types of pharmaceuticals  
collected separately 
Responsible party for  
arranging reception 
Collection point 
Denmark All pharmaceuticals Municipality Usually local pharmacy 
Estonia All pharmaceuticals Veterinarians or  
veterinary practices 
Licensed waste management 
company 
Finland All pharmaceuticals Veterinarians or  
veterinary practices 
Organized by the veterinarian or 
veterinary practice 
Germany Cytotoxic and cytostatic  
pharmaceuticals 
Veterinarian or veterinary 
practice or municipality 
Organized by the veterinarian or 
veterinary practice 
Latvia All pharmaceuticals Veterinarians or  
veterinary practices 
Organized by the veterinarian or 
veterinary practice 
Lithuania No information No information No information 
Poland All pharmaceuticals Veterinarians or  
veterinary practices 
Organized by the veterinarian or 
veterinary practice 
Russia No information No information No information 
Sweden All pharmaceuticals Veterinarians or  
veterinary practices 
Pharmacies  
3.2.5 Veterinary pharmaceuticals used for livestock in farms 
The main findings on national take-back practices on unused veterinary pharmaceuticals used for live-
stock are as follows (Table 26): 
• There is variation in the responsible party for arranging the collection and it can be the farmer, 
municipality or veterinarian. 
• The collection point can also be: 
• a pharmacy in Denmark, Finland (small amounts), Germany (small amounts), Poland and 
Sweden (non-hazardous only) 
• a veterinarian in Poland 
• a farmer is obligated to arrange the collection in Estonia (if the farm is a legal entity), Finland 
(large amounts), Germany (large amounts), Latvia (big farms) and Sweden (hazardous waste) 
• In Lithuania and Russia the situation is unknown. 
 
In general, in several Baltic Sea countries unused veterinary pharmaceuticals used for livestock in 
farms is collected together with other types of veterinary waste by veterinarians or returned to local col-
lection points (e.g. pharmacies) by farmers or managed via contracted waste operators organized by 
farmers or they are directly disposed of in the municipal waste stream.  
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Table 26. The national practices on take-back of unused veterinary pharmaceuticals in farms. 
Country Types of pharmaceuticals  
collected separately 
Responsible party for  
arranging reception 
Collection point 
Denmark All pharmaceuticals Municipality Usually local pharmacy 
Estonia All pharmaceuticals Farmer (if legal entity) Licensed waste management 
company 
Finland All pharmaceuticals Municipality Usually local pharmacy*  
(depends on municipality) 
Germany Cytotoxic and cytostatic  
pharmaceuticals 
Farmer / Service provider / 
Municipality 
Usually local pharmacy* 
Latvia All pharmaceuticals Farmer; 
Municipality / State for  
hazardous waste 
Pharmacies or waste sorting  
areas/ farmers of large productive 
animal sheds must have an  
agreement with managers of  
hazardous waste 
Lithuania No information No information No information 
Poland Lack of information Veterinarian or veterinary 
practice / municipality 
Veterinarian or veterinary practice. 
Usually local pharmacy  
(depends on municipality) 
Russia No information No information No information 
Sweden All pharmaceuticals Farmer Pharmacies / for hazardous waste 
farmers must have an agreement 
with transport and facilities  
licensed to destroy medical waste 
* Farmer is obligated to arrange the delivery to proper treatment in case of unreasonable amount of unused veterinary 
pharmaceuticals. 
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3.3 Disposal of unused medicines and other waste containing 
pharmaceutical residues 
3.3.1 Households 
The findings on national disposal practices on unused pharmaceuticals from households are as follows 
(see Table 27 in the 3.3.6.): 
• The main disposal method for the sorted unused human and companion animal medicines in the 
Baltic Sea region is incineration (Denmark, Estonia, Finland, Germany, Latvia, Poland, Swe-
den). 
• High temperature incineration (> 1100 °C) appears to be a controlled and efficient treatment 
method at least in Estonia (1300 °C), Finland (1100-1300 °C), Poland (1100 °C) and Denmark 
(>1100 °C). The incineration temperature is in Latvia 850 °C, in Germany 850–1300 °C and in 
Sweden 850–1100 °C. 
• In Russia the unused household medicines are not collected separately and the main disposal 
method is landfilling at designated sites 
• Uncertainties related to disposal of unused human pharmaceuticals from households are:  
• Few public data and information on the high temperature incineration operated by compa-
nies (e.g. Denmark). 
• Is it possible that lower than 1100–1300 °C incineration temperature would be enough for 
irreversible treatment of pharmaceutical wastes. 
3.3.2 Pharmaceutical industry 
The findings on national disposal practices of waste from pharmaceutical industry are as follows (see 
Table 27 in the 3.3.6.): 
• The main method of disposal for hazardous wastes produced in manufacturing activities is in-
cineration (temperatures varying from 800 to 1300 °C). 
• Other treatment methods: wet chemical treatment and biological treatment. 
• In Russia waste is treated with incineration, discharge into industrial sewers and landfilling 
at designated sites. 
• At least in Latvia, pharmaceutical wastes originating from wholesaler and production activities 
may eventually be disposed of in a municipal landfill.  
• No information available from Lithuania. 
3.3.3 Hospitals and health care institutions 
The findings on national disposal practices of waste containing pharmaceutical residues from hospitals 
and health care institutions are as follows (see Table 27 in the 3.3.6.): 
- The main disposal method of pharmaceutical waste from hospitals and health care institutions is 
incineration with temperatures varying from 800 to 1300 °C (Denmark, Estonia, Finland, Po-
land, Sweden). 
- In Germany advanced solid waste incineration (850–1300 °C) or high temperature incineration 
(1000–1300 °C) are used. 
- In Latvia the method is disposal at hazardous waste landfill or recycling in a bioreactor. 
- In Russia waste is treated with incineration and with chemical and thermochemical destruction 
method. 
- In Lithuania the situation is unknown. 
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3.3.4 Veterinarians and veterinary practices 
The findings on national disposal practices of unused veterinary pharmaceuticals from veterinarians and 
veterinary practices are as follows (see Table 27 in the 3.3.6.): 
- Incineration with temperatures varying from 850 to 1300 °C is the general method of disposal 
of veterinary medicine waste (Denmark, Estonia, Finland, Germany, Poland, Sweden).  
- Mechanical and biological treatment of veterinary medicine waste is also used in Estonia, Ger-
many and Sweden and landfilling in Estonia.  
- In Latvia the veterinary medicine waste is disposed at hazardous waste landfill or recycled in a 
bioreactor. 
- In Lithuania and Russia the situation of this specific sector is unknown.  
3.3.5 Veterinary pharmaceuticals used for livestock in farms 
The findings on national disposal practices of unused veterinary pharmaceuticals used for livestock in 
farms are as follows (see Table 27 in the chapter 3.3.6.): 
- The incineration with temperatures varying from 850 to 1300 °C is the general method of dis-
posal. Mechanical and biological treatment is also used in Sweden, Estonia and Germany and 
landfilling in Estonia. 
- In Lithuania and Russia the situation of this specific sector is unknown.  
3.3.6 Summary of the disposal of unused medicines 
Summary of the information presented in chapters 3.3.1–3.3.5 are presented in the Table 27. 
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Table 27. Summary of the disposal of unused medicines and other waste containing pharmaceutical 
residues in the Baltic Sea region. 
Country Households  
(human & com-
panion animal) 
Pharmaceutical 
industry 
Hospitals and 
health care  
institutions 
Veterinarians  
and veterinary  
practices 
Farms 
Denmark High temperature incineration for collected waste (1100 °C) 
Finland High temperature incineration for collected waste (1100–1300 °C) 
Sweden 
Incineration for collected waste 800–1000 °C. 
For hazardous waste may other methods be used, such as wet chemical treatment,  
biological treatment or disposal 
Lithuania Incineration Unknown 
Russia Landfilling 
Incineration,  
discharge into  
industrial sewers 
and landfilling 
Incineration,  
chemical and  
thermochemical  
destruction 
Unknown 
Estonia 
Hazardous waste 
(prescribed  
pharmaceuticals): 
high temperature 
incineration  
(1300 °C).  
Non-hazardous 
waste: incinera-
tion or biological 
and mechanical 
treatment or  
landfilling 
Hazardous waste: high temperature incineration (1300 °C).  
Non-hazardous waste: incineration or biological and  
mechanical treatment or landfilling 
Germany 
Mechanical  
biological  
pre-treatment 
stage, advanced 
solid waste  
incineration 
(850–1300 °C) or 
high temperature 
incineration 
(1000–1300 °C) 
High temperature 
incineration 
(1000–1300 °C), 
physico-chemical 
treatment,  
or incineration in 
power plants 
Hazardous waste: high temperature  
incineration (1000–1300 °C). 
Non-hazardous waste: mechanical biological  
pre-treatment stage or an advanced solid waste  
incineration (850–1300 °C) 
Latvia 
Incineration at 
850 °C or waste 
disposal at land-
fills for collected 
waste. Waste  
disposal at  
landfills for  
unsorted waste. 
Incineration at 
850 °C or waste 
disposal  
(depending on 
waste class – 
hazardous waste 
is incinerated) 
Waste disposal at municipal landfill after sterilization, shredding 
Poland 
High temperature 
incineration  
(1100 °C) 
High temperature 
incineration 
(1100 °C) 
High temperature incineration (1100 °C) 
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4 Good practices and recommendations for 
take-back and disposal of unused 
pharmaceuticals and other waste containing 
pharmaceutical residues 
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At the EU level, the Strategic Approach to Pharmaceuticals in the Environment 
emphasizes e.g. sharing good practices, cooperating at international level, and 
improving understanding of the risks. It has identified action areas throughout 
the life cycle of pharmaceuticals, with a strong emphasis on source-directed 
and use-oriented approaches, as opposed to end-of-pipe treatment options. 
OECD Policy paper on pharmaceuticals (OECD 2019) states that “a focus on 
preventive options early in the pharmaceutical life cycle, may deliver the most 
long-term, cost-effective and large-scale benefits”. 
4.1 Preventive recommendations 
4.1.1 The rational use of pharmaceuticals  
The rational use of human and veterinary pharmaceuticals reduces the amount of pharmaceutical waste 
produced and is referred in European Commission strategy paper (EC 2019) as one of six areas for ac-
tion to reduce the risk posed by medicines released into the environment. The mis- and over-use of anti-
biotics is an important factor contributing to antimicrobial resistance (AMR) which is a global health 
crisis with enormous negative health, food security and economic consequences. Up to 50% of the anti-
biotics prescribed for human use are considered unnecessary; the share is even greater in the agriculture 
and aquaculture sectors where in some countries antibiotics are administered as a growth promoter and 
as a substitute for good hygiene. Over-prescription, self-medication (over-the-counter pharmaceuticals) 
and misdiagnosis of symptoms increase the amount of medicines administered and improperly disposed 
of but also increase the levels in the environment. The use of advanced diagnostics is very important in 
order to avoid unnecessary prescriptions (OECD 2019).  
About 3–4% of the sold medicines (as price of medicines, not as amount) in Finland are left unused 
(Association of Finnish Pharmacies 2017) and the same figure for Sweden is estimated to be 5% (BIO 
Intelligence Service 2013, CCB 2017). European Federation of Pharmaceutical Industries and 
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Associations (EFPIA) has estimated that the unused human medicines represent 3-8% of the sold 
amount in Europe (BIO Intelligence Service 2013). In some EU countries 5-50% of purchased medi-
cines end up unused or outdated because of treatment interruptions, mostly due to intolerance to the ini-
tial medicine and voluntary discontinuation (BIO Intelligence Service 2013). In the USA, about one-
third of the prescription items annually become waste (OECD 2019). 
Thus, unnecessary and duplicated use of medications should be reduced (Recommendation 1). 
Patients getting new prescriptions could initially be given a small package of the medication, as this 
would minimize the amount of pharmaceutical waste if it becomes necessary to switch this medicine for 
another (Nystén et al. 2019). Thus, in order to reduce the amount of pharmaceutical waste the human, 
companion animal and other veterinary medicines should only be prescribed and used when needed and 
based on the diagnosis. This is specifically important for antibiotics due to increasing problem related to 
AMR.  
Widening and making the requirement for a compulsory prescription stricter in the human and com-
panion animal medicines is an effective way to control the use of environmentally risky medicines and 
may decrease the amount of pharmaceutical waste produced (Lockwood et al. 2017). This could be ef-
fective especially concerning highly problematic or environmentally risky pharmaceuticals. The share of 
non-prescription medicines, especially analgesics, is steadily increasing in the total consumption of me-
dicinal products in Germany and has already reached an order of magnitude similar to that of prescrip-
tion medicines (Ahting et al. 2018). Information about environmental effects of pharmaceutical emis-
sions should be included into the studies of medical doctors already as incorporated in pharmacy studies 
at least in Finland (Sivén et al. 2020). Information campaigns should be carried out also to practicing 
medical doctors in order to ensure that similar information is available for all doctors regardless of the 
career stage. 
Instructions on the safe usage of medical products, could be given by pharmacy staff or veteri-
narians when they hand out the pharmaceuticals to the customers (Recommendation 2). As medicine 
experts, pharmacists are well placed to increase public awareness, promote the prudent use and correct 
disposal of pharmaceuticals (PGEU 2019). These instructions could concern for example picking up the 
faeces of companion animals if medicated with cytostatic. 
4.1.2 The unification of take-back and disposal requirements or the harmonization of 
hazardous waste classification 
There are national differences on which pharmaceutical wastes are classified as hazardous, resulting in 
differences in the collection and treatment of these wastes. To unify their treatment, either the take-back 
and disposal requirements need to be unified and separated from the waste classification, or the classifi-
cation criteria need to be harmonized regionally or at the EU-level. To unify the take-back and disposal 
of wastes contaminated with pharmaceutical residues, it is recommended that these kinds of wastes 
should be collected separately and disposed of appropriately, irrespective of the classification of 
wastes (Recommendation 3).  
This issue is connected to promotion of e.g. Recommendation 6 (human medicines), Recommenda-
tion 7 and 8 (companion animal medicines) and Recommendation 19 (industry) 
4.2 Households 
This chapter deals with both human medicines and companion animal medicines. In general, the range 
of APIs available for human medication is much broader than the range of APIs used for veterinary pur-
poses. Antibiotics account for a large part of the veterinary market. In general, at EU level only 1-2% of 
the veterinary antibiotics sold are for companion animal only, as the large majority is for farming ani-
mals (93%), About 5 to 7% of veterinary antibiotics can be used for either companion or farming 
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animals. Nevertheless, a growing segment of the veterinary products market is the companion animals – 
in contrast with farming animals (BIO Intelligence Service 2013). 
4.2.1 Human medicines 
Scarce data makes the validation of the national take-back schemes in the Baltic Sea region questiona-
ble. More research-based information regarding the take-back fractions and actual quantities of sold and 
unused pharmaceuticals are needed in order to follow and improve the efficiency of take-back of human 
pharmaceuticals.  
Thus, it is recommended that the studies about the fate of unused household medicines in all 
Baltic Sea countries should be regularly (e.g. every 3 years) made in order to follow up the situation 
(Recommendation 4).  
- The studies should cover not only the share of people that return the unused pharmaceuticals 
properly to the collection point but also e.g. the share of the weight of the pharmaceuticals.  
- The studies should be linked to the information campaigns on proper handling of unused medi-
cines (see also Recommendation 5). 
One of the reasons mentioned for incorrect disposal of unused medicines, e.g. in Finland and Lat-
via, is that citizens misleadingly believe that the unused pharmaceuticals and pharmaceutical waste is 
harmless or that pharmaceuticals are removed from waste waters in municipal WWTPs. Therefore, it is 
recommended to increase the awareness of citizens concerning pharmaceuticals in the environment 
(Recommendation 5) with the following ways: 
- Information campaigns will be arranged on proper handling of unused human and companion 
animal medicines stressing the harmful environmental impacts of incorrectly disposed unused 
medicines targeted to citizens. Campaigns should consider also environmentally safe use of vet-
erinary medicines. 
- Information campaigns could be promoted by different actors such as authorities like national 
ministries of social and health affairs and environment, medical or environmental agencies and 
pharmacies or their interest groups. However, it is advantageous if several actors would make a 
joint campaign.  
- The pharmacies should actively give sorting instructions for customers e.g. when selling medi-
cines. As medicine experts, pharmacists are well placed and motivated to increase public aware-
ness, promote the prudent use and correct disposal of unused pharmaceuticals. 
This action, i.e. increase public awareness on proper handling of unused medicines, has been stated 
in European Commission strategy paper (EC 2019) as one way to reduce the risk posed by medicines 
released into the environment. OECD’s Policy paper on pharmaceuticals (OECD 2019) recommends 
e.g. to “Educate and engage with health professionals, veterinarians, consumers and farmers to raise 
awareness about inappropriate disposal of unused medications”. Education about the proper disposal is 
a relatively low cost and effective reduction measure (Ahting et al. 2018). 
 
For the citizen the easiest and the most recommended way is to return both prescribed and over-
the-counter pharmaceuticals (i.e. all unused household medicines) independent of its waste classifi-
cation to permissible collection point (Recommendation 6). 
- Sufficiently high density of permissible collection points as well as their location near citizens is 
important. 
- Information about collection points and sorting instructions should be concise and understanda-
ble but also easily accessible for citizens. 
- Permissible collection points could be pharmacies or hazardous waste collection sites. 
- Costs should be divided to several actors in order to avoid “overload” one actor such as phar-
macy. 
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- Citizens should be able to return unused pharmaceuticals to dedicated permissible collection 
points free of charge. The costs for separate collection and treatment of these waste fractions 
should not have to be covered (via separate price tag) by pharmacies.  
• As an incentive, pharmacies should be allowed to put their own pharmaceutical waste with-
out charge into the waste transported to disposal.  
• Municipalities should partly cover the costs e.g. by arranging the delivery of unused medi-
cines from pharmacies to disposal site. 
Extra incentives for returning unused pharmaceuticals to pharmacies should be looked into. For ex-
ample, by giving extra bonus points to customers returning unused pharmaceuticals like has been done 
via campaigns in Sweden. 
4.2.2 Companion animal medicines 
Customers should be able to return all unused companion animal medicines, irrespective of their 
waste classification, to same collection point (e.g. to pharmacies), where the collection of human 
medicines takes place (Recommendation 7). This possibility should be advertised to citizens in order to 
avoid confusion. 
Customers should be given the option of returning all unused veterinary pharmaceuticals, irre-
spective of their waste classification, to veterinary clinics, if this is in line with national legislation 
(Recommendation 8). Costs could be covered in same country-specific way that is already done in 
cases of pharmacies. This means that the costs for separate collection and treatment of these waste frac-
tions should not have to be covered with separate price tag by veterinary practices. As an incentive, vet-
erinary practices should be allowed to put their own pharmaceutical waste without charge into the waste 
transported to disposal. 
As in the case of unused human medicines, customers should be provided with information 
about the proper handling of unused companion animal medicines (Recommendation 9). It is recom-
mended that companion animal medicines are included to information campaigns mentioned in Recom-
mendation 5.  
All Baltic Sea region countries lack information about the amounts and quality of unused com-
panion animal medicines. Statistics about returned unused companion animal medicines should be 
produced for the sake of achieving a better view (Recommendation 10). But before this, it is recom-
mended that the consumption information of companion animal medicines should be collected from 
each country. 
4.3 Hospitals and health care institutions 
Efficient practice is that hospitals collect their own pharmaceutical waste and send it directly to waste 
treatment facilities as it is now taking place (Recommendation 11).  
Other health care institutions, such as facilities providing service housings, retirement homes, 
private clinics or other operators providing domiciliary care, should have centralized collection 
scheme for the pharmaceutical wastes (Recommendation 12). This collection scheme should cover the 
pharmaceuticals administered to patients in the activities within the facility, but also the unused pharma-
ceuticals from the personal medications of individual patients. This would ensure, that also people with 
possible disabilities would have an easily accessible collection point for all of their unused pharmaceuti-
cals. 
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4.4 Farms 
It is stated in the regulation (EU) 2019/2016 that “antimicrobial medicinal products shall not be applied 
routinely nor used to compensate for poor hygiene, inadequate animal husbandry or lack of care or to 
compensate for poor farm management” and ”antimicrobial medicinal products shall not be used in 
animals for the purpose of promoting growth nor to increase yield”. In EU’s Strategic Approach to 
Pharmaceuticals in the Environment (COM/2019/128 final) is presented the Commission’s intention to 
promote prudent use of pharmaceuticals. 
The implementation of take-back systems in EU member states is very heterogeneous: the take-
back is better organised for human medicines than for veterinary medicines in several EU member 
states. Veterinary medicine waste is collected together with other types of veterinary waste by veterinar-
ians or directly disposed of in the municipal waste stream (Lockwood et al. 2017). These collection 
methods and the returning to local collection points (e.g. pharmacies) by farmers or managed via con-
tracted waste operators organized by farmers were found to be current practices in several Baltic Sea 
countries. But in general information on the take-back schemes for unused human medicines is more 
readily available than the information concerning veterinary medicines in the Baltic Sea region. 
When the veterinarian is making check-up visits to the farm, the farmer should have the option 
of returning unused veterinary medicines to the veterinarian, who should have a possibility to charge 
the collection costs. (Recommendation 13). 
If the amount of accumulating unused medicines is unreasonable, farmers should be responsible 
for organizing the delivery of medicines to appropriate treatment in the same way as pharmacies and 
hospitals do. Reasonable amounts of unused medicines should be allowed to be returned to the same 
collection points same way as the unused household medicines. However, “reasonable” and “unrea-
sonable” amounts should be defined more specifically (Recommendation 14). 
Information campaigns targeted on farmers could improve the knowledge about how unused 
medicines should be handled appropriately (Recommendation 15). National ministries for the environ-
ment and agriculture should promote and offer financial support for the information campaigns. 
4.5 Veterinarians and veterinary practices 
Efficient practice is that veterinarian and veterinary practices collect the pharmaceutical waste pro-
duced by their own activities or returned to them by farmers or households and send it directly to 
waste treatment facilities as it is now taking place at least in some BS countries (Recommendation 
16).  
Information about proper disposal and handling of unused medicines and potential harmful en-
vironmental effects of pharmaceutical emissions should be included into the education of veterinari-
ans (Recommendation 17).  
The information campaigns (incl. guidelines/good practices) should be also carried to veterinari-
ans and other medical staff of veterinary practices in order to ensure that similar information is 
available for already practicing veterinarians (Recommendation 18).  
These information campaigns should be promoted by different actors such as national ministries for 
agriculture and environment, medical or environmental agencies or agricultural interest groups. 
4.6 Pharmaceutical industry 
Currently the treatment of industrial wastes contaminated with pharmaceutical residues depends on its 
waste classification. At the moment, industrial pharmaceutical wastes classified as hazardous are to be 
collected separately and to be disposed of properly in each of the countries.  
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However, there are national differences on the application of waste classification criteria. Addition-
ally, the waste directive (2008/98/EC) allows national deviations from the classification to a certain ex-
tent. Currently the pharmaceutical wastes produced by industry are not categorically classified as haz-
ardous in any Baltic Sea country but are only classified as such based on the properties of the waste. 
According to 2008/98/EC, waste is to be classified as hazardous if it has one or more properties listed in 
Annex III of 2008/98/EC. However, some countries also classify e.g. final products (DK) or unusable 
products (DE) generated by pharmaceutical industry as hazardous waste, while some others may clas-
sify industrial wastes as hazardous based on their cytotoxic or cytostatic properties (LV & PL).  
Therefore, it is recommended either that the disposal requirements are unified and separated from 
the waste classification, or that the classification of pharmaceutical waste is unified regionally or at the 
EU-level. Harmonizing and clarifying waste classification in the BSR, or at the EU-level, would help to 
unify the properties that make pharmaceutical waste fraction hazardous.  
To unify the disposal of industrial wastes contaminated with pharmaceutical residues in the Bal-
tic Sea region, it is recommended that this kind of wastes should be collected separately and disposed 
of appropriately, irrespective of its waste classification (Recommendation 19). However, to prevent 
unnecessary climate impacts and waste of resources, wastes contaminated exclusively with vitamins, 
electrolytes, amino acids, peptides, proteins, carbohydrates and lipids should not be considered to re-
quire intensive treatment (e.g. high temperature incineration) or separate collection, unless there is rea-
son to expect them to cause environmental risk. This applies also to vaccines and herbal medicinal prod-
ucts. 
4.7 Disposal 
High temperature incineration (at around 1 100–1 300 °C) is recommended treatment method for un-
used medicines and other pharmaceutical waste, unless a lower temperature is proven to irreversibly 
transform the active ingredients into non-hazardous substances (Recommendation 20).  
All operators managing the disposal of wastes containing pharmaceutical residues must have the 
appropriate environmental permits required by national legislation (Recommendation 21).  
These recommendations apply also to wastes generated in industrial activities with exceptions indi-
cated in Recommendation 19. 
4.8 Summary 
The proportion of surveyed citizens who return unused pharmaceuticals via designated collection points 
varies greatly amongst Baltic Sea countries, from about 10% to 70%, with 16–80% disposing of them of 
as mixed household waste and 3–30% flushing them down the drain. Nevertheless, this kind of infor-
mation is not available from Denmark, Estonia and Germany. The most commonly cited reason for im-
proper disposal of medicines on households’ part is lack of information about their environmental im-
pacts and how to get rid of them in an environmentally sound manner.  
Separate collection of unused household pharmaceuticals does not exist in Russia, and the collection 
mechanism functions poorly in Latvia, Lithuania and Poland. In Germany, where mixed household 
waste is often incinerated, people are instructed to dispose unused pharmaceuticals with mixed house-
hold waste. However, in case household waste is not incinerated, disposal of pharmaceuticals at mobile 
collection vehicles or recycling centres is recommended in Germany. Pharmacy-based take-back system 
seem to be well established, extensive and functions quite well. There is clear legislation which states 
the division of responsibility for take-back of unused pharmaceuticals in Denmark, Estonia, Finland and 
Sweden.  
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The take-back for human medicines is usually better organised than for veterinary medicines. Statistics 
about pharmaceutical waste do not currently allow for comprehensive comparison between masses pro-
duced by households, industrial activities and other sources for the whole Baltic Sea Region. Pharma-
ceutical industry may produce more waste in areas, where there are more industrial activities such as in 
Poland, Denmark and Sweden. 
Information on the take-back schemes for unused human medicines is more readily available than is 
corresponding information on veterinary medicines. The information basis of this study is scarcer for 
Lithuania and Russia than for Denmark, Estonia, Finland, Germany, Latvia, Poland and Sweden. 
We identified 21 good practices and recommendations for take-back and disposal of unused phar-
maceuticals and other pharmaceutical waste and for promoting the rational use of pharmaceuticals in the 
Baltic Sea region (Table 28).  
One of the main recommendations is that citizens should be able to take all unused medicines – both 
prescribed and over-the counter – to designated collection point such as the site where it has been 
bought (e.g. pharmacy) or hazardous waste collection site (Recommendation 6). This way, the unused 
medicines can be properly disposed of. This practice is simple to remember and also easy enough for the 
citizens. The same practice should also count for the medicines of companion animals. 
For pharmaceutical waste generated in hospitals the most efficient practice is that for hospitals to collect 
their own waste and send it directly to the waste treatment facilities (Recommendation 11). This is also 
the current practice in the Baltic Sea Region. Other health care institutions, such as private clinics, re-
tirement homes, and facilities providing service housings or domiciliary care, should have centralized 
collection schemes for their pharmaceutical wastes (Recommendation 12). 
In the Baltic Sea region, veterinary medicinal waste is currently mainly either collected together with 
other types of veterinary waste by veterinarians or returned to local collection points (e.g. pharmacies) 
by farmers or managed via contracted waste operators organized by farmers or they are directly dis-
posed of in mixed household waste. It is recommended that when a veterinarian makes check-up visits 
to farm, the farmer should have the option of returning unused veterinary medicines to the veterinarian, 
who should be able to charge collection and waste management costs (Recommendation 13).  Addition-
ally, if the amount of accumulating unused medicines is unreasonable, farmers should be responsible for 
organizing the delivery of medicines to appropriate treatment in the same way as pharmacies and hospi-
tals do. Reasonable amounts of unused medicines should be allowed to be returned to the same collec-
tion points same way as the unused household medicines. However, “reasonable” and “unreasonable” 
amounts should be defined more specifically (Recommendation 14). 
To unify the disposal of industrial wastes contaminated with pharmaceutical residues in the Baltic Sea 
region, it is recommended that this kind of wastes should be collected separately and disposed of appro-
priately, irrespective of its waste classification (Recommendation 19). 
Targeted information campaigns on the environmental effects of pharmaceutical emissions and how un-
used medicines should be handled appropriately are recommended for citizens, medical doctors and stu-
dents, veterinarians and veterinary students and farmers (Recommendation 1, 5, 15, 17, 18). These pro-
fessionals play a key role in helping implement several practices suggested by the CWPharma project. 
In general, high temperature incineration at around 1 100–1 300 °C is recommended treatment method 
for unused medicines and other pharmaceutical waste unless a lower temperature is proven to irreversi-
bly transform the active ingredients into non-hazardous substances (Recommendation 20). 
Nevertheless, implementing recommendations at national level requires particular consideration 
due to differences in national legislations and other characteristics in EU Baltic Sea countries and Rus-
sia.  
The good practices identified in this report answer the call for an EU strategic approach for an effi-
cient risk reduction strategy that combines policy options at various stages of the pharmaceutical life 
cycle. These measures can be divided in the following way (e.g. OECD 2019): 
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• Source-directed measures: for example, to expand world-widely the regulatory framework for 
good manufacturing practice (GMP) of pharmaceuticals to include mandatory environmental 
criteria. 
• Use-orientated measures: for example, to reduce self-prescription of pharmaceuticals with high 
environmental risk. 
• End-of-pipe measures: for example, to upgrade wastewater treatment.  
Table 28. The good practices and recommendations for take-back and disposal of unused 
pharmaceuticals and other pharmaceutical waste and to promote the rational use of pharmaceuticals  
in the Baltic Sea region. See more detailed information in chapters 4.1–4.7. 
Preventive 
Recommendation 1 (p. 91): Unnecessary and duplicated use of medications should be reduced.  
• The human, companion animal and other veterinary medicines should only be prescribed and used when needed  
and based on the diagnostic. This is specifically important for antibiotics due to increasing AMR problem. 
• Widening and making the requirement for a compulsory prescription stricter in the human and companion animal 
medicines is an effective way to control the use of environmentally risky medicines and may decrease the amount of 
pharmaceutical waste produced.  
• Information about environmental effects of pharmaceutical emissions should be included into the studies of medical 
doctors. Information campaigns should be carried also to practicing medical doctors to ensure that similar information is 
available regardless of the career stage. 
Recommendation 2 (p. 91): Instructions on the safe usage of medical products, should be given by pharmacy staff or 
veterinarians when handed out the pharmaceuticals to the customers. 
Recommendation 3 (p. 91): To unify the take-back and disposal of wastes contaminated with pharmaceutical resi-
dues, it is recommended that these kinds of wastes should be collected separately and disposed of appropriately,  
irrespective of the classification of wastes. 
Households 
 
Recommendation 4 (p. 92): The studies about the fate of unused household medicines in all Baltic Sea countries 
should be regularly (e.g. every 3 years) made in order to follow up the situation. 
Recommendation 5 (p. 92): Increase the awareness of citizens concerning pharmaceuticals in the environment.  
• Information campaigns on proper handling of unused medicines stressing the harmful environmental impacts of  
incorrectly disposed unused human and companion animal medicines targeted to citizens will be arranged. 
• Pharmacies should actively give sorting instructions for customers e.g. when selling medicines. 
Recommendation 6 (p. 92): Citizens should be able to return all unused medicines to dedicated, easily accessible  
collection points. 
• Sufficiently high density of collection points as well as their location near citizens should be ensured. 
• Information about collection points and sorting instructions should be concise and understandable but also easily  
accessible for citizens. 
• Permissible collection points could be pharmacies or hazardous waste collection sites. 
• Citizens should be able to return unused pharmaceuticals to collection points free of charge. 
Recommendation 7 (p. 93): The customers should be able to return all unused companion animal medicines, irrespec-
tive of their waste classification, to same collection point (e.g. to pharmacies), where the collection of human medicines 
takes place.   
Recommendation 8 (p. 93): The customers should be given the option of returning all unused veterinary pharmaceuti-
cals, irrespective of their waste classification, for free to veterinary clinics. 
Recommendation 9 (p. 93): The customers should be provided with information about the proper handling of unused 
companion animal medicines (see Rec 5). 
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Recommendation 10 (p. 93): Statistics about returned unused companion animal medicines should be produced for 
the sake of achieving better view (see Rec 4). 
Hospitals and health care institutions 
 
Recommendation 11 (p. 93): Hospitals should collect their own pharmaceutical waste and send it directly to waste 
treatment facilities. 
Recommendation 12 (p. 93): Other health care institutions, such as facilities providing service housings, retirement 
homes, assisted-living facilities, private clinics or other operators providing domiciliary care should have centralized col-
lection scheme for the pharmaceutical wastes. It covers all personal medications of patients. 
Veterinarians and farms 
 
Recommendation 13 (p. 94): When the veterinarian is making check-up visits to the farm, the farmer should have the 
option of returning unused veterinary medicines to the veterinarian, who should have a possibility to charge the collec-
tion costs. 
Recommendation 14 (p. 94): If the amount of accumulating unused medicines is unreasonable, farmers should be 
responsible for organizing the delivery of medicines to appropriate treatment in the same way as pharmacies and hospi-
tals do. Reasonable amounts of unused medicines should be allowed to be returned to the same collection points same 
way as the unused household medicines. Terms “reasonable” and “unreasonable” amounts should be defined more 
specific. 
Recommendation 15 (p. 94): Information campaigns targeted on farmers should be implemented to improve the 
knowledge about how unused medicines should be handled appropriately. 
Recommendation 16 (p. 94): Veterinarian and veterinary practices should collect the pharmaceutical waste produced 
by their own activities or returned to them by farmers or households and send it directly to waste treatment facilities. 
Recommendation 17 (p. 94): Information about proper disposal and handling of unused medicines and environmental 
effects of pharmaceutical emissions should be included into the studies of veterinarians. 
Recommendation 18 (p. 94): Information campaigns (incl. guidelines/good practices) should be also carried to veteri-
narians and other medical staff of veterinary practices in order to ensure that similar information is available for already 
practicing veterinarians. 
Industry 
 
Recommendation 19 (p. 95): To unify the disposal of industrial wastes contaminated with pharmaceutical residues in 
the Baltic Sea region, it is recommended that this kind of wastes should be collected separately and disposed of  
appropriately, irrespective of its waste classification. 
• Wastes contaminated exclusively with vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids 
should not be considered to require intensive treatment (e.g. high temperature incineration) or separate collection,  
unless there is reason to expect them to cause environmental risk. This applies also to vaccines and herbal medicinal 
products. 
Disposal 
 
Recommendation 20 (p. 95): High temperature incineration (at around 1 100–1 300°C) is recommended treatment 
method for unused medicines and other pharmaceutical waste, unless a lower temperature is proven to irreversibly 
transform the active ingredients into non-hazardous substances. 
Recommendation 21 (p. 95): All operators managing the disposal of wastes containing pharmaceutical residues must 
have the appropriate environmental permits required by national legislation. 
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Glossary 
Companion animals Animals that are kept as pets rather than for work or food 
Health care institutions Defined as public or private institutions that provide people with health 
care services – hospitals, clinics, retirement homes, assisted-living facili-
ties, dentists, etc. 
Livestock  Domestic animals raised in agriculture or aquaculture  
Pharmaceutical waste Covers unused pharmaceuticals from households, health care opera-
tors/providers, and farms, also encompassing waste material contaminated 
with pharmaceutical residues, originating from industrial activities  
Waste codes Based on the European List of Waste (2000/532/EC, 2008/98/EC) and are 
explained in Appendix 1. 
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Appendices 
 
Appendix 1. Waste codes. 
Waste code  
18 01 Wastes from diagnosis, treatment and medical prophylaxis 
18 01 08 Cytotoxic and cytostatic drugs 
18 01 09 Medicines other than those mentioned in 18 01 08 
18 02 Wastes from diagnosis, treatment and veterinary prophylaxis 
18 02 07 Cytotoxic and cytostatic drugs 
18 02 08 Medicines other than those mentioned in 18 02 07 
20 01 Municipal waste segregated and collected selectively 
20 01 31 Cytotoxic and cytostatic drugs 
20 01 32 Medicines other than those mentioned in 20 01 31 
 
Appendix 2. Latvian study on medicine waste within CWPharma project made by 
LEGMC   
There is no statistical information about medicaments of class 20 01 31 (cytotoxic and cytostatic medi-
cines) nor for medicines of class 20 01 32 (other medicines than class 20 01 31). The statistical infor-
mation of statistical report “3-Waste” regarding medical waste in Latvia is not sufficient to assess the 
functionality of disposal practices of unused medicines, especially for municipal waste.  
There is information about the amount of hazardous and municipal waste sent from and received in 
Latvia in Waste shipment accounting system (WSAS).  
Amounts of transported medicine waste 2012–2017 are summarized in Figure 8. 
Figure 8. Transported amount of medicine waste in years 2012–2017 (data from Waste shipment  
accounting system, WSAS). 
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180109: Waste, that occurs in the process of human chilbirth, diagnosing, treating or preventing
human illness - human medicaments not meeting the class 180108
18018: Waste, that occurs in the process of human childbirth, diagnosing, treating or preventing
human illness - cytotoxic and cytostatic medicines
200131: Cytotoxic and cytostatic medicines
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There is information of waste classes 18 01 08 (only for 2017), 18 01 09, 20 01 31 (only for 2014; 
WSAS). Waste of category 18 01 08 are sent to BAO Olaine Hazardous Waste Processing Complex for 
storage. Waste of category 200131 were sent to Corvus Company for storage. Waste of categories 18 01 
09: 
• from pharmacies are sent to Lautus for recycling or BAO for storage; 
• from hospitals are sent to BAO for waste disposal or recycling, or to “Lautus” for recycling; 
• from “Grindeks”, Olainfarm to BAO for waste disposal; 
• from veterinary pharmacies or wholesalers or consultants – to Lautus for recycling. 
The waste delivered to Lautus” are disinfected and shredded and further delivered to the Getliņi bi-
oreactor. 
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